Let me save you some time. If you open the earnings release and see a big loss, do not panic, and do not celebrate the revenue jump either. This quarter ended June 30. That is before the huge SHASTA trial results, before the launch really got going, before everything that actually moved this stock. The numbers you are looking at are a photograph of a company that has already changed, so we are not going to spend much time on them.

Here is what I actually care about today, in plain terms.

1. They just paid to make their biggest approval come faster

This is the headline, and most people will walk right past it. Arrowhead bought something called a priority review voucher. Think of it as a fast-pass at the FDA. Normally the agency takes about 10 months to review a drug application. This voucher cuts that to 6.

They are going to use it on plozasiran, their triglyceride drug, to expand it to the much larger group of patients with severe hypertriglyceridemia. Here is why that matters to you as an owner: that bigger approval is by far the most valuable single thing in this company. On the call today management put a number on it, saying the broad indication could drive peak sales in the $3 to $4 billion a year range. The analysts who put a price on Arrowhead give that one approval far more weight than the small rare-disease version already on the market.

How much did they pay? The filings show $215 million for the voucher, in cash. That is a real number, not a rounding error, and they spent it to shave four months off the review of the one approval that matters most. On the call the finance chief said that moving the launch forward those four months is worth, by their own math, more than three times what they paid for the voucher, before you even count the edge of beating a competitor to market.

You do not spend $215 million to speed up an approval you are worried about. Companies hedge when they are nervous. Arrowhead just did the opposite of hedging. That tells you how they feel about their own data.

There is a quieter signal here too, for those who have followed the SHASTA story with me. People kept asking whether Arrowhead would have to wait for one more trial, SHASTA-5, before filing. Buying a fast-pass to file now is your answer. They are not waiting. On the call, asked directly whether they would shut SHASTA-5 down now, management said no, they are keeping it running to help shape the label, not because the filing needs it. That is the definition of a backup, not a gate.

2. The launch is not just starting, it is speeding up

Prescriptions for REDEMPLO roughly doubled in three months. More than 400 different doctors have now prescribed it, mostly heart-prevention and hormone specialists, and the big insurers are covering it. They also got approved to sell it in Europe and Australia during the quarter.

On the call they connected this to the bigger prize. The rare-disease launch is a dry run. The team said the broad triglyceride launch would roughly quadruple the doctors they need to reach, from about 5,000 to more than 20,000, and that they are onboarding the extra salespeople now, ahead of a possible broad launch in the second quarter of next year. In other words, they are staffing up for the big label before they even have it, which is another way of saying they expect to get it.

Why does a simple investor care about launch numbers for a small rare-disease drug? Because this is the floor under the whole stock. The exciting part of Arrowhead, the brain program, has not reported yet. While we wait for that, it matters enormously that there is a real, growing, actual business selling actual medicine in five countries underneath it. A launch that doubles in its first full quarter is that floor getting stronger.

3. Another partner is paying to use Arrowhead’s technology

This one is not today’s news, it was struck earlier in the quarter, but its revenue shows up in these numbers so it is worth a word. Arrowhead licensed one of its earlier-stage liver programs to Madrigal Pharmaceuticals. Madrigal paid $25 million up front and could pay up to $975 million more down the road, plus a cut of sales.

Forget the exact numbers. Here is the pattern that matters, and it is the same one Novartis and Sarepta showed before with much bigger checks. Other drug companies keep paying Arrowhead to use its technology, while Arrowhead keeps its best programs for itself. That is the single hardest thing to see on an earnings statement and the single hardest thing for a competitor to copy: a machine that other people will rent. One detail I enjoyed: Madrigal already licensed similar liver technology from a Chinese competitor, and it came to Arrowhead anyway.

4. The pipeline behind it kept moving

One genuinely fresh item beyond the headline. Their cholesterol drug zodasiran finished enrolling its big trial, and demand was strong enough that they raised the target from 60 to 70 patients, with results expected in mid-2027. It is a small thing on its own, but it is one more program moving forward on schedule while the main event waits in the wings.

5. The one thing I was waiting for: a date on the brain

Now the big one, and the call delivered it. Management gave a date for the first look at ARO-MAPT, the brain program: topline data in September. That is not the vague second-half-of-the-year language we had before. It is next month.

Be clear about what this readout is and is not. This first look is from the healthy-volunteer part of the study, so it is a proof-of-concept test, does the drug reach the brain, silence its target, and stay safe, rather than a result in Alzheimer’s patients showing they got better. The patient part of the study is enrolling separately. September is the moment we find out whether Arrowhead can do the thing no one has done: reach a brain target with a simple injection under the skin, instead of a needle in the spine. If that works, it does not just matter for this one drug. It validates the whole delivery platform behind a stack of other brain programs, including ones partners have already paid for.

That is the readout that could genuinely re-rate this company, and it is now weeks away, not quarters.

A quieter thing I noticed on the call

This one is a read on tone, not a fact, so take it as one investor’s ear rather than anything the company said outright. When you listen to how management talks now, they are not really asking you to value a triglyceride drug. The CEO closed by saying, in so many words, of course look at plozasiran, but also look at the engine we have built and the dozens of medicines it can produce. That is a company telling you, and telling anyone else listening, to price the factory, not the one product coming off the line.

The tell that stuck with me was on the brain program. Management noted that a good September readout would not just help this one drug, it would validate the delivery platform behind a set of other brain programs, including ones that partners have already licensed. Read that again with a big drugmaker’s deal team in mind. It says the moment this platform is proven, the partners who signed early look smart, and the window to get in before proof is closing. Companies do not usually spell that out unless they want the right people to hear it.

I want to be careful here, because it is easy to talk yourself into a takeover story, and I am not doing that. There is nothing in these remarks about a sale, a process, or a banker. What I hear is a company deliberately raising the value of its platform in the minds of both investors and potential partners, right before the event that could prove that platform is real, while keeping every option open, including going it alone. That is posture, and it is smart posture. It is not a deal. I would not want you reading it as one.

What I make of all this

Strip it down and the quarter did four good things: it made the biggest approval come faster, it showed the launch speeding up, it booked revenue from another partner paying for the technology, and it moved the pipeline forward. None of that is the brain readout, which still decides how big this story gets.

That is the setup I want heading into the fall, and I mean setup in the chess sense. A strong player does not win by grabbing a piece early. They spend the game quietly improving their position, and then, when the pieces are where they need to be, one move decides it. Arrowhead has spent this year building the position: an approved drug, a launch that works, a balance sheet that lets them wait, partners paying to use the platform. That built-up position is the base under the stock. What comes next is the move that resolves it.

September is when the pieces start to move. First data on ARO-DIMER-PA, their two-genes-in-one drug, and, more importantly to me, that first look at the brain. The brain readout is the move I am watching, because if it lands, it does not just win a piece. It changes what kind of game this is.

The quarter itself was never the point, and a recap of moves already made rarely is. The point is that the position is ready and the decisive move is finally on the board. It is next month, and I will be watching.

Subscribe now

A Note on Supporting Independent Research

If this reaction note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This reaction note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of August 2026. Numbers from Arrowhead's Q3 FY2026 release, quarter ended June 30, 2026. Cash and investments about $1.57 billion.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Reaction Note Arwr 08042026

180KB ∙ PDF file

Download

Download

Every argument for Arrowhead eventually rests on one claim: the platform works. That is an execution claim, and execution can be measured. This note measures it.

The headline, from Arrowhead’s own filings: 19 company-discovered drug candidates now in clinical trials, spanning Phase 1 through Phase 3, on a platform proven to deliver to 7 distinct cell types. The company spent $607 million on research and development in fiscal 2025 to run that engine. Alnylam spent roughly $1 billion. Ionis spent $916 million. Both are excellent companies, and by the estimates of their disclosed pipelines used here, neither reaches as many tissues.

In chess, development means bringing your pieces off the back rank into active play. The player who develops more pieces in fewer moves controls the board. It is the same word drug developers use, and it means very nearly the same thing.

1. Tissue breadth is the number that matters

Program counts flatter whoever runs the most trials. The harder measure is how many different tissues a company can actually deliver medicine to, because each new tissue is not one drug. It is permission to attempt every disease in that tissue.

Arrowhead’s disclosed clinical programs already span five tissues: liver, lung, muscle, adipose, and the central nervous system. The company has also disclosed that it is extending the platform into two more, ocular and cardiomyocyte, its sixth and seventh tissues, though it has not yet named targets in either. Most of the field, including the two larger peers, remains concentrated in the liver, which is the easiest destination in the body to reach and the one everyone solved first. Getting anywhere else is the hard part, and it is where Arrowhead has spent its moves. Cardiac tissue alone, once the cardiomyocyte work reaches patients, would open one of the largest untouched territories in medicine.

Figure 1. Tissue breadth against annual research spending. Bubble size is the number of clinical-stage programs. Arrowhead reaches more tissues, with a larger pipeline, on less money than either larger peer. Arrowhead is shown with 19 clinical-stage programs and seven tissues: the five in which it has disclosed clinical programs, plus ocular and cardiomyocyte, which it has disclosed it is entering. Targets in those two have not been named. Peer program and tissue counts are estimates drawn from company disclosures.

2. Tempo: the pace of getting to the clinic

Breadth is one half of the execution claim. Speed is the other, and it is the half the chess metaphor points at. In the opening, the player who develops pieces fastest dictates the game, forcing the opponent to react rather than build. Arrowhead develops quickly.

The company describes its discovery engine, in its own filings, as capable of generating multiple new clinical candidates every year, and the record bears that out: the clinical count has climbed from roughly 10 candidates a few years ago to 19 today. For context, the industry benchmark from hit identification to a nominated candidate averages 33 to 36 months, before the further stretch of studies required to reach human testing. An engine that adds multiple clinical candidates a year is running well inside the field’s typical cadence.

The most telling evidence is that a competitor pays Arrowhead for its speed. Under the Sarepta collaboration, Sarepta nominates targets and Arrowhead delivers investigational-ready constructs across six programs spanning muscle, cardiac, and central nervous system tissue. A sophisticated partner chose to outsource the distance from target to clinic to Arrowhead rather than cover it itself. That is the market pricing Arrowhead’s tempo directly, and it is the same tempo that produced ARO-033 in the registry before the market knew the program existed.

3. Why a tissue is worth more than a drug

The case for tissue expansion is usually made as a matter of ambition. It is better understood as a matter of structure. Four reasons make it the variable that decides this field.

The liver is commoditized. Every serious company in this modality cracked liver delivery years ago. That is precisely why the fight between plozasiran and olezarsen is being waged over percentage points on the same gene in the same organ: two good drugs, one destination, competing on margins. When everyone can reach a place, arriving there stops being an advantage. The only exit from that kind of competition is a tissue no one else has reached.

Most disease is outside the liver. A company that can only deliver to one organ has a ceiling on what it can ever treat, no matter how elegant its chemistry becomes. Each new tissue does not add a drug. It adds every lowerable disease in that tissue at once, which is why the list of targets Arrowhead could credibly pursue runs to hundreds rather than dozens.

Breadth is a hedge, and this is the reason most often missed. In a single-tissue company, every program shares one point of failure: if the delivery mechanism disappoints, the whole pipeline disappoints together. 7 validated tissues mean 7 substantially independent delivery problems already solved, so a setback in one does not travel to the others. That is a lower risk of ruin, not merely a wider set of chances, and it is why a broad platform deserves a different valuation framework than a deep one.

Each tissue makes the next one cheaper. Every conquest leaves behind reusable knowledge: ligand chemistry, molecules that tune how the drug moves through the body, safety experience with regulators, and a manufacturing plant whose cost is spread across everything that follows. Tissue expansion is not a series of equally expensive conquests. It gets easier as it goes. An engine that becomes more efficient the longer it runs does not converge with its competitors over time. It separates from them.

The honest objection is that focus has value too. Alnylam concentrated on the liver and has six approved products to Arrowhead’s one, which is a serious argument that depth converts to revenue sooner than breadth does. It is correct about the past decade. The question this paper raises is which approach owns the next one.

4. The cost picture, stated honestly

Divide research spending by clinical-stage programs and you get a rough cost per program: roughly $34 million at Arrowhead, and, using estimated peer program counts, on the order of $40 million at Alnylam and $46 million at Ionis. Arrowhead is leaner, though not dramatically so, and that distinction matters more than the direction of it.

The proxy is crude, and it deserves the caveats. Spending is lumpy. Programs sit at different stages, and a Phase 3 trial costs many times what a Phase 1 does. Partnered programs have some of their costs carried by Takeda, GSK, Sarepta, Amgen, Novartis, and Sanofi, which lowers Arrowhead's reported spending for reasons the counter-case takes up below. Smaller companies such as Silence and Wave spend far less in absolute terms, but they run a handful of programs across one to three tissues. Cheap alone is not the achievement.

What the numbers support is narrower and more durable than a claim of dramatic cost advantage. Arrowhead occupies the productive middle: more breadth and throughput than the small players, less spending than the large ones. It is the best combination of the two on the board.

5. Why it costs less, mechanically

Efficiency without an explanation is a coincidence. Arrowhead’s annual report supplies the mechanism. The design philosophy is to begin with a structurally simple molecule and add only the chemistry strictly necessary to achieve the required knockdown and duration. The company states plainly that its platform is built for simplified manufacturing and reduced costs. Simpler molecules take fewer synthesis steps, which makes each batch cheaper and faster to produce.

Two further structural advantages compound it. Arrowhead identifies potent RNA sequences rapidly using proprietary selection rules, which shortens the distance from target to candidate. It also manufactures in its own facility rather than queuing for slots at a contract manufacturer, which removes a bottleneck that routinely costs competitors months.

6. The proof that is audited rather than asserted

Any company can claim it executes well. Milestone payments are different, because the counterparty sets the bar, verifies the result, and pays in cash. In fiscal 2025, Arrowhead earned $300 million in milestones from Sarepta alone: $100 million when it hit the first enrollment target and won authorization to escalate dosing in the ARO-DM1 study, and $200 million when it cleared a safety committee review and reached the second enrollment target. Nobody pays $200 million for a good slide. They pay because the trial enrolled and the review cleared, on time.

Novartis then paid $200 million up front, with up to $2 billion in milestones, for a program that had not yet entered human trials. That is a sophisticated buyer pricing the engine rather than the asset.

There is a quieter piece of evidence as well. In June, a new Arrowhead candidate called ARO-033 appeared in the clinical trial registry, a placebo-controlled first-in-human study in roughly 42 healthy volunteers dosed subcutaneously. While Arrowhead has not yet officially disclosed the program’s target, research indicates it is an ocular program, most likely aimed at dry age-related macular degeneration. A candidate reached human testing before most of the market noticed it existed, which is what a running engine looks like from the outside.

On that basis the commercial logic is considerable. Dry age-related macular degeneration is a market generally sized at $3 to $5 billion, and it is underpenetrated because the approved therapies require an injection directly into the eye every one to two months. The mechanism is telling as well, since the complement proteins that drive the disease are made largely in the liver, which raises the possibility of treating an eye condition with a subcutaneous injection rather than a needle in the eye, and which fits the two complement programs Arrowhead already runs. The company has not formally confirmed the indication, so it should be held as a strong inference rather than a fact. What does not depend on it is the execution point: the engine put another candidate into humans before the market knew it existed.

7. The engine pays for itself

Here is the fact that separates Arrowhead from nearly every company running a pipeline this size. In fiscal 2025 it reported $829 million in revenue, $98 million in operating income, and $30 million in net income. It was profitable. Most companies running 19 clinical programs burn hundreds of millions and return to shareholders for more money. Arrowhead ran one of the broadest pipelines in the field, across more tissues than either larger peer, and finished the year in the black.

8. Quality, not just volume

Throughput proves the machine runs. It does not prove the output is good. For that, look at the cases where Arrowhead and a competitor pursued the identical target, which controls for the possibility that Arrowhead simply chose easier problems.

In alpha-1 antitrypsin deficiency, Arrowhead’s fazirsiran and Dicerna’s belcesiran went after the same gene. Fazirsiran published in the New England Journal of Medicine, showed a 94 percent reduction in the accumulated disease protein in the liver, produced fibrosis regression in a majority of biopsied patients, and advanced into Phase 3 with Takeda. It got further, faster. In severe hypertriglyceridemia, plozasiran and olezarsen target the same gene, and plozasiran has just delivered replicated 79 and 81 percent triglyceride reductions with a statistically significant reduction in acute pancreatitis, dosed four times a year against twelve.

One more marker of capability rather than volume: ARO-DIMER-PA is, by the company’s account, the first clinical candidate designed to silence two genes with a single molecule. The engine is not only fast. It does things the other engines have not done.

9. The honest counter-case

Four objections deserve a hearing, and one of them lands.

Alnylam has six approved products. Arrowhead has one. On cost per approval, which is the metric that ultimately matters, Arrowhead loses today and it is not close. The rebuttal is that approvals lag the engine that produces them, and Arrowhead only reached commercial stage in November of 2025. That is a real answer, but it is an answer about the future, and readers should weigh it as such.

The other three objections are weaker. Alnylam’s larger spending partly reflects a commercial organization supporting six marketed drugs, which is a different cost, not a worse one. Some of Arrowhead’s speed comes from RNAi biology in the liver rather than from management. Partnering also genuinely offloads late-stage costs, so the claim that Arrowhead would be cheaper standing alone remains unproven. That last point deserves a caveat of its own, though. Persuading Takeda, GSK, Sarepta, Amgen, and Novartis to fund your trials, pay you milestones for hitting them, and leave the wholly owned cardiometabolic, obesity, and brain programs untouched is not an accounting artifact. It is a deliberate strategy, and executing it is itself a form of efficiency.

10. What it means, and what to watch Tuesday

An acquirer buying Arrowhead is not buying 19 programs. Programs can be licensed one at a time. It is buying the machine that produced them, and machines of this kind have proven very hard to build from scratch. Novo Nordisk understood this in 2021 when it paid roughly $3.3 billion for Dicerna, acquiring an RNAi platform rather than any single approved drug, and notably paying that price for the platform even though the head-to-head program discussed above was lagging Arrowhead’s. Every large pharmaceutical company facing the patent expirations of the coming decade needs replacement revenue, and the fastest route is to buy an engine that is already running.

Arrowhead reports fiscal third quarter results on Tuesday, August 4. The quarter closed on June 30, before the SHASTA readout and before the first look at the brain program, so the financial statements are history. The engine is what to watch instead: the research spending line and what it bought, the pace of programs moving between phases, the launch of Redemplo, and above all the guidance on when the tau readout arrives. The numbers describe a quarter that has already ended. The commentary describes the machine that determines every quarter after it.

Arrowhead has developed more pieces, onto more squares, in fewer moves than anyone else on this board. Development is not the same thing as winning. It is what makes winning possible, and it is the part that cannot be improvised later.

Subscribe now

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. Financial figures are drawn from audited annual filings. Peer program and tissue counts are estimates from public disclosures and are approximate. Cost per program is an indicative proxy, not a precise measure of development cost. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Note Arwr The Execution Engine 08032026

262KB ∙ PDF file

Download

Download

Going back through Arrowhead’s recent public comments changed my read on one important point from my last note, enough that it deserves its own write-up. The company spoke directly about the pancreatitis question, the one everyone is watching in the coming SHASTA results, and what management said shifts how that result should be understood. Everything here comes from those public comments.

What management has said

In two public investor appearances, the RBC Capital Markets and Jefferies fireside chats, Arrowhead’s Chief Medical Officer, James Hamilton, addressed the acute pancreatitis endpoint directly, and the transcripts are on the record. He said the company is cautiously optimistic that SHASTA-3 and SHASTA-4 will actually prove a reduction in pancreatitis to the standard scientists treat as proof, and that the trials are large enough to do it based on the number of pancreatitis cases showing up so far. A quick word on what that means. To prove an effect on something, a trial needs enough of those events to occur during the study, otherwise there is too little to measure. Hamilton gave the number on those calls, the RBC Global Healthcare and Jefferies fireside chats in mid-2026: if roughly nine or more pancreatitis events occur, at rates like those seen in the company’s earlier CORE studies, that is enough to give a reliable answer. He noted, too, that the events seen so far have not fallen far outside what they expected. A word on how a company knows anything while blinded: treatment assignments stay hidden, but the company can still see the total number of adjudicated pancreatitis events piling up across the whole trial. That aggregate count, without revealing which arm the events landed in, is enough to gauge whether the trial is likely to have the statistical power it needs.

How that reframes the endpoint

This puts pancreatitis in a more precise light than the market conversation, mine included, has generally allowed. Here is the cleanest way to hold it. Triglyceride lowering is the main thing these trials were built and sized to prove, and it is widely expected to come through. Pancreatitis is a second thing they track, and whether they can prove it depends on one variable: how many pancreatitis events actually occur during the study. If enough occur, the trials can prove it. If too few occur, they cannot, no matter how well the drug works. Management is saying it believes enough will occur, and that proof on pancreatitis is genuinely within reach, not out of the question the way my first note implied.

Squaring this with the sell side

This is worth squaring with the sell side, because there is a real tension in how the pancreatitis endpoint is being described. Pancreatitis is not a vague hope hanging off these trials. It is a formally named secondary endpoint in both SHASTA-3 and SHASTA-4, an adjudicated count of pancreatitis events and related hospitalizations, assessed by an independent committee against pre-set criteria. It was built into the trials on purpose.

Against that, JPMorgan’s July 17 note, the same one that raised its price target to $95 while valuing the entire brain platform at a single dollar, carries a one-line caveat that the trials are not powered to show a pancreatitis reduction. Both things can be true, and the reconciliation is the whole point. The trials are powered first for triglyceride reduction, which is the primary endpoint. Pancreatitis is a secondary endpoint, and whether it reaches statistical significance depends on one thing: whether enough pancreatitis events happen during the study to measure a difference. The honest statement is not that the trials cannot show pancreatitis, it is that they will show it only if the event count cooperates. Management, watching the blinded event rate, is guiding that it expects it will.

There is a strong reason to take that guidance seriously, and it is the piece the sell-side framing tends to skip. Plozasiran has already hit statistical significance on pancreatitis once, in the Phase 3 FCS trial, where the reduction in adjudicated events came in at an odds ratio of 0.17 with a p-value of 0.03. The drug has demonstrably moved this endpoint in a pivotal setting before. The open question in SHASTA-3/4 is therefore not whether the drug can reduce pancreatitis, which is already on the record, it is whether the larger and somewhat less severe sHTG population will generate enough events for the effect to clear significance again. That is a question about event counts, not about whether the biology works.

Which is what makes JPMorgan’s own scenarios worth reading closely. Its best case, worth 15 to 30 percent upside, is built on proving a statistically significant pancreatitis reduction, and its middle case treats a result that falls short of significance as, in the bank’s words, perceived negatively at first, with buyers stepping in depending on the magnitude. The point is not to guess at what the analysts privately believe. It is simpler and entirely on the page: JPMorgan’s own valuation framework assigns real additional upside to a significant pancreatitis result. Whatever the caveat about powering, the endpoint plainly remains an important determinant of value in the model itself. That is consistent with what management is guiding.

Worth adding on that dollar: valuing the brain platform at a single dollar, up from the zero it carried before, concedes the platform is worth more than nothing while still pricing it at a rounding error, a tacit admission of the point I made in Zero.

Why it raises the stakes

There is a cost to management raising expectations this way, and it should not be glossed over. Guidance sets the bar, and by guiding to proof on pancreatitis, management has raised the standard the readout will be judged against. The comfortable reading from my first note, that a pancreatitis miss would just mean the trials were too small to prove it and could be shrugged off, does not survive the company itself saying it expects to prove it. The result now carries real weight in both directions: proof would be a genuine win the market is primed for, and falling short would sting more than an underpowered endpoint otherwise would, because it would miss a bar the company set for itself. Higher expectation, higher stakes.

What it clarifies about SHASTA-5

It also corrects a piece of the surrounding debate that has the logic backwards, and this part cuts in Arrowhead’s favor. SHASTA-5 is not a fallback that exists because SHASTA-3/4 cannot demonstrate pancreatitis. Per Hamilton, it is a separate, dedicated outcomes trial in high-risk patients, those with prior pancreatitis events, designed to provide even stronger, confirmatory evidence, particularly for payers. The framing that treats SHASTA-5 as the consolation study for an endpoint the main trials cannot reach is mistaken. The main trials may reach it, and SHASTA-5 is built to reinforce the case rather than to rescue it.

The real question into the readout

Strip it down and the question was never whether SHASTA-3/4 can show pancreatitis. Management has publicly guided that it believes they can. The question is whether enough pancreatitis events actually occurred during the study, which no one will know for certain until the final data is unblinded and analyzed. That is the single thing the result turns on, and it is the one to watch. Everything else, the triglyceride result almost certainly coming through, the underlying biology, the real-world case, sits on firmer ground. This is what makes the coming readout more than another triglyceride study. It is a direct test of whether Arrowhead’s confidence in the pancreatitis endpoint was warranted, a test the company chose to invite by telling the market it expects to pass.

The discipline of this work is separating what a trial can prove from what the market assumes. This update tightens exactly that line on the pancreatitis question, and it is on the record straight, ahead of the results rather than after them.

Subscribe now

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Note Arwr Shasta Pancreatitis Update 07182026

172KB ∙ PDF file

Download

Download

Robert Toczycki, JD, MBA
bioboyscout.com
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout

A pivotal readout is coming for Redemplo in severe high triglycerides, the SHASTA-3 and SHASTA-4 topline, expected within days, with the full 12-month data set for a Hot Line presentation at the European Society of Cardiology Congress in Munich in late August, the slot the congress reserves for its most practice-changing trials. Before it lands, it is worth separating what the trial was designed to measure from what the market has decided to judge it on, because those are not the same thing, and the gap between them is where the stock is most likely to be mispriced in the first hour after the results.

What the trial is built to show

One piece of vocabulary makes the whole thing clear, so here it is in plain terms. When statisticians say a trial is powered to prove something, they mean it was built big enough, with enough patients and enough time, to give a reliable yes-or-no answer on that specific question. A trial can measure a hundred things, but it is only powered to prove the one or two it was sized around. Power depends largely on how often the event happens and on how many patients are enrolled: when an event is uncommon, even a drug with a substantial effect may require thousands of patients or years of follow-up before statistical significance can be demonstrated. Measuring something is not the same as being able to prove it, and that single distinction is the entire point of this note.

The primary job of this trial is triglyceride reduction, and on that measure the bar is not really in doubt. Investors look for something above roughly 60 to 70 percent. The earlier SHASTA-2 study already delivered about 74 percent, and the main competing drug has shown triglyceride reductions in a comparable neighborhood, roughly 55 to 72 percent across its trials. Triglyceride lowering is the mechanism, it is what the drug is designed to do, and it is what this trial is powered to demonstrate. On the thing the trial was built to prove, expectations are high and, by most reckoning, likely to be met.

What the market has decided to grade

The number investors are actually fixated on is different. It is the reduction in acute pancreatitis events, the dangerous real-world consequence of very high triglycerides. The benchmark in everyone’s mind is the competitor’s headline of an 85 percent reduction in those events. That figure, worth understanding, came from a trial run in a pancreatitis-prone population and built around pancreatitis events, not from a triglyceride-sized study like this one, which is precisely why it makes an unfair yardstick for SHASTA. The reflex on results day, then, will be to compare Redemplo’s pancreatitis number against that bar and grade the drug a winner or a loser on the spot.

Here is the problem with that reflex, and it is not a subtle one. Pancreatitis is not an afterthought in these trials. It is a formally tracked outcome, the studies count pancreatitis events, related hospitalizations, and emergency visits, and they were described from the start as designed to look at whether the drug lowers both triglycerides and the rate of pancreatitis. The events are measured, in other words, and measured carefully.

What the trial can prove is a different matter, and this is the crux. The trial was sized around triglycerides, roughly 750 patients over a single year, which is enough to give a clean answer on triglyceride lowering. Pancreatitis, though, is a rare event. In a group that size over one year, only a small number of pancreatitis cases will occur at all, and that is simply too few to produce a statistically reliable result, the kind that clears the bar scientists and regulators treat as proof. The drug can genuinely reduce pancreatitis and the trial can still be unable to prove it to that standard, purely because it was not built to. Measured, yes. Powered to prove, no. Much of the print-day risk lives in that gap.

There is a clean piece of evidence that this is deliberate, and it is the most convincing detail of all. Arrowhead built a separate trial, SHASTA-5, for the specific purpose of proving a reduction in pancreatitis, enrolling only high-risk patients who have already suffered multiple pancreatitis attacks, and running for up to three years rather than one. A company does not construct a dedicated, years-long trial to prove something its main trials could already prove. The existence of SHASTA-5 is the clearest possible confirmation that SHASTA-3 and SHASTA-4 were never meant to settle the pancreatitis question. That job was handed to a different study, on purpose.

Why the distinction matters on print day

Follow that through to print day. If the pancreatitis numbers do not reach that bar of statistical proof, the quick, headline-reading reaction will be that the drug missed. That reading would be wrong, or at least badly incomplete, because you cannot miss a bar the trial was never built to clear. A pancreatitis result that falls short of formal proof, in a trial sized for triglycerides, is a feature of how the study was designed, not a verdict on whether the medicine works. What actually matters in that case is the size of the pancreatitis reduction and which direction it points, not whether it crossed a proof threshold the trial was never meant to reach.

The medical reality and the market reaction are likely to split here, and even the Wall Street analysts have quietly admitted it, noting that doctors will lean on the established biology, lower triglycerides mean fewer pancreatitis attacks, even where one trial cannot prove the reduction to a statistical certainty. Doctors treat the mechanism. Headlines grade the statistics. Those are two different audiences drawing two different conclusions from the very same result.

Figure 1: Powered to prove one thing, graded on another

The trial is sized to demonstrate triglyceride reduction, where the bar is expected to be cleared. The market will grade it on acute pancreatitis reduction, an outcome the trial is not powered to prove statistically. A significance miss on the second is a design feature, not a drug failure. Illustrative framing of the powering distinction.

How to read the result without being whipsawed

Hold three cases in advance, so the headline does not set the interpretation for you. If triglycerides clear the bar and pancreatitis shows a large reduction that also reaches significance, that is an unambiguous win, and the market will treat it as one. If triglycerides clear the bar and pancreatitis reduction is large in magnitude but short of significance, the headline may read negative for an hour, and it should not, because that is the trial doing exactly what a triglyceride-powered study does with a rare event. The number to read in that case is the size and direction of the pancreatitis effect, not whether it earned a stamp of statistical proof. Only the third case, a triglyceride result that falls short of the expected range, would be a genuine disappointment on the terms the trial was actually built to test.

The tie to the larger thesis

This is the same distinction that runs through everything I have written on this company. Separate the question a study was designed to answer from the question the market wants answered, and the mispricing usually lives in the gap. On results day the gap will sit between a triglyceride result the trial can prove and a pancreatitis result it cannot, and the first reaction is likely to judge the second as if the trial had been built to settle it.

Chess has a precise word for this situation. A player can hold a winning position, material up, the outcome not in doubt to anyone who actually reads the board, while the scoreboard still shows the game as undecided, because checkmate has not yet been forced. The impatient spectator glances over, sees no mate, and assumes nothing has happened. The player knows the win is already on the board and simply has not been delivered yet. Lower the triglycerides and you have the winning position. The forced mate, statistical proof on pancreatitis, was assigned to a different game, SHASTA-5, on purpose.

When the results land, do not ask whether Redemplo delivered checkmate in a trial that was never set up to force one. Ask whether it is winning. On triglycerides, it almost certainly is, and a winning position converts. The market may spend a headline or two confusing an undelivered mate for a lost game. That confusion is not a verdict on the drug. It is the buying opportunity.

Subscribe now

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Note Arwr Powered For What 07172026

210KB ∙ PDF file

Download

Download

Every so often an argument arrives fully assembled, made by someone with no interest in making it. This is one of those. JPMorgan published a note last week reiterating an Overweight rating on Arrowhead with a price target of $88. Inside that note is a sentence that should stop any careful reader, and a table that contradicts it.

The sentence says the brain program is the first asset in Arrowhead’s pipeline aimed at crossing the blood-brain barrier to reach the clinic, and that management expects a substantial expansion of the entire central nervous system pipeline if its first readout is encouraging. The table says that program is worth nothing.

Where the $88 comes from

A price target is not a slogan. It is arithmetic, and the arithmetic is published. Here is how JPMorgan builds its $88.

Figure 1: What JPMorgan’s $88 is made of

The stated components of JPMorgan’s December 2026 price target for Arrowhead, per share. The brain platform, the company’s most differentiated asset, appears nowhere. Composition from JPMorgan’s published note, July 2026.

Roughly $43 a share for the approved triglyceride drug in its larger indication. About $4 for the same drug in the rare disease where it is already approved. Around $5 for a second cardiometabolic drug, about $10 for the obesity programs, and roughly $12 for potential milestone payments from partners. The rest is cash, tax assets, and an unspecified remainder labeled pipeline value.

Read that list again and note what is missing. The delivery platform that lets Arrowhead put gene-silencing drugs into tissues nobody else can reach carries no line. The brain program, ARO-MAPT, carries no line. The bench of central nervous system targets behind it carries no line. The platform is not modeled conservatively. It is not modeled at all.

The contradiction, stated plainly

Hold the two halves of that note side by side. In the text, JPMorgan tells clients that the brain readout is important derisking, that it is the first blood-brain-barrier asset the company has put into humans, and that a good result triggers a substantial pipeline expansion beginning at the end of 2026. In the model, the same firm assigns that asset, that platform, and that expansion a value of zero.

Both cannot be right. Either the platform matters, in which case the price target is missing its most important input, or it does not matter, in which case the note should not describe it as a major derisking event. What JPMorgan has actually published is a valuation of Arrowhead as a cardiometabolic company that happens to own a brain platform for free.

This is not a criticism of the analyst. It is how sell-side models work, and it is precisely the mechanism I have been describing for months. A discounted cash flow can only value what it can forecast, and it cannot forecast a platform whose first human data does not exist yet. Faced with an unproven asset, the model does the only thing it knows how to do. It assigns zero and waits. The result is a price target that captures the company Arrowhead is today and none of the company it is becoming.

Zero is not the conservative answer

The defense an analyst would offer is that a model cannot value what has not read out. Set that defense against the same analyst’s own arithmetic. Roughly $10 of the $88 sits on the obesity programs, which is the right call, since those programs have already produced human data, meaningful reductions in visceral, total, and liver fat, and doubled weight loss in combination with tirzepatide. About $12 sits on milestone payments that hinge on other companies’ trials. Both are estimates of things not yet certain, and the analyst is right to make them, because making them is the job. The model is entirely willing to price an early clinical asset on a probability, right up to the moment it reaches the brain platform, where it suddenly assigns nothing. That is not caution. It is selective, and the selection lands on the single most valuable asset in the company.

The point cuts deeper than one note, because risk-adjusting unproven assets is not something biotech analysts occasionally do. It is the job. In most industries an analyst forecasts revenue that already exists. In biotechnology almost nothing exists yet, so the entire discipline is built on putting numbers on things that have not happened. Probability of technical success, phase-by-phase attrition rates, risk-adjusted net present value, probability-weighted peak sales: these are not exotic instruments. They are the daily vocabulary of the profession, and analysts rightly take pride in wielding them. Assigning a defensible number to a deeply uncertain asset is the craft itself.

A zero, in any case, is not a number the model produced. It is the number that appears when nobody enters one. There is a difference between running the calculation and arriving at something small, which is rigorous, and never creating the line item at all, which is an absence wearing the costume of an estimate. A conservative analyst would take a low probability of success, apply a modest value, and publish a small figure. That is defensible and it is honest work. Zero is not conservatism. Zero is the only output that requires no analysis whatsoever.

There is a cost to that absence, and it is not merely academic. A price target is supposed to be a forecast, which means it should already carry the probability-weighted value of events that are foreseeable. The brain readout is about as foreseeable as an event in this business gets. It is scheduled, the company has said when to expect it, the bar for success is public, and the consequences of clearing that bar are estimable within a range. A model that carries no expectation for it is not forecasting the future. It is photographing the present and putting a future date on the frame.

Notice the date on that frame. The price target runs to December 2026. The readout arrives in the fall. The target is therefore dated after the single most important event of Arrowhead’s year, and priced as though that event will not occur.

To be clear about what is and is not being argued. A stock should move sharply when a great deal is learned, and a large repricing after a genuine binary readout is the correct outcome, not a failure. What should not happen is that the repricing comes as news to the model. The purpose of risk-adjusting an unproven asset is to hold, today, a considered view of what tomorrow might bring, so that when tomorrow comes the analyst is updating a number rather than inventing one, and is not blindsided by an event that was on the calendar all along.

The fair objection is that sell-side convention often does keep early-stage and preclinical assets out of a formal discounted cash flow, handling them qualitatively in the text instead. That convention is real, and in most cases it is harmless. It stops being harmless when the excluded asset is the most valuable thing the company owns, and when the same analyst, in the same document, calls it major derisking. At that point the convention is not prudence. It is the reason the mispricing exists.

Recognize what a zero actually asserts. It is not a shrug, and it is not caution. Written down, a zero is a specific and aggressive claim: probability of success multiplied by value equals nothing. Not small. Not uncertain. Nothing. To hold that view of Arrowhead’s brain platform, an analyst must believe either that ARO-MAPT has essentially no chance of working, or that a proven subcutaneous route into the human brain would be worth nothing once it did. No analyst would say either sentence out loud, and yet the model says both.

The minimum honest answer is not a zero. It is a range. Take a probability of success, take a value if it works, multiply, and publish the number. That is the ordinary machinery of sell-side valuation, applied everywhere else in the very same note. The anchors for that estimate are not hard to find. What informed buyers have actually paid for brain access, examined below, sets a floor, and discounting those prices aggressively still does not get you to zero.

The asset is not undifferentiated guesswork either. Arrowhead has spent years removing risk from this program in ways an analyst can actually see: primate data showing roughly 50 to 60 percent knockdown in the brain sustained for months, an approved trial enrolling patients today, a partner who paid real money for a piece of the platform, and a patent estate built around the delivery route itself. The target has now been derisked as well, by someone else’s capital. Biogen’s diranersen has shown that lowering tau in the human brain produces measurable clinical benefit, which removes the most fundamental question hanging over ARO-MAPT: whether the thing it is aimed at is worth aiming at. The platform is more derisked today than it was on the day the price target was published. The valuation assigned to it has not moved.

Why this is the strongest evidence yet

For months these white papers have argued that the market prices Arrowhead’s drugs and ignores its platform. That was an assertion. This is a receipt.

Consider the source. This is not a bearish analyst reaching for reasons to be negative. It is a bulge-bracket firm that rates the stock Overweight, that recommends buying it, and that in the same document praises the brain program in the warmest terms available. Even in the mouth of a bull, the platform is worth nothing. If the most enthusiastic sell-side model in the room carries a zero in that line, ask what is actually inside the roughly $72 a share the market is paying today.

The answer is: the triglyceride franchise, the obesity programs, some milestones, and the cash. That is the whole stock. Everything these white papers have called the crown jewel, the delivery technology, the brain pipeline, the strategic scarcity that makes three large pharmaceutical companies pay attention, is being handed to buyers at no charge.

What the platform is worth to someone who has to buy it

Set the models aside and look at what strategic buyers actually pay, because they cannot afford the luxury of a zero. Novartis committed $200 million upfront and as much as $2 billion for a narrow slice of Arrowhead’s neurology work, and it did so while already owning its own liver-targeted RNAi drug and while cheap liver-focused licensing deals were freely available. It was not buying the cardiometabolic pipeline that makes up the whole of JPMorgan’s price target. It was buying access to the brain.

BioArctic makes the point sharper still. With a blood-brain-barrier delivery technology but no approved drug of its own riding on it, it has signed four separate agreements in about two years, with Bristol Myers, Novartis, Lilly, and Eisai, each worth from hundreds of millions to well over a billion dollars, for nothing more than a way across the barrier. Four large pharmaceutical companies have paid, repeatedly and in public, simply for the right to try. Arrowhead has the only platform of its kind already in the clinic, a brain drug dosing humans today, and a partner that has committed as much as $2 billion to one corner of it. Whatever the right number is, the observed evidence says it begins in the billions. Zero is not a conservative estimate of it. Zero is a placeholder for a number the model cannot generate.

Sarepta is the third data point, and it tests a different claim than the other two. Novartis and BioArctic price the value of reaching the brain. Sarepta prices the value of the platform itself, its capacity to keep producing licensable programs across tissues. In late 2024 Sarepta licensed a suite of Arrowhead’s clinical and preclinical programs spanning muscle, lung, and the central nervous system, including central nervous system targets in Huntington’s disease and the spinocerebellar ataxias. It paid $825 million immediately, $500 million in cash plus a $325 million equity stake taken at a 35 percent premium, committed a further $250 million over five years, and put up to roughly $10 billion in milestones behind the collaboration, with the right to commission six more targets from the platform on demand.

Read what that structure actually says. A sophisticated partner did not buy one drug. It bought standing access to the factory, the right to keep pulling new programs off Arrowhead’s delivery platform for years. That is the precise asset JPMorgan labels pipeline value and scores at nothing. Sarepta named the reason itself, calling Arrowhead’s approach to crossing the blood-brain barrier with a subcutaneous shot a potential paradigm shift for the central nervous system programs it was licensing. The acquiring partner identified, by name, the capability the model refuses to value. Note the honest limits: several of these programs are early, the headline figure is milestone-heavy rather than banked, and Sarepta has had its own turbulence, so the realized total will depend on execution. None of that touches the point, because the point is not what Sarepta will eventually pay. It is what an informed party agreed the platform was worth paying for in the first place, and that number was not zero. It was among the largest platform-licensing commitments in the sector.

The event that removes the excuse

Here is why this matters now rather than in the abstract. A model can carry a zero only while the asset remains unproven. The moment human data exists, the zero becomes indefensible, and every analyst carrying one has to replace it with a real number.

Arrowhead’s first human brain readout is expected late in the third quarter or early in the fourth. The bar is public: diranersen, the competing intrathecal drug, lowered tau in the spinal fluid by roughly 50 to 60 percent, and Arrowhead management has said it is looking for a comparable reduction in its own study as the mark of success. Its primate data already sits in that range, and its modeling projects sustained knockdown of 50 to 70 percent on quarterly dosing.

Consider what a positive result would do to a model like JPMorgan’s. It would not adjust an assumption. It would force the creation of a line item that does not currently exist, in a valuation where the largest single component is a triglyceride drug. Analysts do not re-rate gently when they have to build a new section of the model from nothing. That is the mechanical path from $88 to something that starts with a different digit.

What would make this wrong

Honesty requires the obvious caveat. The zero is only wrong if the platform works. If the brain readout disappoints, if the knockdown comes in well below the 50 to 60 percent bar, then the models were right to assign nothing, and the stock is roughly worth what the cardiometabolic franchise is worth. That is the risk, stated without varnish.

Note the asymmetry, though. If the platform fails, the market was correct and the stock is priced about right. If the platform works, the market is carrying a zero on the most strategically scarce asset in the sector, and it has to fix that in a hurry. Losing is being right about the price you already paid. Winning is a repricing that no model in the room is currently prepared for.

The hanging piece

Chess has a word for this. A piece is hanging when it sits on the board undefended, fully available for capture, and the player who should be watching it simply has not noticed. The piece has lost none of its value. Nobody is counting it.

That is what a zero in a valuation model actually describes. It does not say the brain platform is worthless. It says nobody has been forced to put a number on it, so the line stays empty and the position looks quieter than it is. The asset sits there in plain sight, undefended, worth exactly what it was worth before anyone bothered to look.

The trouble with a hanging piece is that it does not stay hanging. Somebody eventually looks at the board and counts it. It might be an analyst, obliged to build a line item after a readout leaves no excuse for the zero. It might be a strategic buyer who has been counting all along, which is what Novartis was doing when it wrote a check for the brain while the models were writing nothing.

What it all means

The most valuable thing Arrowhead owns does not appear in the arithmetic of the bank that recommends buying it. That is the entire thesis in a sentence, and this time it is not a claim from a letter with a position. It is published, sourced, and reiterated with an Overweight rating.

The market is not wrong about the triglyceride drug. It is not wrong about obesity, or the milestones, or the cash. It is simply not counting the road into the brain, because nothing has yet compelled it to. A price target is a bet on the company you can already see. The whole argument for owning this one rests on the company nobody has priced yet.

In chess, a piece that nobody defends is not a piece without value. It is a piece about to change hands.

Subscribe now

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. Figures cited from JPMorgan’s published research note dated July 2026 and from company disclosures. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Note Arwr Zero 07162026

247KB ∙ PDF file

Download

Download

Biogen presented the full Phase 2 CELIA results for diranersen at AAIC today, and by tonight every summary will have converged on the same question: does lowering tau treat Alzheimer’s disease. That is a fair question. It is not the one that moves the most value, and the gap between those two questions is where this note lives.

Two things were tested in that trial, not one, and only one of them is being talked about.

Two questions were on trial, not one

Think of a drug as a package that has to reach an address. The first question is whether the package arrives and does its job once it gets there. The second is whether that job actually helps the patient.

Those questions are worth very different amounts. A delivery answer travels. Prove that you can get a gene-silencing drug into the human brain and switch off a gene there, and you have opened the door for every drug that follows down the same road, whatever it aims at. An efficacy answer does not travel. Prove that lowering tau helps in Alzheimer’s, and you have proved exactly that, and nothing about the next target or the next disease. One answer opens a portfolio. The other adds a drug.

The market will grade the second question and shrug at the first. It has that backwards, and the rest of this note explains why.

What the data actually showed

Start with what was already public. In May, Biogen reported that CELIA missed its primary endpoint. The trial was supposed to show that higher doses worked better than lower ones, and it did not. Everything else, though, worked. Tau came down in the spinal fluid and, more impressively, tau came down in brain scans, at every dose, and it stayed down. Patients declined more slowly at every dose. The oddity: the best result came at the lowest dose, 60 mg given every 24 weeks, while the most serious side effects showed up at the highest dose. Biogen is pushing ahead to final-stage trials anyway.

Today’s presentation filled in the numbers, and they are better than the May summary implied. Tau in the spinal fluid fell by 50 to 65 percent across the dose arms by week 72, and tau also came down on brain scans in every brain region they looked at. No tau drug had ever moved both of those measures at once in a study this size. On the patient side, the winning dose slowed the decline of the disease by 26 percent, a difference of 0.54 points, on the main scale doctors use to track cognition and daily function, and by 42 and 50 percent on two pure memory-and-thinking tests. For scale, Leqembi, the amyloid drug already approved and on the market, slowed decline by 27 percent on that same main scale. A tau drug just matched an approved Alzheimer’s drug, and beat it on the thinking tests.

Then comes the detail almost no one will write about. Diranersen is injected into the spinal canal, a lumbar puncture, the same procedure people call a spinal tap. The three most common side effects in the whole trial were pain from the procedure, post-puncture syndrome, and confusion in the days right after dosing. Two of those three are the needle rather than the medicine, and the cleanest evidence for that is the placebo group: 57.9 percent of the patients who received no drug at all still had an adverse event attributed to the injection procedure. Fifty-eight percent, from the needle alone.

The third one, confusion, is more interesting, and it is not procedural. Every arm in the trial received an intrathecal injection every 12 weeks, drug or placebo, so the number of punctures was identical no matter which group a patient landed in. Confusion nonetheless grew more common the more drug a patient received. A side effect that tracks the dose cannot be caused by a procedure that does not vary with the dose. It is not the puncture. It is what the puncture delivers, and the concentration spike a bolus into the spinal fluid creates. Biogen also confirmed that this class does not carry the brain swelling and small bleeds that come with the amyloid drugs, because that risk belongs to the amyloid approach, not the tau one.

The full safety table adds something the May topline concealed. Harm climbed with dose while benefit did not. Side effects that Biogen’s own investigators judged related to the treatment affected 24.6 percent of the placebo group, then 37.7 percent at the winning low dose, 40.9 percent at the middle dose, and 57.8 percent at the highest dose, rising at every step. Serious side effects judged related to treatment ran from zero on placebo to 10.3 percent at the top dose, though not in a straight line, since the middle dose came in slightly below the low one. Set the exception aside and the shape is unmistakable. The most harm was concentrated in the arm that received the most drug, and Biogen’s own words for what that arm delivered in return were a lower effect size at the higher dose levels.

Figure 1: Level on the global scale, ahead on cognition, absent on function

Slowing of decline versus placebo at 18 months, as compiled by Biogen. Diranersen figures are the 60 mg every-24-weeks arm from the Phase 2 CELIA study (nominal significance, 60 patients); lecanemab and donanemab figures are from their Phase 3 trials (roughly 900 patients each). NR indicates the endpoint was not reported for that trial. Cross-trial comparisons are illustrative, not head-to-head. Source: Biogen AAIC 2026 investor presentation, July 14, 2026.

How it stacks up against the amyloid drugs

The comparison everyone will want, and almost no one will run properly today, is diranersen against the approved amyloid antibodies. Run it carefully, because the honest version is more interesting than the cheerleading one.

Take the main scale first, the one regulators weigh most heavily, which measures cognition and daily function together. Diranersen slowed decline by 26 percent at its best dose. Leqembi slowed it by 27 percent. Kisunla, the other approved amyloid drug, managed 29 percent. The tau drug therefore landed level with both approved drugs on the measure that matters most. On the pure thinking-and-memory tests, the picture tilts. Diranersen slowed decline by 42 percent where Leqembi managed 26 percent and Kisunla managed 20 percent, and it produced a 50 percent effect on a standard memory test where Kisunla managed 16 percent. On the two composite scales that blend cognition and function, diranersen scored 23 percent on ADCOMS against Leqembi’s 24, and 30 percent on iADRS against Kisunla’s 22, the only scales on which each of those drugs reported. On cognition alone, the tau drug looks better than the drugs already on pharmacy shelves. Everywhere else, it looks like a peer.

There is one column where it does not look like a peer, and Biogen printed it without comment. On the standalone measure of daily functioning, the ability to manage money, drive, keep up hobbies, diranersen showed zero separation from placebo. Leqembi showed 36 percent on that instrument. Aducanumab, in the trial that worked, showed 42 percent. Zero is not a small number. Daily functioning is what families actually feel, and it is a large part of what regulators are buying when they approve an Alzheimer’s drug.

Biogen’s answer to that, and it is a real answer rather than a dodge, is that the functional subdomains inside the main scale did move. Community affairs slowed by 21 percent, home and hobbies by 24 percent, personal care by 29 percent. Two instruments measuring roughly the same thing disagreed, and the one Biogen highlighted is the one that agreed with the drug. That may be noise in a 60-patient arm. It may be a real gap between what a clinician observes and what a caregiver questionnaire captures. It cannot be waved away, and it is the single largest hole in the registrational case.

Four further caveats keep this from being a victory lap. This is a mid-stage result resting on 60 patients in the winning group, the smallest arm in a study that put nearly twice as many patients in each of the others, against late-stage trials with roughly 900 patients each, and effects of this kind shrink more often than they grow when the trial gets bigger. The brain-scan substudy at the winning dose rested on 19 patients at baseline and 16 at the end. The statistics behind diranersen’s numbers are softer, too, held to a looser standard than the approved drugs were. The winning arm also entered the trial carrying less amyloid and fewer double copies of the highest-risk Alzheimer’s gene than the arms it beat, which is the kind of imbalance that can flatter a result. In fairness, it cuts both ways: that same arm started with worse cognition and more advanced disease, which would ordinarily predict faster decline, not slower. Randomization did its job imperfectly in both directions, which is what happens when an arm has 60 people in it. No single trial settles a question like this.

The safety comparison runs firmly the other way, and it is the more durable advantage. The amyloid drugs can cause brain swelling and small brain bleeds. That risk brings the FDA’s strongest warning label, repeated brain scans to monitor for it, and a genetic test before treatment even starts. The tau approach does not carry that risk, and this trial confirmed it. Nothing in diranersen’s safety profile is a mechanism attacking the brain’s blood vessels. Its burden is the route and what the route delivers. Put those together and the strategic picture is clear. Tau is now a proven target rather than a theory, and the drugs competing to hit it will be separated by how they are delivered and how safe they are, not by whether the idea works. That is precisely the ground Arrowhead built ARO-MAPT to fight on.

The endgame is a combination, and that changes everything

Look at those two columns again. The amyloid drugs did better on daily functioning. The tau drug did better on thinking and memory. Those do not look like two drugs competing to do the same job. They look like two drugs doing different halves of one job.

The biology says the same thing. Alzheimer’s is a two-protein disease. Amyloid builds up first, tau follows, and tau is the one that tracks most closely with symptoms, the protein that tangles inside brain cells in the places where memory actually fails. Clearing amyloid alone treats the trigger and leaves the bullet in flight. Almost everyone in this field now expects the eventual answer to be both, an amyloid drug and a tau drug together, and Biogen happens to own one of each.

Here is what almost no one is saying about that. If combination therapy is the destination, then how a drug is delivered stops being a matter of convenience and becomes the thing that decides whether the destination is reachable at all. Build that combination out of the standard of care as it stood until this week and you get an intravenous infusion in a clinic every two weeks for eighteen months, then an infusion every four weeks after that, plus a lumbar puncture every six months, for the rest of a patient’s life. Burdens do not simply add when you combine therapies. They compound, because the patient has to accept all of it, the doctor has to schedule all of it, and the payer has to fund all of it. Two clinic-bound drugs is not twice as difficult as one. It is disqualifying.

The timing here is almost too neat. One day before this presentation, the FDA approved Leqembi Iqlik, a once-weekly subcutaneous autoinjector, as a starting dose for early Alzheimer’s, which makes lecanemab the first anti-amyloid therapy a patient can take at home from the first dose through maintenance. The Alzheimer’s Drug Discovery Foundation said out loud what the approval means: a step toward the scalable care model the disease will need as the field moves from single drugs toward combinations. The amyloid half of the future combination just left the infusion center. The tau half is still in it.

Now picture the combination built out of what exists after this week: an at-home autoinjector for the amyloid drug, alongside a tau drug given as a shot under the skin once a quarter. There is exactly one tau program in clinical development that fits that description, and it is Arrowhead’s ARO-MAPT. Diranersen cannot be that drug, because a spinal tap does not happen at home. Every anti-tau antibody that might have been that drug has already failed. The regimen an ordinary neurologist can prescribe and an ordinary patient can live with for years is amyloid by autoinjector plus tau by subcutaneous injection, and Arrowhead owns the only candidate for the second half of it.

Readers of my first paper, The Needle Wins, will recognize the argument, because this is that argument arriving in a new disease. The thesis there was that the auto-injector had already normalized self-administration for tens of millions of people, and that any therapy which could migrate into that format would capture a market that clinic-bound competitors could not reach. Alzheimer’s crossed that line yesterday. The needle wins in neurology too, and the drug positioned to benefit most from it is not the one that just won the tau argument.

Be honest about the caveats. No one has run the combination trial, so the benefit is a hypothesis rather than a result, the costs of stacking two branded biologics will meet real resistance from insurers, and the safety of combining them has to be established rather than assumed. ARO-MAPT has also not yet shown a single human data point. Grant all of that, and the strategic point still stands. The moment the field decides the future is combination therapy, the drug that can be given as a simple shot is not merely the more pleasant option. It is the only version of the future that actually works, and Arrowhead is the only company holding a tau asset built for it.

The finding nobody else will write about

The strangest result in the trial is the one most likely to be glossed over. The lowest dose worked best. Diranersen was tested at three dose levels, and the smallest one, given twice a year, beat both of the bigger ones on essentially every measure of patient benefit. That is why the study technically failed its main goal, which was to show that more drug produces more benefit. More drug did not.

The full data sharpens this into something stronger than the topline allowed. More drug did not merely fail to help. More drug did more of everything except help. The highest dose lowered tau the furthest in the spinal fluid, drove tau down the furthest on brain scans, produced the most treatment-related side effects, produced the most serious ones, and delivered the worst clinical result of the three. The lowest dose lowered tau the least of the three and helped the most. That is not a flat dose-response curve. That is an inverted one, running through both benefit and harm at the same time.

Figure 2: Harm scaled with dose. Benefit ran the other way.

Treatment-emergent adverse events assessed by the investigator as related to study treatment, by randomized arm, from Biogen’s CELIA safety table (data cut 11 March 2026). Treatment-related adverse events rose at every step of the dose ladder. Serious treatment-related events rose from zero on placebo to 10.3 percent at the top dose, with a small non-monotonic dip at the middle dose. Clinical benefit ran the other way: the 60 mg every-24-weeks arm produced the largest slowing of decline on CDR-SB, and Biogen reports a lower effect size at the higher dose levels. Source: Biogen AAIC 2026 investor presentation, July 14, 2026.

There are two ways to read that, and the whole tau field turns on which one is true.

The first reading is biological. Tau is not purely a villain. Healthy brain cells use it for ordinary jobs, so stripping out too much of it may carry a cost of its own, and the curve turns down because the target itself has a floor. If that is right, the ceiling belongs to tau, and it applies to every drug that lowers tau, including Arrowhead’s.

The second reading is the needle. Harm rose monotonically with intrathecal exposure in Biogen’s own safety table, from zero treatment-related serious events on placebo to 10.3 percent at the top dose, with confusion specifically growing more common at higher doses. A drug that is helping a patient and injuring him at the same time will show exactly this curve, and the injury here is concentrated in events that trace to the route and to the peak concentrations a bolus into the spinal canal creates. If that is right, the ceiling belongs to the delivery, not to the target, and a route that reaches the brain gently and evenly does not inherit it.

Today’s data cannot separate those two readings, and any analyst who tells you otherwise is selling something. What it does establish is that the ceiling is real, that it arrived well below the doses Biogen tested, and that at least part of it is attributable to the way the drug gets in. Both readings converge on the same commercial conclusion. The winning technology in tau is not the one that hits hardest. It is the one that can hold a steady, moderate, precisely controlled reduction without paying an escalating toxicity toll to get there, which happens to be a description of what a quarterly injection under the skin is built to do.

The read-through to ARO-MAPT

The data landed on the most favorable branch available, and it landed on two of them at once. The mechanism worked and the route hurt.

Start with the mechanism. Deep tau knockdown produced a real cognitive signal, which validates tau as a target and, with it, the premise beneath Arrowhead’s ARO-MAPT. Someone else spent the capital to de-risk the target. Arrowhead inherits the benefit. The competitive question now narrows to delivery burden, and that is precisely where a subcutaneous injection has an obvious advantage over a repeat spinal tap.

Then the route. The winning regimen, 60 mg every six months, means two lumbar punctures a year, for life. Two of the three most common adverse events in the trial are the puncture itself, and the third is the concentration spike the puncture delivers. Every one of them is an argument for changing the route rather than changing the drug. The subcutaneous case no longer needs to be argued in the abstract. It is written into Biogen’s own safety table.

Steelman the other side, because there is a real counterargument and it appeared in this deck. Ninety-four percent of the patients who finished the study chose to continue into the extension, which means they signed up for years of further spinal taps. Patients tolerate the needle better than the delivery thesis assumes. Two honest responses. Clinical trial volunteers are the most motivated patients in the disease and are not the population that decides whether a drug reaches millions of people. Twice-yearly dosing is also genuinely less frequent than a quarterly subcutaneous injection, so the argument for a shot under the skin cannot rest on how often, only on what kind and where. The case is invasiveness and setting, not arithmetic, and it should be argued on those terms.

Where the route stops being a preference and becomes the whole game

Alzheimer’s is the largest tau market. It is not the market where delivery decides the winner, because in Alzheimer’s the two routes cover roughly the same ground. Tau pathology in Alzheimer’s begins in the entorhinal cortex and hippocampus and spreads through the association cortices, and those structures sit reasonably close to the fluid spaces that a spinal injection can reach. Diranersen’s 50 to 65 percent reduction in spinal fluid tau is evidence that intrathecal delivery gets to the places Alzheimer’s lives.

Now consider what today’s result opens up. CELIA validated tau lowering as a mechanism, not as an Alzheimer’s drug. The same mechanism points at a set of rarer diseases where tau is not one of two proteins but the only one: progressive supranuclear palsy, corticobasal degeneration, and the inherited frontotemporal dementias caused by mutations in the tau gene itself. None of them has an approved disease-modifying therapy. All of them are now more investable than they were yesterday, because the target has been reached and lowered in a human brain with a cognitive signal attached.

These are also the diseases that live in exactly the wrong part of the brain for a needle in the spine. Progressive supranuclear palsy is a disease of the subthalamic nucleus, the substantia nigra, the red nucleus, and the brainstem nuclei, including the structure whose degeneration produces the vertical gaze palsy that defines the illness. A drug injected into the lumbar spine travels up the fluid column and diffuses inward from the brain’s outer surfaces, so the structures nearest the fluid see the most drug and the structures buried deepest see the least. That gradient is a property of the route, not of the molecule, and no amount of chemistry improvement repeals it.

Look at what Biogen has published from its own animal work, and then at what it has not. Its intrathecal tau drug produced 77 percent knockdown in the frontal cortex and 74 percent in the hippocampus, which are precisely the structures the spinal fluid bathes most easily, and those are strong numbers. There is no published figure for the substantia nigra, and none for the brainstem. A program this far advanced, in a field this competitive, does not leave favorable data unpublished. The silence is the gradient. Arrowhead’s drug travels through the bloodstream instead, using a receptor expressed on the lining of brain blood vessels everywhere. Across 14 brain regions in primates, drug accumulation ran from 0.47 micrograms per gram in the substantia nigra to 1.55 in the motor cortex, a spread of roughly threefold, with the lowest region still above the threshold that produces knockdown. Arrowhead’s own slide put it plainly: the distribution overcomes the intrathecal limitation in deep brain delivery.

Hold the caveat firmly. That is a monkey, not a person, and the human distribution data does not exist yet in any program. Grant the caveat and the strategic shape is still unmistakable. In Alzheimer’s, the route is a commercial advantage. In the rare tauopathies, the route is the difference between a drug that reaches the disease and one that does not, and those are the indications with no competition, orphan pricing, and an accelerated regulatory path.

One more thing the route argument gains today. Arrowhead is not the only company that concluded the failures in tau were about getting there rather than about tau. Denali’s DNL628 uses the same class of receptor-mediated brain transport, delivered intravenously, with its first patient data expected in the first half of 2027. A third serious player betting on brain-crossing tau knockdown is corroboration of the thesis rather than a threat to it, and on the current timelines Arrowhead reads out first and is alone in the subcutaneous lane.

The number to grade the autumn on

The most useful thing to take from today is a bar, and it is now a precise one. Diranersen lowered total tau in the spinal fluid by 50 to 65 percent across the dose arms, and the arm that produced the clinical benefit sat at the shallow end of that range. Arrowhead’s management has said it is looking for a comparable reduction in its own healthy-volunteer study as the mark of success. The autumn readout now has a number rather than a mood, and the number is roughly half.

Arrowhead’s animal data already sits there. In primates, ARO-MAPT produced roughly 50 to 60 percent reductions in tau in the spinal fluid, holding for up to four months after the last dose, and its modeling projects sustained knockdown of 50 to 70 percent on quarterly dosing. My own translation framework, published before today, was more conservative than the company’s: 40 to 55 percent in humans at an optimal loading dose, with anything above 55 percent exceptional and anything below 30 percent a translation failure. That conservatism used to be a concession. Today it is a fit. Since the arm that produced the benefit sat at the shallow end of the band, a 40 to 55 percent human result for ARO-MAPT is not a disappointing near-miss of the benchmark. It lands in the range that worked.

Be clear-eyed about the flip side, because this is the real risk and it is quantitative rather than binary. The advantage of a shot under the skin only counts if the knockdown lands in the right range. Convenience does not rescue a weaker drug. If ARO-MAPT reaches the brain but silences only a fraction of what a spinal injection achieves, the delivery win is real and the commercial case is not. What today changed is the shape of the target. Arrowhead no longer has to beat diranersen on depth of knockdown, because depth of knockdown is not what won this trial. It has to land in the band, hold it steadily, and then win on everything else.

Set expectations correctly on what the autumn actually delivers. The readout coming in late September or October is the healthy-volunteer portion of the Phase 1/2a study. It answers whether a subcutaneous injection crosses into the human brain and lowers tau, and how much. It does not answer whether patients decline more slowly, because it does not enroll patients. Alzheimer’s patient data comes later, in 2027. Anyone expecting a cognitive result this autumn is going to be disappointed by a study that was never designed to produce one, and anyone who understands what is actually being tested will recognize it as the only question that has ever mattered for this program.

One practical note on timing

Expect the readthrough to be a slow burn rather than a same-day move. Arrowhead has its own topline coming in severe hypertriglyceridemia, the SHASTA readout, and that is the nearer and louder catalyst. JPMorgan made the point plainly: full credit for the tau work may only be realized on the back of that cardiometabolic topline. A tape focused on one readout does not price a second one that belongs to a competitor. The derisking today is real, and it will still be real in the autumn, when Arrowhead’s own brain data arrives and the market finally has to price it directly.

The gambit

Chess has a word for what Biogen just did. A gambit is a deliberate sacrifice, material given up on purpose to gain position. The player who offers it accepts a visible, immediate loss in exchange for something harder to see on the board: open lines, freer pieces, a position that pays out later.

Biogen sacrificed the endpoint. It gave up the clean win, a met primary and an unambiguous headline, and what it purchased with that loss was position for the entire field. Tau is now a target that has been reached, engaged, and lowered in the human brain, with a cognitive signal attached that matches the approved amyloid antibody. That knowledge did not exist in a randomized trial before today, and Biogen paid for it with a missed primary, an invasive route, and a dose curve that turned out to argue against its own higher doses.

Look closely at what Biogen is now proposing to do with the position. Its final slide says the data supports moving diranersen into registrational studies. Its next-steps slide commits to nothing firmer than continued engagement with regulators on Phase 3 planning, with no start date and, tellingly, no declared dose. The company intends to take the lowest dose, from the smallest arm, in a trial that failed the prespecified test of whether dose matters at all, into a program that will cost it hundreds of millions of dollars. That is the second half of the gambit, and it is the half that has not been paid for yet.

Here is the thing about a gambit, though. The player who sacrifices is not always the player who collects. A gambit opens a line, and whoever has a piece already trained on that line is the one who benefits from it. Biogen opened the tau file with a drug that has to go into the spine. Arrowhead is aiming down the same line with a shot under the skin, and it did not pay a dollar for the position it just inherited.

What it means

Today was a delivery win dressed up as an argument about tau. A drug reached the human brain, found its target, and cleared out tau, which is what this field has been chasing for a decade. Whether tau is the right thing to chase is a separate question, still open, and it will be settled in years of late-stage trials, not in a conference room in London.

The lesson for a platform investor is the one I keep returning to. Bet on the road, not on the destination. Targets fail, and they fail often. A validated way into the brain does not, and it can be pointed at the next target, and the one after that. Arrowhead’s own first human brain readout arrives later this year, and it should be judged on exactly the terms this note has laid out: can it get there, how much drug it takes, and how precisely the knockdown can be controlled. Whether it cures anything is a question for a different year.

Biogen made the sacrifice. The position is open. Watch who plays into it.

Subscribe now

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Note Arwr Diranersens Gambit 07142026

310KB ∙ PDF file

Download

Download

The hottest worry in biotech right now is China. Chinese drug companies are rising fast, copying proven Western medicines cheaper and quicker, and selling them to big pharma. A reader asked me a fair question: does this hurt Arrowhead? The honest answer is not a simple no. China is real, it has reached Arrowhead’s field, and it does threaten part of the business. What it cannot touch is the part that actually matters, and this note explains where that line is, in plain terms.

First, take the threat seriously

Any answer that just brushes China off is worthless, so let me give the threat its due. Chinese drug companies signed a record $137.7 billion of licensing deals in 2025, and 2026 is on pace to beat it. Chinese medicines now make up about half of all the big licensing deals in the world. The reason is simple: Western drug giants have huge products losing patent protection, and they can fill the gap by buying Chinese drugs for a fraction of what it costs to buy a Western company. This has already reached Arrowhead’s corner of medicine. Earlier this year, a U.S. company, Madrigal, signed a deal worth up to $4.4 billion with a Chinese firm called Ribo for liver-disease drugs of the same type Arrowhead makes.

These Chinese companies are not amateurs, either. Ribo has raised about $250 million and even runs a lab in Sweden. Another, Sirnaomics, has been at this since 2007. A third, Argo, was started by a scientist who used to work at Arrowhead. The skill is real, then, and some of it has walked right out of Arrowhead’s own door. Any honest look starts by admitting that.

What China can copy, and what it can’t

Here is the key idea, and it is simpler than it sounds. Think of one of these drugs as a package that has to be delivered to a specific address in the body. The medicine itself is the package. The organ it needs to reach, the liver, the muscle, the lung, the brain, is the address. The hard part was never making the package. It was always the delivery.

Delivering to the liver is like dropping a package at a house on a busy main road. Everybody knows how to get there, the route is published, and it is no longer a secret. That is why the liver drugs, the ones for cholesterol and triglycerides, are the copyable part. China is strong at exactly this kind of copying, so over time cheaper Chinese look-alikes can chip away at prices in that area, and that touches a slice of Arrowhead’s income. That much is fair to admit, and admitting it is what makes the rest believable.

The real edge is delivery, and it grows the farther from the liver you go

Beyond the liver, everything changes. Getting a drug into muscle, lung, or brain is not a matter of copying a known route. It is a hard problem that takes years of trial and error to solve, and this is where Arrowhead is ahead. By its own count, and it is a fair one, Arrowhead has spent more than a decade learning to make these drugs potent, long-lasting, and safe, and it now has drugs in human testing across seven different parts of the body. Reaching one hard organ is impressive. Reaching seven is a different league.

Figure 1: The farther from the liver, the fewer competitors

How crowded each part of the body is with companies testing this kind of drug. The liver is crowded and easy to copy, and it empties out as you move away from it. No one has followed Arrowhead into the brain yet. Numbers are a rough illustration; Arrowhead reports drugs in testing across seven parts of the body.

Be fair about what this edge is, though. It is a head start, not a locked door. The leading Chinese companies already have their own delivery methods and are working on organs beyond the liver, and talent moves around, as the ex-Arrowhead scientist at Argo shows. The honest claim, then, is not that no one can ever follow. It is that Arrowhead is years ahead, and the further you get from the liver, the wider that lead becomes.

The brain is where the lead is widest

At the far end sits the brain, and here Arrowhead’s lead is not just wide, no one has reached it the easy way at all. Every RNAi drug ever approved works only in the liver, Arrowhead’s own approved drug included. Getting this kind of medicine past the brain’s natural wall, with a simple shot rather than surgery or a spinal tap, has never been done in people by anyone, Western or Chinese. The Chinese brain work that exists is early lab research in animals, not a real human program. Arrowhead’s brain drug, ARO-MAPT, is on track to be the first to show it can switch off a target gene in the human brain, with early results expected in 2026. Say that plainly: it has not happened yet. That readout is the hinge the whole brain case turns on. If it confirms Arrowhead can reach the brain, being first is not a slogan, it is the whole advantage, because a proven way in works for every drug that follows. If it disappoints, the brain lead is a promise, not a fact. Whether this one drug then goes on to beat the disease is a further question, harder and years away.

Why being first in the brain matters so much

Suppose the readout lands. Being first is often overrated, but in the brain it is unusually powerful, and it snowballs. Here is why it is different from being first with a liver drug.

Figure 2: The head start that keeps growing

Why a rival lands years behind. It has to crack brain delivery first, the very thing that has stalled the field for years, before it can even begin the long testing process. The timeline is a rough illustration; the order is not.

The delivery problem comes before the clock even starts. A competitor cannot begin the long years of brain-disease trials until it has first figured out how to get the drug into the brain, which is the very thing that has stalled the whole field for a decade. A rival is therefore not one step behind Arrowhead. It is a whole delivery breakthrough plus a full round of trials behind, and brain trials are among the longest in medicine. The head start is measured in years before anyone else even reaches the starting line.

The lead also feeds on itself. By going first, Arrowhead grabs the best targets: it already has drugs aimed at the proteins behind Alzheimer’s, Parkinson’s, and Huntington’s. Being first attracts the big partners who pay to fund the next round, Novartis has already committed up to $2 billion for the brain platform, and that money buys the next drugs, which produce the data that lands the next partner. The first approved brain drug also becomes the standard everyone else is measured against. Each of these advantages makes the next one bigger. That is why a company that reaches the brain first is far harder to catch than one that is merely first in a crowded liver market.

Then comes the part that outlasts all of it. Once a brain drug is actually being prescribed, it digs in. Brain specialists are a small, careful world, and doctors who have learned one treatment, watched it work, and grown comfortable with its quirks do not switch on a whim. Treatment guidelines get written around the drug that got there first. Insurers put it in the preferred slot and make every latecomer fight for coverage. Patients doing well on a long-term medicine are rarely moved off it. A rival showing up years later with a slightly better drug still has to pry all of that loose, one doctor and one insurer at a time. Being first also makes the next drug easier: every brain program teaches Arrowhead something about delivery it can reuse, so its tenth brain drug costs less and moves faster than its first, while a competitor is still struggling through its first.

The patents are hard to get around

There is a legal layer on top of all this, and being first shapes it too. A patent can only protect something new, something no one has done before. In a crowded field, where a lot of similar work already exists, a company can patent only narrow slivers, because everything else is already taken. In a brand-new field, where almost nothing came before, the first company in can patent broadly. Arrowhead is first into the brain, so there is very little earlier work to box in its claims, which means its patents can cover wide ground. It also runs its own in-house patent team, building that protection from the start.

This matters most where the money is. A rival that wanted to sell a copycat brain drug in the United States, the market that counts, would not just have to match the science. It would have to invent a completely different route around a wide wall of Arrowhead patents. Patents are not a magic shield, and a determined competitor can sometimes design around them. Doing so is slow and expensive, though, and it often leaves the copycat a step behind with a weaker drug, while Arrowhead keeps pulling further ahead.

Why China’s rise actually helps Arrowhead

Put the two halves together and something surprising happens. If the brain bet pays off, China’s rise raises Arrowhead’s value instead of lowering it. When everything that can be copied gets copied and turns cheap, the one thing that cannot be copied becomes rarer, and rare is exactly what makes something valuable. This also sharpens the buyout case rather than weakening it. A big drug company can now buy a cheap liver drug from China, which means the reason to buy Arrowhead was never its liver drugs in the first place. It is the delivery skill and the head start in the brain, and those are the two things no amount of money can buy from China. The proof is already on the table, and it is stronger than it first looks. Novartis already owns a liver drug of exactly this kind, called Leqvio, so it had no need of Arrowhead for the liver at all. It still paid Arrowhead $200 million up front and promised up to $2 billion, every dollar of it for the brain platform. Buyers have already shown which part they will pay up for.

What could go wrong

It is only fair to say how this could be wrong. The largest risk is the most basic one: the brain lead is not proven yet. Everything in the brain half of this note rests on the 2026 readout showing that Arrowhead can actually reach the brain. If that result disappoints, there is no first-mover position to defend and the brain advantage does not exist. Even if the delivery works, whether lowering the target treats the disease is a separate and harder question that will take years. The other risks are about how long the lead lasts rather than whether it starts: China is pouring money into reaching organs beyond the liver and learning fast, helped by talent that keeps moving, so the years-ahead lead could shrink quicker than expected, and the copycat pressure on the liver drugs could prove bigger than the modest hit described here. None of these turns the easy-to-copy drugs into the crown jewel. The honest posture is simple: the liver headwind is real and here now, and the brain prize is real but still unproven.

The move no one can copy

Chess has a useful idea here. Every serious player memorizes the openings, the published moves that begin a game. They are free for anyone to study and copy, move for move, which is exactly what the copycats do best. The real edge shows up later, in positions the book has never seen, where the memorized moves run out and only the player who arrived first knows what to do. The liver is the opening. Everyone has it by heart. The brain is a position with no book at all, and Arrowhead is about to make the first move into it.

Here, then, is the whole paper in a breath. China can copy the drug. It cannot copy the move no one has played yet, and the first move into the brain is the one that wins the game. The more the world fills with cheap copies of the openings, the more valuable the one player becomes who is writing a book everyone else will have to study. That player is Arrowhead, and it is the one thing a cornered buyer cannot buy from China at any price.

Subscribe now

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Note Arwr What China Cant Copy 07132026

253KB ∙ PDF file

Download

Download

This note translates the game theory trilogy into plain numbers. The Forced Move series argues that three large drugmakers, Novartis, Lilly, and Roche, may each be pushed toward acquiring Arrowhead, not because they want to, but because the cost of letting a rival buy it first can be worse than the cost of buying it themselves. That is what a forced move means in chess: a move you make because every alternative is worse. This note shows how that idea looks once you attach real numbers to it, and how those numbers are built.

A quick word on the patent cliff

Every large drugmaker lives in fear of the patent cliff. A drug is protected by patents for a set number of years. When that protection ends, cheaper copies, generics for ordinary pills and biosimilars for the more complex biologic drugs, flood in, and the original medicine can lose most of its sales within a year or two. A company with a big drug going off patent has a revenue hole to fill, and filling it is urgent.

The three companies in this story face that cliff on very different clocks. Figure 1 shows the cumulative sales each one is set to lose to expiring patents over the next ten years.

Figure 1: The patent cliff arrives on three different clocks

Cumulative branded revenue each company is projected to lose to patent expiry, 2026 through 2035. Modeled from public sales and known expiry dates.

Novartis is bleeding now. Its heart-failure blockbuster Entresto, which sold roughly $7.7 billion in 2024, began losing United States protection in 2025, and the company has called 2026 its largest patent-expiry year ever. Roche faces a slower wave that builds mid-decade, led by its multiple-sclerosis drug Ocrevus losing protection around 2028 and 2029. Lilly barely bends, because its giant obesity and diabetes franchise, Mounjaro and Zepbound, is protected into the late 2030s, so its near-term hole is small.

The shape of those three lines is the first half of the story. Novartis needs a replacement engine today. Roche needs one soon. Lilly can afford to wait.

The one idea that changes everything

Arrowhead is attractive to all three because its platform works like a factory for new medicines, which is exactly what a company with a revenue hole needs. That much is ordinary. The idea that turns this into a forced move is less obvious, and it is the heart of the argument.

Most people weigh an acquisition as buy versus do not buy, where not buying simply saves the purchase price. That framing is wrong here. The real choice is buy it yourself versus let a rival buy it. Letting a rival win is not free. You still face your own patent cliff with no new engine to fill it, and now a competitor owns a platform it can turn against your business. Inaction carries a price tag, and once you see that, the math tips.

The payoff grid

Figure 2 puts that logic onto a single grid.

Figure 2: The three-way payoff grid

Net present value to each company (columns) under each possible winner (rows), in billions of dollars, at an assumed $120 billion acquisition price. Green is a gain from winning; red is a loss when a rival wins. Modeled base case.

Each row is one possible outcome, the company that wins Arrowhead. Each column is the result for one company. Every square then answers a single question: if the company on the left wins, what happens to the company named at the top?

The green squares run down the diagonal, where a company wins the auction itself, and those are gains. Every red square is an outcome where a rival wins instead, and those are losses. Here is the punchline. Pick any single column and read down it. You will find one green square and two red ones. No company has a comfortable do-nothing option, because if it stays out, one of the other two wins and it takes a loss. The only good outcome is the one you have to pay for. That is the forced move.

A few specifics are worth seeing. Novartis has the most to gain by winning, because its cliff is the most urgent. Roche faces the steepest single loss on the board, the $45 billion it would suffer if Novartis wins, because Arrowhead’s brain-delivery work sits right next to Roche’s own brain franchise, so a Novartis-owned Arrowhead would be a direct threat. Lilly’s squares are the smallest in both directions, because it is the least cornered.

Where the numbers come from

None of these figures are facts pulled from a filing. They are estimates, built from a few simple rules, and it is worth knowing exactly how, so you can judge them for yourself.

Start with the price. The base grid assumes a sale clears at about $120 billion, which sits in the middle of a realistic range for an asset like this.

Next comes the value of owning Arrowhead, which differs by buyer. It starts from a common baseline, the standalone worth of the platform and pipeline, built from the parts in the next section at about $90 billion, then adds an amount unique to each buyer for the synergies and cliff-filling it gains. Subtract the price from that total, and the result is the green diagonal number, the net gain of winning.

Then come the losses, and here a tempting mistake was avoided. It is natural to think a company that loses Arrowhead loses two things: the cliff-filling it misses and the competitive damage of a rival holding the platform. Counting both is wrong. Your patent cliff is unfilled whether Arrowhead stays independent or a rival buys it, so you never actually had that cliff-filling to lose; it belongs entirely to the gain from winning. The only genuine loss from a rival winning is the extra competitive damage that rival does with the platform, over and above the competition an independent Arrowhead already poses, so that is the single thing the red squares count. This keeps the same pipeline from being counted twice, once as a gain and once again as a loss.

What the platform is worth on its own

That $90 billion baseline is not a number borrowed from thin air, and it is worth building from the parts. Figure 3 does that.

Figure 3: Building the $90 billion standalone value

A modeled sum of the parts. The tangible floor rests on named programs and signed contracts; the platform option value is the contested estimate. Risk-adjusted and illustrative.

The tangible floor comes first. Arrowhead’s wholly-owned pipeline, led by the approved triglyceride-lowering drug plozasiran and its much larger late-stage program, alongside the obesity, tau, and complement candidates, carries the most identifiable value, on the order of $43 billion on a risk-adjusted basis. Its partnership streams, the milestones and royalties owed by Sarepta, Amgen, GSK, Novartis, and others, together with net cash, add roughly $12 billion. Those pieces give a tangible floor near $55 billion, the part grounded in named assets and signed contracts.

The platform option value is the rest, about $35 billion, and it is the real bet. This is the worth of the delivery engine itself, its proven ability to reach the liver, lung, muscle, fat, kidney, and now the brain, and to keep generating new programs not yet named. It is the hardest piece to pin down and the easiest to argue over, which is why Figure 3 shows it separately. Value the engine conservatively and the standalone value sits near $90 billion; value it the way a true believer in the platform would, and it climbs well past that.

Two things follow. The $90 billion baseline used throughout this note is a deliberately conservative reading, a solid tangible floor plus a restrained platform value, sitting at the low end of the wider sale range. The single largest source of disagreement about what Arrowhead is worth is therefore not the pipeline, which is fairly concrete, but how much credit to give the engine that keeps building it.

What the precedents say

Modeled numbers feel less abstract when set against real deals, and three precedents are worth knowing. In 2019, Novartis bought The Medicines Company for $9.7 billion, a premium of about 41 percent over the prior month’s average price, to acquire a single siRNA drug, inclisiran, which became its cholesterol medicine Leqvio. That deal put nearly $10 billion behind one asset, from the very company at the center of this analysis. Arrowhead is not one asset; it is a platform with roughly a dozen programs across the body, including the brain.

Two larger deals fill in the picture. In 2021, Novo Nordisk paid $3.3 billion for Dicerna, another RNAi company. In 2023, Pfizer paid $43 billion for Seagen to own an antibody-drug-conjugate platform, financing most of it with about $31 billion of new debt. Large platform deals happen, they clear regulators, and acquirers take on serious debt to do them.

Two lessons carry over. Biotech takeovers routinely price at premiums of 40 percent to 100 percent or more over the trading price, so a wide gap between Arrowhead’s roughly $12 billion market value and a strategic price is the norm, not a stretch. A buyer with an urgent need also pays up, as Novartis did with a double-digit premium for one cardiovascular siRNA when it wanted to anchor that franchise. The platform logic that justified $9.7 billion for inclisiran applies with far more force to an entire delivery engine.

How high would each company bid?

There is a clean way to put a floor and a ceiling on what each company should rationally pay, with the real bid landing somewhere between the two.

The floor is the denial value, the competitive damage a company avoids purely by keeping the most threatening rival from winning. A company should be willing to commit at least this much for defense alone, before counting a single dollar of owning the asset, because preventing that particular rival is worth exactly that avoided loss. For Novartis, letting Roche win would cost about $30 billion, so $30 billion is its floor. For Roche, letting Novartis win would cost about $45 billion, the steepest figure on the board, because a Novartis-owned Arrowhead would aim the brain-delivery platform straight at Roche. For Lilly, letting Novartis win would cost about $20 billion.

The ceiling sits far higher. The most a company should pay is that same denial value plus the full value of owning Arrowhead in its own hands. That works out to roughly $200 billion for Novartis, $205 billion for Roche, and $160 billion for Lilly. Every one of those ceilings towers over any realistic clearing price, which is precisely why a contested auction would run hot.

Put plainly: the floor is the loss avoided, the ceiling is that loss avoided plus the gain from owning, and the rational bid lives in the band between them, pushed upward by how hard the other two press. Folding the gain into the floor would be a mistake, because it would collapse the floor and the ceiling into one number and erase the band entirely.

One subtlety is worth getting right: the ceiling has two layers. The bottom layer is the plain value of owning Arrowhead, and it holds whether or not anyone else bids, because even an independent Arrowhead competes with these three in lipids, in metabolic disease, and in complement, and could partner with any of their rivals at any time. Owning it neutralizes that competitor either way, so part of the ceiling has nothing to do with a bidding war.

The top layer is the rival-control premium, the $30 billion for Novartis or the $45 billion for Roche, the extra harm of a specific, deep-pocketed rival seizing the platform and aiming it at you. That premium exists only while a live rival is actually bidding, and it falls away the moment the rival steps back. The forced move is sharpest in that top layer, yet the layer beneath still gives each company a standing reason to want Arrowhead off the board.

Notice that Roche carries both the highest floor and the highest ceiling, even though its patent cliff is less urgent than Novartis’s. What drives Roche is not its own revenue hole but the prospect of a rival seizing the brain platform, which makes its case a matter of defense rather than need.

Arrowhead’s walk-away: the $90 billion floor

Every walk-away price so far has belonged to a buyer. Arrowhead has one of its own, and it anchors the entire deal. A seller’s walk-away is the value of its best alternative to selling, which for Arrowhead is simply continuing to operate independently. That value is the standalone worth built in Figure 3, about $90 billion. It is the price below which Arrowhead should refuse any offer and stay independent, because below it shareholders are better off keeping the company than selling it. That single number is the floor under everything.

This floor is not a negotiating pose; it has real force. A public-company board owes its shareholders a duty, and accepting a bid beneath the company’s own standalone value would hand shareholders less than they already hold by doing nothing. No board can defend that, and few would survive trying. That makes $90 billion a line with teeth, not a wish.

What makes the floor robust is what sits inside it. The $90 billion is not a snapshot of today’s revenue; it already includes roughly $35 billion of platform option value, the future programs the delivery engine will keep producing. Staying independent means keeping all of that upside for existing shareholders. A buyer must therefore pay at least $90 billion simply to match what Arrowhead’s owners already possess by doing nothing at all. Anything less asks them to sell the future at a discount, and they should not.

Arrowhead also feels none of the pressure its suitors feel, and that is the heart of the matter. It is not a distressed seller. It has an approved drug generating revenue, a deep partnered pipeline throwing off milestones, and the runway to keep building. The whole thesis of this series is that the buyers are cornered by their patent cliffs; the seller is cornered by nothing. A party under a clock negotiating against a party with no clock does not set the price low. That asymmetry is precisely what lets Arrowhead hold its floor and push the final number up toward the buyers’ ceilings rather than down toward its own.

The floor is not even static. A successful first readout from the brain program would lift the platform’s standalone value, and with it the price below which Arrowhead refuses to sell. Time and data work for the seller. The same event that tightens the screws on the buyers raises Arrowhead’s walk-away, which is itself a reason a confident board would wait rather than take an early offer.

Put both sides on the table and the deal space is clear. Arrowhead should not sell below roughly $90 billion, while every buyer ceiling, the $160 to $205 billion figures from the bidding section, sits far above that floor. The zone of a possible deal is therefore wide, and with three motivated buyers competing inside it, the clearing price is pushed up through that zone rather than down to its floor. The realistic $90 to $150 billion sale range is simply where a rising seller floor and a contested set of buyer ceilings are most likely to meet. The $90 billion anchors the bottom of that range for one reason: it is the least Arrowhead should ever accept to give up its independence.

What changes if the price changes?

A fair question is how sensitive all of this is to the price. Figure 4 redraws the grid across the realistic sale range, at $150 billion, $120 billion, and $90 billion. Watch what moves and what holds still.

Figure 4: The grid across the realistic sale range

The payoff grid recalculated at $150 billion, $120 billion, and $90 billion. The red losses are identical across all three; only the green gains change as the price moves.

The red squares never change. The damage a rival does by owning the platform has nothing to do with what was paid for it, so the cost of losing is identical across all three panels. Only the green gains move, and watching them move across the range is instructive.

At $90 billion, the low end, every buyer wins handsomely: Novartis nets $80 billion, Roche $70 billion, even Lilly $50 billion. At $120 billion the gains shrink but stay clearly positive for all three. At $150 billion, the top of the range, something telling happens. Lilly’s own square turns red, because $150 billion now exceeds what Arrowhead is worth in Lilly’s hands. The instinct is to say Lilly should walk away, and the instinct is wrong. An overpriced win at $150 billion costs Lilly about $10 billion, while letting Novartis take the asset instead costs it $20 billion, so Lilly keeps bidding rather than accept the worse outcome. That red square is the winner’s curse made visible: a forced move can push a buyer past the point where winning makes sense on its own, purely because losing is worse.

That dynamic decides how an auction would actually end. As the price climbs past the top of the realistic range, the weakest-fit buyer drops out first, Lilly at its $160 billion ceiling, leaving the two most motivated, Novartis and Roche, to set the final price. The grid shows the outcome at each fixed price; how high each would actually go is the separate question answered by the floors and ceilings above.

Why not build, license, or buy someone else?

A fair challenge runs through all of this: if these companies need RNAi and brain delivery, why must they buy Arrowhead? They could build the capability themselves, license a single program, or buy a different company. The honest answer is that each alternative is weaker, and seeing why strengthens the case.

Building takes time the cornered companies do not have. Delivering RNA into tissues beyond the liver, and especially into the brain, has taken Arrowhead more than a decade of chemistry. A Novartis staring at its cliff in 2026 cannot wait out a ten-year internal program.

Licensing one program solves one problem, not the strategic one. A license gives a buyer a single drug on someone else’s terms; it does not hand over the platform, the delivery toolkit, the dozens of future programs, or the people who built them, the scientists who have solved one hard delivery problem after another, pushed RNAi into tissue after tissue beyond the liver, and engineered trigger chemistry at the leading edge of the field. A license leaves all of that, and the asset itself, on the table for a rival. The Sarepta and GSK deals with Arrowhead show that licensing happens, yet none of them removed Arrowhead as a target.

Buying a different RNAi company is the strongest objection, and the obvious candidate is Alnylam. Here the distinction matters. Alnylam is a finished franchise: profitable, with 2026 product revenue guided to roughly $4.9 to $5.3 billion, anchored by its heart drug, and valued near $42 billion before any premium. It is the better company to own outright, a mature and cash-generative business. It is the worse fit for this particular need, because its delivery is concentrated in the liver, it carries less of the brain and extrahepatic optionality a cliff-facing buyer is reaching for, and it is already entangled with two of the three buyers, since Novartis commercializes its Leqvio and Roche partners on another of its drugs. Arrowhead is the engine: broader tissue reach, a real path into the brain, a deep cardiometabolic pipeline, and far more future revenue still ahead of it. That does not make Arrowhead cheaper. Its market value is a fraction of Alnylam’s today, near $12 billion against $42 billion, yet the strategic price it would command, the $90 to $150 billion in this note, sits above what Alnylam would cost to acquire. A buyer pays more for Arrowhead precisely because it is buying the future and the breadth rather than a single mature franchise. Alnylam is the better company to own, Arrowhead the better company to acquire.

Can they actually pay, and clear the regulators?

A ceiling no one can fund or clear past regulators is not a real ceiling, so two practical checks matter. On the money, all three can write the check. Lilly, valued at over $1.1 trillion, has by far the most room. Roche is large and cash-generative across drugs and diagnostics. Novartis carries more debt, with net debt around $22 billion after recent moves, yet it has shown it will borrow for the right asset, and the Pfizer purchase of Seagen showed a buyer raising roughly $31 billion in fresh debt for a platform it wanted. A price in the range discussed here is large, yet within reach for each, especially with a mix of debt and stock.

On the regulators, the path looks clearer than for a typical mega-merger. Arrowhead’s only marketed product today is plozasiran, a therapy for a rare triglyceride disorder, and none of the three buyers sells a competing product in that small market, so a deal eliminates almost no existing competition, which is the usual antitrust trigger. The closest concern is overlap inside a single disease area, for instance Novartis already holding an RNAi cholesterol drug, and the standard remedy there is a narrow divestiture rather than a block. Pfizer cleared its Seagen deal by giving up one product’s United States royalties to satisfy the regulator. The lesson is that these deals get done, sometimes with a minor concession, rather than stopped.

How firm are these numbers

Honesty matters here. The patent-cliff figures behind Figure 1 are the most solid, drawn from public sales and known expiry dates, though they remain projections of how fast sales erode. The gains rest on two assumptions you can change: the $90 billion baseline value, whose softest piece is the platform option value broken out in Figure 3, and the price, which Figure 4 flexes across the realistic range. Both move the green numbers dollar for dollar. The competitive-damage figures in the red squares are the softest of all. Their relative size is well reasoned, with Roche losing most to a Novartis win, yet the exact dollars are estimates and should be read as approximate rather than precise. To make that concrete, the competitive-damage cells are best read with a band of roughly 30 percent either way, so Roche’s $45 billion loss to a Novartis win is better understood as a range from about $30 billion to $60 billion. One thing the model now gets right by construction: it counts each piece of value only once, never as both a gain and a loss.

What would break this thesis

Honest analysis names what would prove it wrong, and several things would. The clearest is the science. Arrowhead’s brain program, ARO-MAPT, has not yet shown that it works in people, and a clear failure at its first human readout would knock out the most valuable part of the platform and deflate the urgency for the brain-focused buyer, Roche above all.

A rival platform could leap ahead. If another company demonstrated cheaper or better delivery into the brain or other hard tissues, Arrowhead’s scarcity, the very thing that makes it worth fighting over, would erode.

The buyers could simply decline. A forced move is a claim about incentives, not a guarantee of behavior. Boards delay, balk at premiums, and sometimes choose to build despite the logic, so the thesis predicts pressure, not certainty.

Arrowhead could take itself off the table. A large financing, a transformational partnership, or a clear statement of intent to stay independent would signal that management does not mean to sell, which would defer the whole question. Watching for those signals is part of testing the thesis rather than merely asserting it.

The clock: when the move gets forced

A forced move needs a trigger, and the triggers are dated. Figure 5 lines them up.

Figure 5: Two clocks running at once

The cliff clock below the line and Arrowhead’s proof points above it. The shaded window is where a revenue hole and a platform proof point overlap.

Two clocks run at the same time. The cliff clock is already ticking for Novartis, whose largest expiries land in 2026, and it builds toward Roche as Ocrevus rolls off around 2028 and 2029. Arrowhead’s side runs hot in the very same window: the sHTG Phase 3 data land in 2026 and a plozasiran sHTG approval could follow in 2027, while the first human readout from the brain program, the event most likely to convert the platform from promise into proof, is also expected in late 2026. That readout is a gate, not a footnote: it opens a substantial CNS pipeline expansion that Arrowhead has slated to begin at the end of 2026 and run through 2027, so it does not add a single proof point; it opens a portfolio. When a cluster of proof points on Arrowhead’s side meets a revenue hole on a buyer’s side, the pressure stops being theoretical. That overlap, more than any single number in this note, is what would set a forced move in motion.

What it all means

One contrast ties it all together. Arrowhead trades near $12 billion today, yet each of the three buyers could rationally justify paying somewhere between $160 and $205 billion, well over ten times that, once the cost of letting a rival win is counted. That gap, between a market price set by today’s results and a strategic price set by tomorrow’s threat, is the entire point of the Forced Move thesis. When all three would pay far more than the asset is likely to clear for, the result is not a quiet negotiation. It is a bidding war.

The grid does not promise that any deal will happen. Real acquisitions turn on personalities, regulators, balance sheets, and timing that no model captures. What it shows is why the pressure exists, why no company can comfortably sit out, and how the squeeze falls differently on each: Novartis cornered first by the timing of its cliff, Roche most threatened by a specific rival, Lilly the most able to wait. Chess players have a name for the moment when every comfortable option has quietly vanished and only one move keeps you in the game. They call it the forced move. The board is nearly set, and the clocks are running. No one at this table wants to pay $100 billion for a company the market prices at $12 billion. That, precisely, is why one of them will.

Subscribe now

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only, and is not investment advice. The figures shown are modeled estimates meant to illustrate a strategic argument, not forecasts of any specific transaction or price. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Note Arwr The Forced Move By The Numbers 07082026

408KB ∙ PDF file

Download

Download

A Clinical Evidence Analysis of Why Almost Every Step of ARO-MAPT's Journey Has Already Been Proven in a Human Being, Across the Five Drugs That Each Cleared One Link of the Chain, the Single Crossing That Remains, and the Subcutaneous Brain-Delivery Platform That a Clean Readout Would Unlock.

Why this matters

Most first-in-human brain drugs are close to a coin flip. The blood-brain barrier, the biological wall that keeps most medicines out of the brain, defeats the large majority of what is sent against it, and a first clinical readout usually carries enormous uncertainty. ARO-MAPT, Arrowhead’s first wholly owned brain program, is an unusual case, because by the time its first human data arrive in the third quarter of 2026, almost every individual step in how the drug is supposed to work has already been demonstrated in a living human being, just not all by the same molecule. This note walks through those proof points in plain language, shows them in a single picture, and then points to the one step that remains genuinely unproven, and what that means. That one step is the last mile, and the last mile is the hardest mile, short in the sequence, but the most demanding leg of the journey, and the stretch the fall readout exists to test.

The journey, in plain terms

ARO-MAPT is a gene-silencing medicine. At its heart is a tiny strand of genetic material, called an siRNA, that works like an off switch for a single gene. Here the gene it switches off is the one that makes tau, a protein that builds up in Alzheimer’s disease and other brain disorders. To do its job, the drug has to complete a short journey: get into the bloodstream from a simple injection, cross the blood-brain barrier into the brain, get inside brain cells, and switch off the tau gene, which brings tau levels down. The clever part is how it crosses the wall. The drug carries its siRNA on a molecular grip, a small antibody fragment known as a Fab, that latches onto a docking point on the surface of cells called the transferrin receptor, or TfR1, which the body uses to ferry iron into the brain. The drug hitches a ride on that same system.

The question every investor really wants answered is simple: how likely is this to work in people? The most useful way to answer it is to break the journey into steps and ask, for each one, has anyone already proven this step in a human? The answer, step by step, is the heart of the case.

Five human proofs

Five different drugs, made by five different companies, have each proven a piece of ARO-MAPT’s journey in actual human beings, with two of them clearing the single hardest step, the wall itself.

Roche’s trontinemab proved the hardest-sounding part: that the transferrin-receptor grip really can carry a large molecule across the human blood-brain barrier. In Alzheimer’s patients it crossed into the brain and rapidly cleared away the sticky plaques that mark the disease. The wall can be crossed using this exact docking system.

That proof is no longer alone. In March 2026 the FDA approved tividenofusp alfa, a Denali medicine that uses the same transferrin-receptor system to carry a working enzyme from the bloodstream across the human blood-brain barrier and into brain cells, where it does its job. It cut a brain disease marker in the spinal fluid by roughly eighty to ninety percent in patients. This matters for two reasons. It is the first medicine ever approved on the strength of crossing the blood-brain barrier by this route, so the approach is now not just demonstrated but regulator-endorsed. Unlike an antibody clearing plaques outside cells, the enzyme has to get inside brain cells and function there, a closer parallel to what a gene-silencing payload must do. Two different payloads, an antibody and an enzyme, made by two different companies, have now crossed the human blood-brain barrier through this exact system.

Avidity’s del-desiran proved the next piece: that a medicine injected into the blood, routed through the same transferrin receptor, can carry a gene-silencing payload into human cells and actually switch a gene off. It lowered its target gene by roughly forty-five percent in human muscle. The approach was convincing enough that Novartis agreed to buy Avidity for about $12 billion, largely on the strength of this platform.

Alnylam’s mivelsiran proved the piece inside the brain: that a gene-silencing medicine can get into human brain cells and shut a gene down, lowering its target in the spinal fluid by roughly seventy to eighty percent. It reaches the brain by a different route, a direct injection into the spinal fluid rather than through the bloodstream, but it settles the question of whether the silencing machinery works in human neurons. It does.

Biogen’s BIIB080 proved the destination: that lowering tau itself is achievable in people, cutting tau in the spinal fluid by up to roughly half. It uses a different silencing tool than ARO-MAPT, so it does not validate the exact mechanism, but it confirms that the target Arrowhead is aiming at is a real and reachable one.

Arrowhead’s own foundation

Underneath those five human proof points sits the most directly relevant evidence of all: Arrowhead has already run the entire ARO-MAPT journey, start to finish, in monkeys. A single injection under the skin, across the blood-brain barrier, into neurons, and deep-brain tau knockdown. The five human drugs prove the individual steps are each possible in people. Arrowhead’s own primate data prove the whole chain works when assembled into one molecule, in a living primate. The human question is whether that complete chain, demonstrated in monkeys, repeats in humans.

One more piece is worth understanding, because it gives a useful measuring stick. In its monkey studies, Arrowhead compared two ways of getting the drug to the brain: the older method of injecting it into the spinal fluid, the route drugs like BIIB080 use, and its own new method of a simple shot under the skin. The spinal route makes a good benchmark, because BIIB080 has already shown, in people, that lowering tau this way works and carries over from animals to humans. In Arrowhead’s monkeys, the under-the-skin route matched or beat that spinal route, and reached deep brain regions the spinal route could not. The new route therefore cleared, in animals, a bar that a real human drug has already set. This does not prove the new route crosses the human wall. It does show that, once the drug is inside, the silencing it produces holds up against the one tau drug already proven in people.

Humans and monkeys, side by side

The same chain, shown two ways. The left column is what has been proven in humans, step by step, by drugs already in the clinic or on the market, with one step still open. The right column is what Arrowhead has proven in monkeys with ARO-MAPT itself: every step, including the one still open in humans. The contrast is the whole thesis in a single view.

The one gap, and what it means

Look closely at the comparison above and a single honest gap appears. Every step has a human proof point except one precise junction: no one has yet shown that a medicine injected into the blood can carry a gene-silencing siRNA payload across the human blood-brain barrier and into neurons. Trontinemab carried an antibody across that wall in humans, and tividenofusp now carries an enzyme across it, approved and in patients, but neither is a gene-silencing payload. Del-desiran carried a gene-silencing payload through the blood into human cells using that same transferrin receptor, but into muscle, not across the brain’s wall. Mivelsiran silenced a gene in human brain cells, but reached them by injection into the spinal fluid, bypassing the wall entirely. The exact intersection, blood-borne delivery, across the blood-brain barrier, with an siRNA payload, has been shown in monkeys but not yet in a single human.

Notice how much narrower this gap has become. The two payloads that have already crossed the human wall, an antibody and an FDA-approved enzyme, are both far larger than an siRNA, so the carrier has proven it can haul heavier cargo than ARO-MAPT asks of it. The size of the cargo was never the problem. What remains unproven in humans is the very last part of the siRNA’s job: once across the wall and inside a brain cell, it has to slip out of the bubble that carried it in and switch the gene off. That final step has already been shown to work in people, just never in this one combination. Mivelsiran showed an siRNA can do it inside the human brain, reaching the brain by the spinal route. Del-desiran showed a blood-borne siRNA can do it through the very same transferrin receptor ARO-MAPT uses, though in muscle rather than brain. What no one has done yet is put the two together: a blood-borne siRNA, on the transferrin-receptor grip ARO-MAPT uses, doing its work across the brain’s wall. The gap is now as narrow as the human evidence can make it, one kind of cargo, at one barrier, with proof on every side of it.

There is one more piece, and for this exact step it may be the most reassuring of all. Until recently, the full journey by the new route, into the blood, across the wall, into brain cells, and the gene switched off, had been shown only by Arrowhead, in its own monkeys. That is no longer true. Independent groups have now reproduced it in monkeys, using the same transferrin-receptor system to drive gene-silencing deep into the brain: one team with an siRNA like ARO-MAPT’s, reported in a preprint, and another with a related oligonucleotide in a peer-reviewed journal. The exact route is no longer one company’s private result, though the siRNA version of it still awaits peer review.

What none of them has shown yet, Arrowhead included, is that same crossing in a human rather than a laboratory animal. These studies use animals engineered to carry the human version of the docking point, because the receptor differs from one species to the next. That is a strong stand-in for human biology, but a stand-in is what it remains, and whether the human receptor behaves in a real patient the way these animals predict is the one thing still left to settle.

It is worth knowing that Arrowhead is not the only company attempting this exact crossing. Denali, whose transferrin-receptor platform produced the approved brain-crossing enzyme described above, has its own program aimed at the same tau target, delivered from the bloodstream across the wall, and it has just entered the clinic. Newer entrants are converging on the same idea: Aerska, co-founded by a veteran of Alnylam’s early CNS siRNA delivery work, raised roughly $60 million across 2025 and 2026 to build the same kind of subcutaneous, transferrin-receptor siRNA shuttle, though its programs remain preclinical, years behind ARO-MAPT. That cuts two ways. It is validation, since serious players are convinced that reaching the brain from the bloodstream is real, and it is a reminder that the prize is contested. It does not change ARO-MAPT’s gap. It underscores that the gap is the field’s central open question, and that whoever crosses it first in humans establishes something genuinely new.

This gap matters more than its size suggests, because the blood-brain barrier is the hardest part of the whole journey, and the siRNA is the one cargo the human proof points have not yet carried across it. Within that single step, though, one half carries little doubt. The silencing that follows the crossing is the part of the process that carries over from animals to people most reliably of all, and Arrowhead’s platform has turned animal results into matching human results in the tissues it has taken into patients, so the deep monkey numbers are a fair guide to what humans would show once the drug is inside. The open question is therefore not whether the silencing works in people, but whether the drug reaches the brain to begin with. On that, the weight of evidence now leans in Arrowhead’s favor: the carrier already crosses the human wall, the silencing already carries over, and the full chain already works in monkeys, reproduced by more than one independent team. This is not a sure thing, the remaining step is genuinely the hard one and no human has yet taken it. It does mean that, for a first look at a brain drug, the odds sit better than they usually do, and on Arrowhead’s side of the line.

In the language of chess, Arrowhead has marched a pawn almost the length of the board and stands one square from promotion, the move that turns a foot soldier into a queen. A winning position, though, is not yet a win. The hardest game to win, players say, is a won one, and the conversion comes this fall.

What the readout will tell us

The first ARO-MAPT data, expected late in the third quarter of 2026, are in healthy volunteers given a single dose, and they will answer the one open question directly: did the drug cross the wall and lower tau in people, the way it did in monkeys and the way every surrounding step suggests it should.

The study is built to measure exactly that. After the injection, blood draws across the first 48 hours track the drug to confirm it reached the bloodstream and to chart how fast it peaks and clears. The brain signal comes from cerebrospinal fluid, sampled by lumbar puncture, a needle that draws fluid from the lower spine. Tau is the pharmacodynamic result everyone is watching for, the same cerebrospinal-fluid tau that fell in Arrowhead’s monkeys and that BIIB080 lowered in patients. The readout is therefore a direct measurement of the decisive step, not an indirect signal standing in for it.

That cerebrospinal fluid is sampled before dosing, for a baseline, and then at several points after, at roughly Day 75, Day 135, and Day 270. The practical meaning is worth sitting with. The first human read on tau knockdown arrives a couple of months after dosing, not on day one, and the full picture, how deep the knockdown goes and how long it lasts, is not complete until around nine months in. An early signal first, then a durability curve that fills in over the better part of a year.

One more feature of the design shapes how that signal arrives. The study is blinded: neither participants nor investigators are told who received the drug and who received the saline placebo, so the early cerebrospinal-fluid results come in as tau numbers without labels attached. Blinding hides who got what, though, not whether tau is moving. Placebo does not lower tau, so if the drug works as the monkeys predict, the data should split into two groups, a drug-sized set whose tau drops sharply from baseline and a placebo-sized set that stays flat, and that separation is itself a signal. A deep, clear knockdown would be hard to miss even before the code is broken. A weak or ambiguous one is where the blinding bites, since a small effect can hide in the noise until assignments are revealed. The clean, patient-by-patient attribution waits for that unblinding; the presence and rough size of an effect do not.

A clean result would close the last gap and turn a well-supported expectation into a proven fact. A disappointing result would say the gap was real, and that the wall, with this cargo, is harder to cross in humans than in monkeys. Either way, this is the test that matters, and it is narrow, specific, and close.

What is at stake

It is worth being clear about why a single early readout carries such weight. If ARO-MAPT crosses that last barrier in humans, the prize is not one drug. It is a proven, repeatable way into the brain. The same delivery that carries this siRNA across the wall, a simple shot under the skin, could then be aimed at one brain gene after another, which is why a clean result would validate a platform, not a product. The brain has been the hardest organ in the body to drug, walled off from exactly the gene-silencing medicines that have already proven themselves in the liver. A simple injection that reliably silences a chosen gene in the brain would turn a long list of once-unreachable targets into a pipeline. That is the real stake, and it rests on the delivery question the fall readout tests, not on any later one. The platform is validated the moment the crossing is, whether or not any single drug goes on to prove it treats a disease.

Tau itself is no small target. It sits at the center of Alzheimer’s and a family of related brain disorders driven by the same protein, an enormous unmet need and, if the biology holds, a commercial opportunity to match. That upside, though, rests on two separate questions, not one: whether the drug reaches and silences tau in people, which the fall readout tests, and whether lowering tau meaningfully changes the course of Alzheimer’s, which no one has yet proven and which years of patient data will decide. The delivery result would be a landmark on its own, and the platform it unlocks larger still. The therapeutic payoff is a further bet placed on top of both.

There is a market consequence worth naming. Arrowhead’s CNS pipeline is, for now, priced largely as option value: a promising route to the brain that no human result has yet confirmed. A clean readout would not re-rate one drug so much as the platform behind it, because proof of the crossing converts that option value into an expectation, and does so across every brain program the same delivery could carry. The size of any such move depends on what the stock already discounts, which is beyond the scope of this note. The direction, if the crossing is shown, is not hard to reason out.

The bottom line

Every step of ARO-MAPT’s journey has already been walked in a human being, just not all by the same molecule, and not yet across the one wall that matters most.

That is the whole case in a sentence. This is not a leap into the dark. It is a short step across a single, well-lit gap, onto ground that five other drugs have already proven can hold weight, with Arrowhead’s own monkeys having made the full crossing first. The science is no longer asking whether any of this can work, because each piece already does, in people. It is asking one question, and only one: can a molecule injected into the blood carry its silencing payload across the human blood-brain barrier and into a neuron? Monkeys have already said yes. This fall, humans will answer.

Subscribe now

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only, and is not investment advice. Comparisons to other companies’ drugs are illustrative of scientific precedent and do not imply equivalence of outcome. Clinical figures are drawn from public company disclosures and peer-reviewed sources. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Note Arwr The Last Mile To The Brain 06252026

264KB ∙ PDF file

Download

Download

The setup

Both Arrowhead Pharmaceuticals (ARWR) and Wave Life Sciences (WVE) are developing drugs that silence a liver gene called INHBE. Silencing INHBE lowers a hormone called Activin E, which in turn helps the body shed visceral fat, the harmful fat around organs that drives diabetes, fatty liver disease, and cardiovascular risk. Both companies are pursuing this as a new approach to obesity and metabolic disease, with twice-yearly subcutaneous dosing as the goal.

Until recently, the market viewed Wave as the clear leader in this race. That view formed on December 8, 2025, when Wave printed the first human data showing visceral fat reduction and lean muscle preservation from a single dose of its INHBE drug, WVE-007. The stock moved 147% that day. “Fat loss without muscle loss” became the headline thesis, and Wave became the consensus INHBE leader.

That consensus lasted just over three months.

On March 26, 2026, Wave released six-month follow-up data from the same patient cohort. The visceral fat number held: a 14% placebo-adjusted reduction (meaning 14% better than placebo). Lean mass was preserved. Activin E suppression was durable through seven months. But total body weight loss was just 1%. Waist circumference fell 3%. And the trial population had an average BMI of roughly 32, meaningfully leaner than the patients typically enrolled in obesity drug studies.

Wave’s stock fell nearly 50% that day, closing at $6.20. Bank of America cut its price target to $21. Wells Fargo cut to $13. The note language singled out “reduced conviction in the liver Activin E knockdown mechanism.”

Read that last sentence carefully. The market did not just punish Wave, it punished the INHBE monotherapy thesis itself.

That is the backdrop against which Arrowhead’s ARO-INHBE data, released at the EASL 2026 liver disease conference this morning, should be evaluated. The right question is no longer “who has the cleaner monotherapy headline?” The right question is the one Wave’s March miss raised: can INHBE silencing meaningfully move metabolic outcomes on its own, or does it need a partner drug (specifically, a GLP-1 like Mounjaro or Zepbound) to deliver?

ARO-INHBE’s EASL data is the cleanest answer yet to that question.

What the March repricing actually meant

The 50% drop in WVE was not just disappointment over a single weight loss number. It was a re-evaluation of the entire pharmacology.

INHBE silencing produces deep, durable suppression of Activin E. Wave proved that, but the downstream effect on the metrics the obesity market cares about (pounds lost, waist inches reduced, BMI change) came in well below the bar the December readout had set. A 1% placebo-adjusted weight loss does not compete with GLP-1s like Ozempic and Mounjaro, which routinely deliver 15-22% in late-stage trials.

This left two interpretations. Either the INHBE mechanism is intrinsically a “body composition” drug (reshaping where fat sits) rather than a “weight loss” drug (reducing total mass), and the December market reaction was overpriced, or INHBE silencing only delivers meaningful outcomes when layered on top of a GLP-1, not used alone.

Both interpretations lead to the same operational conclusion: INHBE-as-monotherapy is unlikely to support obesity peak sales models on its own. Either the asset needs to shift toward MASH (metabolic-dysfunction-associated steatohepatitis, a serious form of fatty liver disease) and broader metabolic dysfunction, where body composition matters more than scale weight, or the development path needs to run through combination with the GLP-1 class.

Wave is pursuing neither yet. Its planned Phase 2a multidose study, due to begin in Q2 2026, is still monotherapy in higher-BMI patients. The GLP-1 add-on trial is announced but unstarted. The MASH endpoint is exploratory in a protocol that has not yet begun enrolling. The bet Wave is making is that monotherapy will simply work better in heavier patients than it did in the leaner Phase 1 cohort.

That may turn out to be right, but it is a single-asset, single-strategy bet, dependent on a thesis the market already partially rejected.

The Zwischenzug

In chess, a Zwischenzug (literally “in-between move”) is an unexpected interjection in what appears to be a forced sequence. The opponent has played their move expecting a specific reply. Instead of responding directly, you play something else entirely, something that forces a reassessment of the whole position.

The ARO-INHBE data released this morning is that move.

The market was waiting for Wave to resolve the open question its March readout raised: whether monotherapy could work in higher-BMI patients. Arrowhead answered the question first, and from a completely different angle. Five data points stand out.

First, deeper target engagement. ARO-INHBE achieved an 85.3% mean maximum reduction in Activin E at the 400mg dose, with effect persisting beyond three months. Wave’s 240mg cohort hit roughly 78%. Deeper Activin E suppression directly addresses the sell-side concern about whether the liver INHBE knockdown mechanism reliably works.

Second, real GLP-1 combination data, in humans, today. ARO-INHBE has now produced clinical data in combination with tirzepatide 5mg (the active ingredient in Mounjaro and Zepbound) in two separate cohorts. The first included obese patients without diabetes. The second included obese patients with Type 2 Diabetes Mellitus (T2DM, the most common form of diabetes). Both were followed through week 24. The combination produced enhanced reductions in both visceral fat and liver fat compared to tirzepatide alone. This is the combination path Wave has yet to begin clinical work on.

Third, fatty liver disease data. ARO-INHBE produced a 44% placebo-adjusted reduction in liver fat content in the subgroup of patients with baseline liver fat above 8% receiving 200mg or higher of monotherapy (n=10, p<0.01). In the T2DM combination cohort, where baseline liver fat content was 16.9% (squarely in MASH territory), the combination produced substantially greater liver fat reduction than tirzepatide alone. In the cleaner week 24 readout from the non-T2DM combination cohort, ARO-INHBE 200mg plus tirzepatide reduced liver fat by approximately 45%, versus approximately 16% for placebo plus tirzepatide. That is a roughly 29 percentage point additive effect on top of what a GLP-1 alone delivers.

Fourth, durability. The longest-exposure data from ARO-INHBE shows visceral fat and liver fat reductions deepening from week 12 to week 24 within a single dose interval. Not waning, but deepening. This is the strongest possible support for a twice-yearly subcutaneous dosing schedule. Effects compound through the back half of the dose window, not the opposite.

Fifth, regulatory engagement. Arrowhead is now in active discussions with the FDA on Phase 2 study designs for both obesity and MASH, in parallel.

Every one of these data points addresses an open question raised by Wave’s March miss. The GLP-1 combination works. The mechanism engages the liver fat target deeply. The dosing interval holds. MASH is a credible second indication. T2DM patients respond.

The combination bet, reconsidered

The most consequential decision either company made in INHBE was structural: whether to run the combination program in parallel with monotherapy, or to sequence them: proving the standalone drug first, then layering on combinations later.

Wave sequenced. This produced the cleaner first headline in December. It also produced the harder second headline in March, because monotherapy on its own had to clear an obesity drug bar that increasingly favors percentage body weight loss, the metric Wave fell short on.

Arrowhead ran in parallel. Monotherapy and tirzepatide combination arms enrolled simultaneously, with T2DM patients included from the start. This produced a messier first data presentation (there is no single hero number in the EASL release), but a much more complete picture of where the asset actually works.

In retrospect, the parallel strategy was the right one. Not because monotherapy will necessarily fail; it may still succeed in Wave’s higher-BMI Phase 2a study, but the strategic value of an INHBE asset is dominated by its ability to layer onto the dominant GLP-1 class. The combination path is where the economics get decided. The company that shows combination data first will get the partnership first.

Wave’s GLP-1 add-on trial is scheduled for initiation sometime in 2026. The earliest that produces meaningful data is late 2027. By that time, ARWR will have Phase 2 combination data in hand, possibly Phase 2 MASH data, and could plausibly be in registrational discussions for the obesity-plus-MASH program.

The gap between the two programs is twelve to eighteen months wide. It is widening, and it is not yet reflected in either stock.

What this means for the acquirer thesis

If Eli Lilly (the obvious GLP-1-side buyer or licensor for an INHBE asset, given its tirzepatide franchise) were running a diligence process today, the operational read is unambiguous.

Wave offers a clean monotherapy lean-mass story, an unstarted combination program, and an exploratory MASH endpoint in a protocol that has not yet started enrolling. The development optionality is there but unproven.

Arrowhead offers deeper target engagement, demonstrated additivity with tirzepatide, in-hand liver fat data at MASH-relevant baseline values, a T2DM patient cohort with real combination data, week 24 durability, and active FDA Phase 2 engagement on both obesity and MASH. The development optionality is largely de-risked.

For an acquirer, de-risked optionality is worth more than narrative optionality. Always.

This does not mean Wave is uninvestable. The monotherapy thesis may yet work in higher-BMI patients. The company has real assets beyond WVE-007, particularly in RNA editing. The current valuation already reflects a damaged INHBE story, but the relative premium the market has historically assigned to Wave as the INHBE leader is not supported by the underlying clinical state of the two programs. If anything, that premium should have been migrating to Arrowhead for months.

What I expect from here

Three things to watch over the next two quarters.

First, ARO-INHBE 400mg plus tirzepatide week 24 data in the T2DM cohort, the single highest-impact pending data point from the current Phase 1/2a study (the 400mg combination week 24 data was not yet available for the EASL presentation). If that arm shows continued liver fat and visceral fat deepening at the high dose, the combination case is essentially closed for ARWR.

Second, Wave’s Phase 2a higher-BMI monotherapy data, with the first assessment expected three months after first dose. If placebo-adjusted body weight loss again comes in below 3-4%, the monotherapy thesis collapses entirely, and Wave’s path forward depends entirely on a GLP-1 combination trial it has not yet started.

Third, sell-side recalibration. Most analysts modeling the INHBE class still anchor on Wave’s December readout as the relative reference point, even after the March price target cuts. Expect models to start splitting INHBE valuation into “monotherapy obesity” and “MASH + GLP-1 combination” buckets, with ARWR taking the larger share of the second bucket. That repricing has not started in earnest. It will.

The narrative will catch up. Headlines win the day. Programs win the decade.

Subscribe now

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of May 2026.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Note Arwr The Inhbe Reset 05272026

180KB ∙ PDF file

Download

Download

The finding

In January and February of 2026, the United States Patent and Trademark Office granted Arrowhead Pharmaceuticals two patents covering the company’s central nervous system delivery platform. The first, US Patent 12,527,877 (Glebocka et al., granted January 20, 2026), claims a platform for delivering RNAi payloads across the blood-brain barrier and to skeletal muscle and heart tissues using antibody fragments that bind the transferrin receptor. The second, US 12,551,569 (Lazzara et al., granted February 17, 2026), claims a specific tau-targeting RNAi conjugate built on that platform, with named therapeutic indications including Alzheimer’s disease, frontotemporal lobar degeneration, progressive supranuclear palsy, and other tauopathies. Both patents are publicly available and run through 2045.

Read together with Arrowhead’s TIDES USA 2026 conference presentation on ARO-MAPT, the patent record reveals a feature of the TRiM SC architecture that public investor materials have not made explicit. The brain delivery platform Arrowhead has described publicly as a “chemistry-engineered targeting ligand” is fundamentally an antibody-fragment platform. The lead binder, identified in both patents as Fab0070, is a Fab fragment: the binding portion of an antibody, the piece that recognizes and attaches to a target on the surface of a cell. Antibody fragments are much smaller than full antibodies but retain the specificity that makes antibodies effective at homing in on particular targets. The transferrin receptor is a protein expressed on the surface of cells throughout the body and is the molecular doorway through which cells take up iron from the bloodstream. By engineering a Fab fragment that binds the transferrin receptor, Arrowhead has built a delivery system that uses that receptor’s natural transport machinery to ferry an RNAi payload into cells. ARO-MAPT, the company’s lead clinical-stage neurology program, is most likely the Fab0070-MAPT siRNA conjugate disclosed in the ‘569 patent claims.

This is a structural observation about the platform’s molecular architecture, not a discovery of hidden technology. The patents are public and the conference presentations have shown the structural imaging of the binder. What the public framing has not emphasized is that the binder is an antibody fragment. The “chemistry-engineered” language is technically accurate (Fab fragments are engineered molecules) but has not conveyed the antibody-fragment nature of the binding component to non-specialist readers.

The distinction matters. Fab-based architectures and small-molecule ligand architectures have different competitive moats, different manufacturing implications, different tissue distribution profiles, and different strategic value. The Fab choice itself is an engineering accomplishment worth understanding. Arrowhead’s scientists looked at how other companies had approached antibody-mediated brain delivery, recognized that the full-antibody approach forces intravenous administration, and engineered a Fab fragment instead. The remainder of this paper works through what the patent record reveals about that engineering choice, why it produces capabilities competing programs have not matched, and what the cross-tissue scope and pipeline breadth imply for Arrowhead’s strategic position.

What the patents and the TIDES presentation disclose

The ’877 platform patent claims an anti-transferrin receptor antibody fragment for delivering RNAi payloads to tissues that express the transferrin receptor. The patent specification describes a screening campaign in which Arrowhead generated and tested dozens of Fab candidates against the receptor, eventually selecting two lead clones called Fab0061 and Fab0070. A screening campaign like this is how antibody-based drugs are developed: a company generates a large library of candidate antibody fragments, tests each one for binding strength and specificity, and selects the best performers as the leads. The patent discloses the full amino acid sequences of both heavy and light chains for both Fabs, which is the level of detail at which the molecular identity of an antibody fragment is publicly established. The connection between the Fab and the siRNA payload is specified as a polyethylene glycol-based chemical tether, the chemistry that holds the antibody fragment and the RNAi payload together in a single drug molecule. The patent claims tissue coverage for the central nervous system, skeletal muscle, and heart muscle, with non-human primate data documenting subcutaneous knockdown across more than fifteen brain regions, both cardiac chambers and ventricles, and skeletal muscle including triceps and gastrocnemius.

The ’569 program patent claims the specific tau-targeting RNAi molecule and its conjugation to an anti-transferrin receptor Fab. The patent identifies the lead conjugate by molecular structure: Fab0070, the lead clone from the ’877 patent, joined through a defined linker chemistry to a specific MAPT-targeting siRNA sequence (MAPT is the gene that produces tau protein, which forms the toxic tangles inside neurons that drive Alzheimer’s disease and related tauopathies). The siRNA sequence is disclosed in the patent’s claims. The conjugation chemistry is the same as that disclosed in the ’877 patent. The therapeutic indications named in the claims include Alzheimer’s disease (Claim 26), frontotemporal lobar degeneration dementia, progressive supranuclear palsy, and other tauopathies (Claim 25). The patent specification frames the disclosure as addressing the historical failure of tau-targeting therapies due to blood-brain barrier penetration challenges, off-target effects, and limited efficacy.

The dual-patent structure (a platform patent and a program-specific patent for a clinical asset) is a meaningful escalation in Arrowhead’s intellectual property strategy. The company’s TRiM-liver franchise has historically relied on program-specific patents covering each clinical asset rather than on a platform-level patent claiming the underlying delivery chemistry. The foundational GalNAc-asialoglycoprotein receptor delivery technology used in the liver franchise is in the public domain and used across the RNAi industry, so platform-level patent protection was not available for that approach. The Fab-based brain delivery technology is different. Because no other company had built a subcutaneously-deliverable antibody-fragment-mediated RNAi delivery platform, Arrowhead was able to secure proprietary platform-level protection. The ’877 patent is the platform patent for the new technology; the ’569 patent is the program-specific patent for a tau program built on it. The ’569 patent provides direct documentary evidence that the antibody-fragment delivery architecture is not a research-stage exploration but a platform that has produced at least one specific clinical-stage molecule with named therapeutic indications, protected by granted intellectual property running through 2045.

The TIDES USA 2026 conference presentation, “Systemic RNAi Targeting MAPT: Advancing Tau Suppression Across the CNS with TRiM SC,” delivered by Kayal Madhivanan of Arrowhead, discloses the public scientific framing of ARO-MAPT. The presentation shows non-human primate data using a dosing regimen of three subcutaneous doses at 3 mg/kg administered weekly on Days 1, 8, and 15, with brain region knockdown of 70 to 80 percent measured at Day 29 across cortex, hippocampus, deep brain regions, and spinal cord, and up to 85 percent in some cortex regions. The durability data extends knockdown to Day 99 and shows tau protein suppression sustained out to Day 239 with a repeat dosing regimen of three weekly loading doses followed by four monthly maintenance doses. The presentation also shows a cryo-EM structure of the TRiM BBB ligand bound at the apical domain of the transferrin receptor (Cryo-EM is a structural imaging technique that uses cryogenic electron microscopy to produce three-dimensional images of biological molecules at near-atomic resolution). The cryo-EM image depicts the binder as a protein-sized molecule rather than as a small-molecule ligand.

The dosing regimen, brain region knockdown profile, durability data, and cryo-EM imaging in the TIDES presentation align with the ’877 and ’569 patent disclosures. The most consistent reading of the available primary-source evidence is that the TRiM BBB ligand publicly described in the TIDES presentation and the Fab0070 conjugate claimed in the ’569 patent are most likely the same molecule, and that ARO-MAPT is the Fab0070-MAPT siRNA conjugate disclosed in the ’569 patent claims.

Figure 1. Schematic of the TRiM SC molecular architecture. The Fab fragment (shown in blue) is the binding component of the delivery system. One end of the Fab binds the transferrin receptor (TfR1) on the surface of cells across the blood-brain barrier and on cardiomyocytes and skeletal muscle. The other end is conjugated to the siRNA payload through a chemical linker. The Fab format is approximately one-third the molecular weight of a full antibody, which is what makes subcutaneous administration possible. Once the Fab binds TfR1, the complex is internalized into the target cell, where the siRNA is released to silence the target gene.

Why the Fab format matters: subcutaneous delivery

The Fab-based architecture is an engineering accomplishment worth pausing on. The competitive landscape for antibody-mediated brain delivery has been dominated by full-antibody approaches that require intravenous infusion. Denali, Roche, JCR, and Alector each took this route. Arrowhead’s scientists studied that landscape and chose differently. In chess terms, the Fab choice was a hypermodern move: a deliberate rejection of the classical approach in favor of an indirect route that proves stronger over time. By engineering a Fab fragment rather than a full antibody, they solved for subcutaneous delivery at the molecular level. The choice was not obvious and the engineering was not trivial. Selecting a Fab that binds the transferrin receptor with the right affinity, conjugating it to an siRNA payload through a stable linker, and demonstrating that the construct produces durable target engagement across the brain at primate scale from a subcutaneous injection is the kind of work that takes years of iteration and represents a meaningful step beyond what the broader field has produced.

The size choice matters more than it might first appear. Full antibodies are large, roughly 150,000 daltons in molecular weight, and at therapeutic doses they require intravenous infusion delivered in a clinical setting. Fab fragments are roughly 50,000 daltons, small enough to be administered as a subcutaneous injection, the same way insulin or a GLP-1 weight-loss drug is administered. The choice between a Fab fragment and a full antibody as the binding component of a brain delivery platform is therefore not just a chemistry decision, it is a commercial decision about how the eventual drug will be administered, where it can be administered, and which patient populations can practically receive it.

Every clinical-stage competitor pursuing antibody-mediated brain delivery has used full antibodies and administered them intravenously. Denali Therapeutics develops enzyme replacement therapies for lysosomal storage disorders such as Hunter syndrome and similar inherited diseases, with its lead clinical programs delivered intravenously. Roche’s Brainshuttle program develops modified antibodies for Alzheimer’s disease and other neurology indications, including trontinemab in the Alzheimer’s space, all delivered intravenously. JCR Pharmaceuticals develops enzyme replacement therapies including pabinafusp alfa for Hunter syndrome, delivered intravenously. Alector develops antibody therapies for neurodegenerative diseases including frontotemporal dementia, delivered intravenously. One preclinical competitor, Dyne Therapeutics, has pursued the same Fab-fragment architecture for muscle delivery and disclosed preclinical NHP MAPT data at the 2026 ASGCT meeting. Dyne’s NHP study used intravenous dosing, with subcutaneous-to-intravenous equivalence demonstrated in mice but not yet in primates. Dyne’s program is preclinical and the company has explicitly framed it as exploratory and capital-efficient rather than as a prioritized clinical development path. ARO-MAPT, by contrast, was demonstrated in primates by subcutaneous administration and has been dosing patients since December 2025. The platform-level engineering required to deliver subcutaneous antibody-fragment conjugates to the brain at clinical scale has been demonstrated only once at the primate-subcutaneous and clinical stages, and that demonstration is Arrowhead’s.

Arrowhead has designed its molecules to do exactly that, and the patent record documents primate subcutaneous knockdown data for both the androgen receptor and tau in Examples 12 and 13 of the ’877 patent. The Day 99 durability data documented in the ’569 patent’s Figure 2 extends the demonstration further, showing tau protein knockdown sustained at approximately three months after the final subcutaneous dose. The TIDES presentation extends this further still with the Day 239 durability data showing tau protein suppression maintained at 16 weeks after the final dose of a three-loading-dose-plus-four-monthly-maintenance regimen. The combination of the patent disclosures and the public TIDES disclosures establishes that Arrowhead’s Fab-based architecture not only enables subcutaneous administration in principle but produces durable target engagement in primates at doses and intervals consistent with quarterly clinical dosing.

The format choice is what makes the platform commercially differentiated. A Fab-based antibody conjugate that crosses the blood-brain barrier from a subcutaneous injection administered every three months is a fundamentally different commercial proposition than a full antibody that requires monthly or biweekly intravenous infusions in a clinical setting. The patient experience differs: a patient with Alzheimer’s disease can receive a subcutaneous injection at home or in a brief outpatient visit, while an IV infusion typically requires hours in an infusion center with skilled nursing. The reimbursement profile differs: payers price subcutaneous therapeutics differently than infused therapeutics, and the lower delivery cost flows through to net economics. The addressable patient population differs because subcutaneous injection at home expands access to patient populations that cannot reliably travel to infusion centers, including elderly patients and patients in rural areas where infusion infrastructure is limited. The cost-of-goods profile differs. The competitive moat against current clinical-stage competitors is substantial, and that moat exists because of an engineering choice (Fab fragment instead of full antibody) that none of the competitors has made.

Cross-tissue scope and pipeline breadth

The transferrin receptor is broadly expressed across the cell types that require iron for normal cellular function. Iron is essential for energy production in cells, and cells with high metabolic demand (the cells that work hardest) express more of the transferrin receptor in order to take up more iron. Beyond the cells of the blood-brain barrier, the receptor is expressed at high density on cardiomyocytes (heart muscle cells, which have particularly high metabolic demand) and on skeletal muscle cells. The Fab0070 conjugate that crosses the blood-brain barrier through transferrin receptor binding also reaches cardiomyocytes and skeletal muscle through the same receptor. The ’877 patent demonstrates this directly. In the same non-human primate study that documented brain knockdown of androgen receptor, the patent reports knockdown across all four heart chambers (77 to 87 percent across atria and ventricles) and across skeletal muscle (with gastrocnemius reaching 72 percent and triceps reaching 33 percent after two subcutaneous doses of 3 mg/kg, given seven days apart). The single Fab architecture, administered subcutaneously, produces deep target engagement in three distinct tissue types from one molecule.

The cardiac delivery data is worth singling out. The androgen receptor is not a therapeutic target in heart disease; the patent used it as a demonstration target to show where the platform reaches. The therapeutically meaningful implication is what this knockdown profile means for other cardiac genes. Several inherited cardiomyopathies are caused by mutations in specific genes that produce proteins inside heart muscle cells. LMNA mutations cause laminopathies, a group of inherited heart muscle diseases that often progress to heart failure and require transplantation. MYH7 mutations cause hypertrophic cardiomyopathy, the most common inherited heart disease, affecting roughly one in every 500 people. PLN mutations cause certain dilated cardiomyopathies. These targets are intracellular structural and regulatory proteins that have resisted small-molecule and antibody-based drug development for decades because conventional drugs cannot reach inside cells to affect them. Transthyretin (TTR) is the closest commercial precedent for cardiac RNAi: Alnylam’s vutrisiran is an approved RNAi drug for transthyretin amyloid cardiomyopathy, though it works through liver delivery to reduce circulating TTR rather than through direct cardiomyocyte targeting. Ion channel genes underlying inherited arrhythmias are another category. None of these therapeutic cardiac target genes is enumerated in the patent claims the way the CNS targets are. The patent claims heart muscle as a tissue the platform reaches but does not list specific cardiac target genes. That gap is notable, and it may indicate either that Arrowhead is reserving cardiac program disclosure for separate patent filings or that the cardiac applications sit at an earlier exploratory stage than the CNS and skeletal muscle programs.

For the CNS, the patent enumerates a substantial target list. More than thirty CNS target genes are claimed by name, including the targets of greatest current commercial interest in neurology. Tau (MAPT) is the target of multiple Alzheimer’s disease and tauopathy programs across the industry. Alpha-synuclein is the target of Parkinson’s disease programs. LRRK2 is another Parkinson’s disease target. Huntingtin is the cause of Huntington’s disease. The ataxin proteins (ATXN1, ATXN2, ATXN3, and others) are associated with various forms of spinocerebellar ataxia, a group of inherited neurodegenerative diseases. SOD1 and FUS are both targets in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Each of these names a clinical-stage or near-clinical-stage program at one or more major neuroscience companies. The breadth of the disclosed target list, combined with the ’569 patent’s confirmation that program-specific patents follow as individual molecules advance, signals that the antibody-fragment delivery platform is intended to support a broad neurology pipeline rather than to serve a single program.

The intellectual property architecture confirms this reading. The ‘877 platform patent protects the delivery technology at the platform level: anti-transferrin receptor Fab conjugates with siRNA payloads for subcutaneous delivery across the blood-brain barrier and to muscle and heart tissues. The ‘569 program patent then protects the specific MAPT-targeting molecule at the asset level. This is a meaningful escalation in Arrowhead’s intellectual property strategy. Arrowhead’s TRiM-liver franchise has historically relied on program-specific patents covering each clinical asset (ARO-AAT for alpha-1 antitrypsin deficiency, plozasiran for severe hypertriglyceridemia and now approved as Redemplo, ARO-ANG3 for cardiometabolic disease, ARO-PNPLA3 for nonalcoholic steatohepatitis, and others). The foundational GalNAc-asialoglycoprotein receptor delivery chemistry is in the public domain and used across the industry, including by Alnylam and Ionis, so broad platform-level patent protection was not available for that approach. The Fab-based brain delivery technology is different. Because no other company had built a subcutaneously-deliverable antibody-fragment-mediated RNAi delivery platform, Arrowhead was able to secure proprietary platform-level protection. The ’877 patent secures proprietary platform-level intellectual property for the antibody-fragment brain delivery technology, the kind of foundational protection that did not exist for the publicly available GalNAc-liver delivery chemistry. Additional program-specific patents would be expected as additional CNS targets advance toward clinical development. The granted intellectual property is the kind that supports a commercial pipeline rather than a research project, and the platform layer means competitors cannot replicate the approach without licensing or working around the ’877 patent.

The scope is therefore broader than the disclosed clinical pipeline reflects. ARO-MAPT is the lead clinical-stage asset. The patent’s thirty-plus CNS targets and the demonstrated extrahepatic reach suggest a multi-program pipeline that current investor materials have not articulated at the level of detail the patents now disclose.

Strategic and valuation implications

The Fab-based architecture has different manufacturing requirements than a small-molecule chemistry-engineered platform would have. Small-molecule drugs are produced through chemical synthesis. Antibody fragments are produced through biological manufacturing, where engineered cells (typically mammalian cells, such as Chinese hamster ovary cells) are grown in large bioreactors and instructed to produce the desired antibody fragment. The cells then secrete the antibody fragment into the surrounding fluid, from which it is purified and conjugated to the siRNA payload. This is a fundamentally different manufacturing process with different capital requirements, different operational expertise, different quality control systems, and different regulatory pathways. The Fab-based architecture means Arrowhead’s manufacturing footprint includes biologics-capable production capacity, either in-house or through contract manufacturing partners, which carries different cost and operational implications than the small-molecule chemistry that the GalNAc-liver programs require.

The cross-tissue scope expands the addressable disease space beyond what current investor materials emphasize. The CNS franchise spans Alzheimer’s, Parkinson’s, Huntington’s, ALS, and the spinocerebellar ataxias. The skeletal muscle extension opens muscular dystrophies. The cardiac extension opens inherited cardiomyopathies and inherited arrhythmias. The platform’s reach across three tissue types from a single subcutaneous injection means an acquirer is buying a multi-tissue intracellular delivery system rather than a brain delivery technology.

The intellectual property protection running through 2045 anchors the long-term strategic value. The ’877 platform patent and the ’569 program patent are granted, defensible, and would require an acquirer to either license or work around if a competitor tried to enter the same space. The platform-plus-program patent architecture also signals that additional program-specific patents will follow as additional clinical assets advance, creating layered intellectual property protection that compounds over time. A platform of this kind, with multi-tissue scope, durable patent protection, and primate-validated subcutaneous delivery, is the kind of asset that justifies acquisition premium above what current sell-side comparable-transaction methodology produces. The Acquisition of the Decade argued that the eventual acquirer of Arrowhead will own the most strategically important platform in biotech this decade. The patent-record evidence developed in this paper strengthens that case. The platform is more sophisticated, broader in scope, and more durably protected than public framing has emphasized. Whichever pharma is currently modeling Arrowhead as an acquisition target needs to model these features as part of the asset they are bidding on.

What this means for the existing thesis

The Acquisition of the Decade argued that Arrowhead is the most strategically important acquisition target in biotech this decade, on the basis of what the company had already publicly disclosed. The patents reviewed in this paper add documentary depth to that case. The brain delivery platform that public materials describe as a “chemistry-engineered targeting ligand” is fundamentally an antibody-fragment platform built around Fab0070. The platform reaches the brain, skeletal muscle, and cardiomyocytes from a single subcutaneous injection. The patent claims protect the architecture and the lead clinical asset through 2045. The platform-plus-program patent structure is stronger than the program-only intellectual property that has historically protected Arrowhead’s TRiM-liver franchise, signaling that the platform is positioned to support a full pipeline of clinical assets behind proprietary platform-level protection.

None of this changes the conclusion of The Acquisition of the Decade. This paper sharpens the supporting evidence. The platform is more sophisticated than public framing has emphasized, broader in tissue scope, and more deeply protected in the patent record. Each of these features strengthens the case that an acquirer of Arrowhead is acquiring a complete operational franchise rather than a single drug or a pipeline of small-molecule conjugates. The strategic value of that franchise is what the prior paper described as the most consequential acquisition available in biotech this decade. The patent-record evidence developed here makes the strategic value more concrete and more difficult for a sophisticated acquirer to ignore.

The public framing told one story. The patent record tells the full one. The Fab-based architecture documented in the patents is a real engineering accomplishment, the kind of work that takes years of iteration. The hypermodern move was the choice. The years of execution between choice and clinic are what turn a choice into a moat. The Fab choice is also a data point in a pattern. The same scientific team that delivered GalNAc-mediated liver RNAi, then extended the platform to skeletal muscle, to inhaled lung delivery, to adipose tissue, and now to subcutaneous brain delivery, has built a track record of solving the delivery problems that define what RNAi drugs can do. Each extension required its own engineering work. The team has not yet failed to find a path. When the next hard delivery problem arrives, the same team will be working on it. Arrowhead made the move, did the work, and arrived at the clinic alone.

The Fab choice was the hypermodern move. The years of execution were the moat. The position is now Arrowhead’s alone.

Subscribe now

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of May 2026. Factual claims about the patent record are sourced from US Patent 12,527,877 (Glebocka et al.) and US Patent 12,551,569 (Lazzara et al.) as published by the United States Patent and Trademark Office. Factual claims about ARO-MAPT scientific data are sourced from the publicly available TIDES USA 2026 conference presentation by Kayal Madhivanan of Arrowhead Pharmaceuticals. The architectural identification of TRiM-CNS as a Fab-based antibody-fragment platform is an analytical inference from the most consistent reading of the available primary-source evidence rather than a direct statement from Arrowhead.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Note Arwr The Fab Choice 05262026

254KB ∙ PDF file

Download

Download

The claim

Whichever pharma company acquires Arrowhead Pharmaceuticals will own the most strategically important asset in biotech this decade. Not because Arrowhead has the most drugs in clinical trials. Not because any single program is the next Keytruda. Because Arrowhead has built, and is translating into human patients across more tissues than anyone else, the broadest RNAi delivery platform in the industry. Everything else follows from that.

This note explains what that means, why it matters more than a pipeline, and why the timing makes this acquisition uniquely valuable to whichever large-cap pharma is willing to act.

The background

RNAi (RNA interference) is a way of silencing specific genes inside cells. Most drugs today work by blocking a protein after the body has already made it. RNAi works one step earlier: it stops the protein from being made in the first place. The practical consequence is that RNAi medicines tend to last longer. A single injection can suppress a disease-causing protein for months, and they can be more precise, because they target a unique genetic sequence rather than a protein shape that may be shared across many parts of the body.

The problem with RNAi, for most of the last twenty years, was delivery. You can design the perfect RNAi molecule in a laboratory, but if you cannot get it into the right cells inside the body, it does nothing. For a long time, the only tissue that could be reached reliably was the liver. A sugar molecule called GalNAc could escort RNAi drugs into liver cells, and that single delivery solution is essentially what the leading RNAi company before Arrowhead, Alnylam Pharmaceuticals, built its business on. Everything beyond the liver remained largely preclinical across the industry.

Arrowhead’s TRiM platform (Targeted RNAi Molecule) changed that. TRiM is a chemistry system that lets Arrowhead design molecular keys for different tissues. The company has now advanced programs into human clinical trials in five tissue types: liver, lung, skeletal muscle, the central nervous system, and adipose. Two further tissues, ocular and cardiomyocyte, are at the preclinical stage, bringing the total platform footprint to seven cell types Arrowhead is actively engineering against.

It is worth being honest about where competitors are. Alnylam is no longer simply a liver company. Its mivelsiran program in central nervous system disease is in Phase 2. Alnylam has also disclosed preclinical delivery work in adipose, muscle, heart, and kidney. That work is real and credible. The gap is at the clinical-stage tissue breadth: Alnylam has clinical programs in two tissues; Arrowhead has clinical programs in five. Translating preclinical delivery into human data is the hard part, and Arrowhead has done it more times, more recently, across more tissues than anyone else.

Ionis Pharmaceuticals, historically the leader in antisense oligonucleotides has now entered the siRNA space as well, with its first clinical-stage siRNA candidate in 2025. Ionis is taking a multi-modality approach, picking ASO or siRNA per target. That sharpens the competitive picture but does not close the tissue-breadth gap, which is the dimension that matters most for an acquirer.

The antibody-oligonucleotide companies, which use a different chemistry to deliver oligonucleotides to specific tissues, are also expanding beyond their initial muscle focus. Dyne Therapeutics’s FORCE platform now targets muscle and the central nervous system, supporting its programs in myotonic dystrophy, Duchenne muscular dystrophy, FSHD, and Pompe disease. Avidity Biosciences extended into cardiology and immunology via partnerships with Bristol Myers Squibb and Eli Lilly, and was acquired by Novartis in a deal that closed in February 2026 at approximately $12 billion. We will come back to that transaction. Both AOC platforms remain narrower than Arrowhead in tissue breadth, but neither is a single-tissue play any longer.

That foundation is what makes the strategic case. The rest of this note develops four arguments that follow from it.

Argument 1: Modality leadership

When a pharma company buys a single drug, they buy a single drug. When they buy a small-molecule company, they buy a library of molecules. When they buy Arrowhead, they buy the most clinically advanced multi-tissue RNAi platform that exists.

This is the difference between buying a product and buying a category. The liver category in RNAi is competitive. Alnylam, Ionis, and several smaller players all have liver-targeting assets. The extrahepatic categories are not competitive in the same way. Arrowhead has advanced more tissues into human studies, in more disease areas, on a faster timeline than any other RNAi developer. Competitors are pursuing extrahepatic delivery; Arrowhead is doing it in patients, across multiple tissues, today. That gap is the moat, and gaps measured in tissues and years are not closed by a single positive data point from a competitor.

Breadth is the headline, but the head-to-head record matters as much. Where Arrowhead’s programs have competed directly against competitor programs targeting the same gene, alpha-1 antitrypsin deficiency, hepatitis B, lipoprotein(a), APOC3, Arrowhead’s molecules have consistently produced more potent, more durable, or better-tolerated profiles than the alternatives. That track record is developed in detail later in this note. For the modality leadership argument here, the point is simpler: Arrowhead is not only broader than its competitors; it is also better than them at the level of the molecule itself.

Modality leadership of this kind is what large-cap pharma pays premium prices for, because it cannot be replicated through licensing or partnership. You can license a drug. You cannot license a decade of accumulated chemistry know-how, screening infrastructure, manufacturing capability, and clinical translation experience spread across seven tissues.

Argument 2: Optionality compounds

This is the argument most investors miss, and it is the one that matters most.

When a company has a pipeline of independent drugs, the value of that pipeline is roughly the sum of the value of each drug, adjusted for the probability that each one works. Each drug stands or falls on its own.

A platform works differently. Each new tissue that Arrowhead validates is not just one asset, it is a permission slip to credibly pursue every disease in that tissue. Validating the lung is not worth one drug; it is worth every lung disease where silencing a gene could help. Validating the central nervous system is not worth one neurological program; it is worth every neurodegenerative disease where the right target exists.

And each validated tissue makes the next one cheaper and faster to validate, because the underlying chemistry, the screening systems, the regulatory precedent, and the manufacturing all carry over. The manufacturing point deserves its own emphasis. Arrowhead built integrated in-house oligonucleotide manufacturing, its Verona, Wisconsin GMP facility, completed at a final capital cost of approximately $300 million, at a time when most RNAi developers were dependent on a small handful of contract manufacturers for large-scale oligonucleotide synthesis and conjugation. The facility now produces GMP drug substance for clinical trials in the United States and, following a successful Qualified Person audit, in the European Union and the United Kingdom as well. That internal capacity is what makes the carryover from one tissue program to the next real rather than theoretical. The same plant, the same process scientists, and the same quality systems absorb each new program without renegotiating contract scope or competing for batch slots with another company’s drug.

Platform value scales super-linearly with the number of validated tissues. Pipeline value scales linearly with the number of drugs. That is a fundamental difference in how value grows, and it is why platform companies command premium multiples when they are acquired.

The compounding is sharpened by a second effect that is easy to overlook. Each new target Arrowhead picks up is not a coin flip on whether the drug works, it is a coin that has been weighted by years of chemistry know-how toward producing better triggers than competitors targeting the same biology. The platform compounds across tissues, and the trigger design capability compounds within each tissue. The acquirer is not just buying more shots on goal; the acquirer is buying shots on goal with a higher per-shot probability of producing a best-in-class molecule.

For the acquirer, the arithmetic is straightforward. The cost of buying Arrowhead today is dwarfed by the cost of trying to rebuild what Arrowhead has from scratch. Even with unlimited money, you cannot compress a decade of validation work and a fully built manufacturing footprint into a few years. The acquirer is buying time as much as technology.

Argument 3: The team is part of the platform

TRiM did not emerge from a single insight. It was built over a decade by a specific group of scientists who made a sequence of correct, non-obvious decisions in chemistry, target selection, clinical strategy, and manufacturing. That knowledge lives in people, in scientists’ instincts about which experiments to run and which to skip, in laboratory notebooks, in screening platforms the team built internally, in the process engineers who know how to make these molecules at scale, in institutional muscle memory that cannot be written down.

This matters because pharma acquisition history is full of cases where the buyer got the assets and lost the scientists within two or three years. Celgene’s drug discovery culture did not survive the Bristol Myers Squibb acquisition. Genentech’s preservation under Roche is the exception that proves the rule. When the platform is the people, retention is the deal.

The Arrowhead team has demonstrated four things consistently:

Pace

They have outproduced the rest of the RNAi field. While competitors were extending their liver franchises, Arrowhead was advancing programs across five tissues into the clinic and adding two more, ocular and cardiomyocyte, at preclinical stage. That cadence is not luck. It reflects an organization that has figured out how to run programs efficiently across multiple targets at once, and it is materially helped by the company having built its own manufacturing. RNAi clinical timelines across the industry have historically been gated by availability at contract manufacturers, where queuing for batch slots has slowed program advancement for everyone dependent on them. Arrowhead largely solved that problem by building Verona. Internal manufacturing is part of why the team’s output cadence outruns competitors who are otherwise scientifically capable.

Target selection

INHBE, the gene Arrowhead is now silencing for obesity and metabolic disease, was a non-obvious choice when the program began. Picking it before the wider scientific consensus caught up signals real biological judgment, not just chemistry execution. The same pattern holds for MAPT in tau-driven neurodegeneration, for the cardiometabolic targets, and for the breadth of programs the team has prioritized over time.

Translation discipline

Across program after program, what Arrowhead sees in preclinical animal studies has carried into human studies. That kind of consistency across many shots on goal is not statistical luck, it reflects a screening and selection process that works.

Trigger design

The fourth capability is the one that matters most at the chemistry level, and the one that distinguishes Arrowhead most clearly from competitors targeting the same biology. Designing an RNAi trigger, the actual silencing molecule that gets delivered to a tissue, involves trade-offs between potency, durability, and tolerability that are not solved by following a formula. The team has to predict, across millions of possible sequences, which specific design will silence the target gene most completely, last the longest in circulation, and produce the fewest off-target effects. It is craft as much as it is chemistry, and Arrowhead has consistently produced triggers that beat competitor triggers head-to-head against the same target.

Three head-to-head comparisons make the point concrete. In alpha-1 antitrypsin deficiency, Arrowhead’s fazirsiran produced deep and durable Z-AAT knockdown and advanced into registrational development with Takeda; Alnylam’s belcesiran program against the same target underperformed on the potency-tolerability balance and was discontinued. In hepatitis B, Arrowhead’s JNJ-3989, partnered with Janssen, produced more profound and more durable HBsAg reductions than competing programs from Alnylam and Dicerna, and the strength of that profile drove a partnership expansion to multiple additional targets. In lipoprotein(a), Amgen’s olpasiran, derived from Arrowhead chemistry, achieves greater than 95 percent Lp(a) reduction at 75 milligrams dosed every twelve weeks. Silence Therapeutics’s zerlasiran, the closest competitor program, requires 300 to 450 milligrams every sixteen to twenty-four weeks for a comparable reduction. That is roughly four to six times the milligram dose for an effect that is, at best, equivalent. Drug volume is not a footnote, it determines injection burden, manufacturing economics, and ultimately commercial competitiveness.

This pattern repeats across the pipeline. Arrowhead’s APOC3 program, plozasiran, demonstrated a cleaner clinical profile than Ionis’s olezarsen in the same disease space. The pulmonary triggers in the lung pipeline have shown deeper knockdown than what competing antisense approaches have delivered in airway tissues. The CNS triggers are producing durable knockdown of difficult-to-target proteins that have resisted other modalities for years. The pattern is not coincidence. It is what happens when a chemistry team that has been doing this work together for a decade keeps getting better at it.

These four traits, pace, target selection, translation discipline, and trigger design, are not independent capabilities that happen to coexist at the same company. They are four expressions of the same underlying culture, and that culture is the most fragile asset Arrowhead would bring to a deal. Christopher Anzalone has been chief executive since December 2007, an unusually long tenure for a biotech of this scale, and the senior scientific bench has stayed largely intact across more than fifteen years of platform development. The decision to build internal manufacturing rather than outsource it was itself a cultural choice, it reflects an organization that prizes operational ownership over short-term cost optimization, and that is willing to invest capital in capability-building when the payoff is years away. The team works as a team because it has been the same team, doing the same work, in the same place, for a long time. That continuity has built a team culture, a bond and a working atmosphere, that the rests of the industry has not been able to replicate.

The acquirer who lands Arrowhead has to recognize that they are buying a research and manufacturing organization, not a pipeline. That recognition actually narrows the list of natural acquirers. It favors buyers with a track record of preserving acquired science over buyers known for aggressive cost-cutting integration. That selection effect is itself useful, it tells you which large-caps will be willing to pay the premium this deserves, and which will not.

Argument 4: The post-cliff decade

The biopharma industry is approaching the largest patent cliff in its history. Between 2028 and 2030, drugs accounting for more than $200 billion in annual revenue are losing their patent protection. Keytruda, Eliquis, Opdivo, Stelara, Xarelto, and a long tail of secondary brands all come off-patent in roughly the same window. The acquirers facing this cliff need replacement revenue, and the standard playbooks, bolt-on small molecules, biosimilar-vulnerable biologics, me-too oncology, do not structurally solve the problem.

RNAi assets are different in ways that matter for this exact situation. The chemistry is patentable in ways small molecules are not, because the molecules themselves are complex and the manufacturing is genuinely difficult. Composition-of-matter patents are one wall against generic competition. The second wall is process know-how. Making oligonucleotide drugs at commercial scale, with the purity and consistency regulators require, involves hard-won operational knowledge that accumulates in plants and process scientists rather than in published methods. Arrowhead owns that know-how because it built and runs its own manufacturing. The regulatory pathway for follow-on or generic-equivalent oligonucleotide drugs remains undefined, which adds a third layer of durability that small-molecule franchises do not enjoy.

Dosing intervals are long, often quarterly or twice-yearly, which builds patient stickiness and creates real barriers to switching. The diseases being targeted, chronic metabolic, cardiovascular, neurodegenerative, are exactly the durable, large-population indications that produce decade-long franchises.

But the timing point is the one that makes this argument actually work. Arrowhead does not solve the immediate 2028 cliff. Plozasiran, now approved as Redemplo, is the only Arrowhead drug already contributing revenue in that window. Everything else, INHBE and ALK7 for obesity and metabolic disease, MAPT for neurodegeneration, the expanding cardiometabolic pipeline, the Sarepta-partnered neuro programs, contributes through the 2030s.

That is the right frame. The acquirer is not patching a 2028 hole. The acquirer is building the franchise that carries them through the post-cliff decade, when their existing blockbusters are off-patent and their pipeline needs to deliver. Arrowhead is the highest-quality answer to that problem in the entire industry.

A real-world reference point

In October 2025, Novartis announced its acquisition of Avidity Biosciences. The deal closed on February 27, 2026 at approximately $12 billion in total value, a 46 percent premium to Avidity’s prior closing share price, for an antibody-oligonucleotide platform with three late-stage muscle programs and an early-stage cardiology effort that was spun out as a separate publicly traded company before close.

The Avidity transaction is the closest recent comparable for what an Arrowhead acquisition could look like, and it makes the strategic logic of this note concrete rather than hypothetical. Novartis framed the deal explicitly as part of its xRNA strategy and as a way to support its 2025-2030 sales growth, with product launches expected before 2030. That is large-cap pharma using RNA acquisitions to position for the same post-cliff decade this note has been describing, and paying a premium to do it.

Arrowhead is broader than Avidity across every dimension that mattered in that deal. More tissues with active clinical programs. An already-approved commercial drug in Redemplo. Internal manufacturing capacity that Avidity did not have, and a longer pipeline runway through the 2030s. The strategic logic that justified the Novartis-Avidity transaction applies with greater force to Arrowhead.

What it adds up to

Four arguments converge on one conclusion.

1. The asset is differentiated. TRiM has the broadest clinical-stage tissue footprint in RNAi, with seven tissues now under active development and five already in human trials. Where Arrowhead has competed head-to-head against competitor programs targeting the same gene, it has consistently produced more potent or better-tolerated molecules. That combination gives the acquirer modality leadership rather than product leadership.

2. The asset compounds. Each validated tissue makes the next one cheaper, and the platform’s underlying chemistry, screening systems, manufacturing capacity, and regulatory experience all carry over. The team’s trigger design capability compounds within each tissue as well. Every new target benefits from a higher baseline probability of producing a best-in-class molecule. Platform value grows super-linearly. Pipeline value does not.

3. The asset cannot be replicated. The team, the manufacturing know-how, and the institutional knowledge are part of what the acquirer is buying, and the acquirers who understand this will pay accordingly.

4. The timing is right. Arrowhead’s value is concentrated in the 2030s, exactly when the rest of large-cap pharma needs replacement revenue to survive the post-2028 patent cliff.

These arguments are not independent. They reinforce each other. The platform is rare because the team built it. The team’s output is large because the platform compounds, and because manufacturing capacity removed the operational bottleneck that slows competitors. The molecules are better because the chemistry team has spent a decade getting better at designing them. The platform’s commercial value is durable because the chemistry, the process, and the regulatory pathway all favor incumbents. The durability matters most in the decade after the cliff.

This is why “the most strategically important acquisition of the decade” is not hyperbole. It is the straightforward consequence of facts about the asset, the team, the modality, and the calendar.

Whichever large-cap pharma acts on this, and the list of natural acquirers is shorter than it looks, because the integration question screens out the wrong ones, will reset its competitive position for the 2030s. The M&A cycle in RNA therapeutics is not hypothetical and not coming; it is already underway. Novartis acted on a narrower version of this thesis in October 2025 and closed on it four months later. Whichever large-cap pharma does not act on the broader version will spend the next ten years watching a competitor consolidate the modality, and wondering what the right price would have been.

In chess, the queen is the most powerful piece on the board. It controls more squares than any other piece, moves in any direction, and is the single piece whose capture changes a game more than any other exchange. Most acquisitions in biopharma are pawn trades and knight exchanges. Some are rook captures. Arrowhead is the queen. The acquirer who captures it acquires the single most consequential piece available on the biotech M&A board this decade. The acquirer who lets it be captured by a competitor spends the next decade playing without a queen.

There is a final point worth making, and then leaving for another day. Original research into Arrowhead's patent record has surfaced findings that materially strengthen the strategic case. A forthcoming note will lay out those findings in detail. The point for this note is narrower: the four arguments above are made entirely on the basis of what Arrowhead has already disclosed publicly, and the case is sufficient on that basis alone. What is coming only strengthens it.

The acquisition of the decade is not a prediction. It is a transaction waiting for its buyer.

Subscribe now

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed; and

• he was not compensated in any form for producing this note.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of May 2026.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Note Arwr 05182026

203KB ∙ PDF file

Download

Download

This morning I published a note on what TIDES revealed about ARO-MAPT. That note framed CELIA, Biogen’s Phase 2 trial of their tau-lowering drug diranersen (formerly BIIB080), as the upcoming question that would tell us whether reducing tau in patients actually slows cognitive decline.

Hours later, Biogen released the CELIA topline results. The question is now answered.

The answer is yes, with important nuances. This note works through what CELIA actually shows, why the headline “missed primary endpoint” framing misreads the data, and why the result is significantly positive for Arrowhead.

Before going further, a quick recap for readers who didn’t see this morning’s note. Alzheimer’s disease involves two abnormal proteins building up in the brain: amyloid (plaques) and tau (tangles inside neurons). The currently approved Alzheimer’s drugs (Leqembi, Kisunla) target amyloid. Tau is the next frontier because tau tangle burden, not amyloid, is what correlates with how fast patients decline cognitively. Diranersen and ARO-MAPT both aim to reduce tau, but through different delivery systems. Diranersen is injected into the spinal fluid via a needle in the lower back (intrathecal). ARO-MAPT is a quarterly under-the-skin injection (subcutaneous) that uses the body’s natural transport system to cross from the bloodstream into the brain. CELIA tested whether tau-lowering therapy works clinically in patients. The next test, ARO-MAPT’s first human readout, comes in late September or October. As Chris Anzalone clarified yesterday at the Bank of America Healthcare Conference, that readout is from the healthy volunteer portion of the Phase 1/2a trial. AD patient data comes later.

What CELIA actually shows

The headline most trading desks saw this morning was “CELIA did not meet its primary endpoint.” To understand why that headline misreads the data, it helps to know what a primary endpoint actually is.

Every clinical trial has one (or sometimes two) pre-specified primary endpoints, the main statistical questions the study is designed to answer. CELIA’s primary endpoint was unusual: it tested whether the three studied doses of diranersen produced a dose-response relationship on cognitive decline. In other words, did giving more drug produce proportionally better cognitive outcomes? The three doses tested were 60 mg every 24 weeks, 115 mg every 24 weeks, and 115 mg every 12 weeks. The answer was no, the dose-response relationship did not reach statistical significance.

But a trial’s primary endpoint isn’t the same thing as whether the drug works. Trials also measure secondary endpoints and pre-specified exploratory endpoints, additional questions designed into the study from the start. CELIA’s secondary and exploratory measures tell a very different story than the headline suggests.

On biomarkers, Biogen reported “robust reductions in both cerebrospinal fluid (CSF) tau and tau pathology, as measured by positron emission tomography (PET), across all studied doses, with reductions maintained throughout the dosing period.” Two of those technical terms matter. CSF tau is the level of tau protein in spinal fluid, a measurable indicator that the drug is working at the gene level to reduce tau production. Tau PET is a brain scan that lights up tau tangles inside the brain. PET reduction means the drug is actually shrinking the disease pathology, not just lowering numbers in a lab test. CELIA showed both, across every dose tested, and the effect held throughout the 18-month treatment period.

On cognition, Biogen reported “pre-specified analyses of cognitive endpoints demonstrated slowing of clinical decline across all studied doses, particularly in participants receiving the lowest dose of diranersen, 60 mg administered every 24 weeks.” Pre-specified means these analyses were designed into the trial before the data were unblinded, this is not data-mining after the fact. Slowing of clinical decline means patients on diranersen got worse more slowly than patients on placebo, which is the entire point of a disease-modifying therapy. The cognitive benefit was present at every dose. The strongest signal came from the lowest dose.

On safety, the side effect rates were similar across doses, but the highest dose produced more serious adverse events. This pattern explains why the dose-response primary endpoint missed. Higher doses didn’t produce proportionally better outcomes because they introduced safety problems that offset their benefit. The trial’s primary endpoint assumed more drug equals more benefit. That assumption was wrong, and that’s why the statistical test missed.

Biogen’s response to this data tells us how to read it. They are advancing diranersen to registrational Phase 3 development. Registrational means a trial designed to support FDA approval, not a smaller exploratory study. Biogen is a company that has been criticized for capital discipline, faces shareholder pressure on R&D spending, and has had a string of disappointing programs. That company is committing hundreds of millions of dollars to Phase 3 development despite the technical primary endpoint miss. They are doing this because the totality of evidence, including data the public hasn’t seen, is sufficient to justify the commitment. Companies do not greenlight expensive Phase 3 trials on weak signals.

Dr. Jeff Cummings of UNLV, one of the most prominent Alzheimer’s disease researchers in the world, characterized CELIA as “an important advance for the field, providing the first evidence that reducing tau, a hallmark of Alzheimer’s disease closely associated with neurodegeneration and cognitive decline, may meaningfully impact disease progression.” Cummings doesn’t endorse studies casually. His framing is that CELIA established a new fact about Alzheimer’s therapy.

Here is what the data actually shows: tau-targeting therapy works. Lowering tau produces measurable reductions in the disease pathology and slows the rate at which patients decline cognitively. The primary endpoint missed on a specific statistical test about dose-response, not on whether the drug works.

Why this validates the tau hypothesis clinically

For five years, the tau-targeting field has been waiting for proof that the underlying mechanism works in patients. Multiple anti-tau antibody programs from Roche, AbbVie, and others have failed in trials. The bear case argued that lowering tau wouldn’t translate to cognitive benefit because of a problem called species-selectivity.

Here is the species-selectivity problem in plain terms. Tau is a normal protein found in healthy brains, where it stabilizes the internal structure of neurons. The problem in Alzheimer’s is not that tau exists, the problem is that a subset of tau gets chemically modified in ways that cause it to misfold, clump up, and form the toxic tangles that kill neurons. The bear case asks: if you lower all tau indiscriminately, are you reducing the toxic version, or just depleting the healthy pool while the toxic version keeps accumulating?

CELIA answers this question. Diranersen lowers total tau, and the lowering produces cognitive benefit in patients. Whatever fraction of the tau being lowered includes the toxic version, the net effect on patients is positive. The mechanism works, despite the species-selectivity concern.

For ARO-MAPT specifically, this changes the structure of the upcoming readout. Before CELIA, ARO-MAPT was testing two things at once: does lowering tau help patients, and does Arrowhead’s specific approach work? Now the first question is answered. ARO-MAPT’s upcoming healthy volunteer data tests a more focused question: does Arrowhead’s subcutaneous delivery produce the foundational pharmacology, drug reaching the brain, target engagement, safety, that justifies advancing to patient cohorts?

This is a meaningfully lower-risk question. The biology is validated. The delivery system is the variable that the upcoming readout tests.

What the late-2026 readout will actually show

Chris Anzalone clarified the scope of the readout at the Bank of America conference yesterday. Worth quoting directly: “The data we will have this year is just in healthy volunteers. Let’s see if this translates from NHPs to humans, let’s see if we get good knockdown of tau. Let’s see if this is well tolerated.”

This is meaningful framing. Phase 1/2a trials for CNS drugs typically have a multi-part design. ARO-MAPT’s trial includes a single ascending dose (SAD) portion in healthy volunteers, where escalating doses are tested in non-AD participants to establish safety, drug exposure in the body and brain, and target engagement (tau reduction). It also includes multi-ascending dose (MAD) cohorts that include Alzheimer’s patients, where the drug is administered repeatedly over weeks to months to evaluate sustained effects.

The late-2026 readout is the healthy volunteer SAD data. It tests three specific questions:

• Does the drug cross into the brain in humans the way it did in monkeys?

• Does it produce target knockdown, meaning measurable reductions in tau, in human CNS tissue?

• Is it well tolerated at doses expected to be therapeutic?

The AD patient data, which will test cognitive endpoints and tau pathology imaging, comes later in 2027 from the MAD cohorts.

This is actually a cleaner read for the late-2026 catalyst than testing cognitive benefit in patients on the first readout. Healthy volunteers don’t have AD pathology, so the readout focuses on what matters analytically: does the drug do in humans what it did in monkeys? Spinal fluid tau reduction is the cleanest measurable endpoint for that question. The animal data and predictive model say 50% or greater reduction in spinal fluid tau is the expected number. Diranersen’s Phase 1b showed approximately 60%. If ARO-MAPT lands in that range in healthy volunteers, the platform translates as designed, and the AD patient cohorts have the foundation needed to test cognitive effects.

Why ARO-MAPT is the better-built version

This early morning’s TIDES note worked through the structural differences between intrathecal delivery (diranersen) and subcutaneous TfR1-mediated delivery (ARO-MAPT). The relevance of those differences just increased substantially.

Diranersen is delivered intrathecally, which means injected into the spinal fluid via a needle inserted into the lower back. The drug pools near the injection site and distributes mostly to the spinal cord and the surface of the brain. Arrowhead’s preclinical data shows intrathecal delivery produces a 22-fold differential between drug concentrations at the surface and concentrations in deep brain regions. The deep regions, including the hippocampus where Alzheimer’s pathology starts, get far less drug than the surface.

ARO-MAPT is delivered as a subcutaneous injection, meaning under the skin, similar to how insulin or a GLP-1 weight loss drug is administered. The drug travels through the bloodstream to the blood-brain barrier, where it hitches a ride on the transferrin receptor (TfR1), a natural transport mechanism the brain uses to bring iron in from the blood. Arrowhead engineered ARO-MAPT to bind to TfR1, which carries the drug across the blood-brain barrier and into the brain. The drug distributes evenly across all brain regions with less than 2-fold variation. Deep brain structures get comparable drug exposure to surface regions.

CELIA’s data adds a specific new dimension to this comparison: the inverse dose response. The lowest dose worked best. Higher doses produced more serious adverse events without proportional benefit. This pattern tells us something important about intrathecal delivery itself.

Think of it this way. Intrathecal delivery puts a concentrated dose of drug directly into the spinal fluid, where it has to spread out, reach the brain, and distribute. Increasing the dose increases the concentration at the injection site. The brain may only need a certain amount of drug to lower tau effectively. Beyond that level, the extra drug doesn’t help, but the higher local concentration can produce side effects. That is what the CELIA data is showing. The therapeutic window for intrathecal delivery, the range between too little and too much, appears narrower than the field assumed.

Subcutaneous TfR1-mediated delivery doesn’t work the same way. The drug enters the bloodstream gradually from the injection site under the skin. It crosses into the brain through receptor-mediated transit, which is a slower and more controlled process than direct CSF injection. The CNS exposure builds up gradually and stays within a narrower range. Arrowhead’s preclinical safety margin is more than 10 times higher than the effective dose, meaning the drug works at concentrations far below where any safety signals appear.

In other words, the dose-response problem that caused diranersen’s primary endpoint miss may be specific to intrathecal delivery. Subcutaneous delivery, by virtue of producing controlled CNS exposure rather than bolus injection, doesn’t face the same constraint. The very issue that complicated CELIA’s primary endpoint may not apply to ARO-MAPT.

There is a sharper version of this point worth making explicit. CELIA’s lowest dose worked best. That tells us less drug in the CNS at any given time produced better outcomes than more drug. The implication for ARO-MAPT isn’t just that subcutaneous delivery avoids the intrathecal-specific safety issue, the implication is that ARO-MAPT’s pharmacokinetic profile, the way the drug actually behaves in the body and brain, naturally operates in the favorable dose range CELIA identified.

Subcutaneous TfR1-mediated delivery produces lower CNS drug concentrations per dose than intrathecal bolus injection by design. The drug enters the brain gradually through receptor-mediated transit, not via direct injection into spinal fluid. The peak concentrations are lower. The exposure is spread over time rather than concentrated at the injection site. This is the dosing profile CELIA found to produce the best clinical outcomes.

Two practical consequences follow. First, ARO-MAPT doesn’t need to discover the right dose through Phase 2 dose-escalation the way diranersen will. Diranersen’s Phase 3 design will be complicated by needing to return to the lowest dose (60 mg every 24 weeks) after running higher doses that introduced safety concerns. ARO-MAPT, by virtue of its delivery mechanism, naturally operates in the favorable range without needing to discover it. Second, the clinical optimum (low CNS exposure, less frequent dosing) matches the commercial optimum (convenient delivery, infrequent administration). These don’t always align in drug development. For ARO-MAPT, they do.

This isn’t speculation. It follows from how the two delivery systems actually work biologically.

Why the first-mover advantage concern is overstated

The standard analytical instinct on competitive timing says diranersen is 4-6 years from potential FDA approval (Phase 3 design, enrollment, follow-up, NDA review, FDA approval process) while ARO-MAPT is 5-7 years away on the same timeline. Diranersen has roughly a 1-2 year lead. The standard framing would be that this lead matters because the first drug to market in a new category typically captures durable competitive advantage.

This framing misreads the dynamics of chronic disease therapy with structurally different delivery modalities. Several real-world examples explain why.

Look at GLP-1 obesity therapy. Wegovy (subcutaneous semaglutide) launched into a market with multiple existing weight loss approaches, including older pills that had been on the market for years. The structural advantage of the GLP-1 mechanism plus a self-injectable subcutaneous pen enabled rapid market displacement of less convenient options despite their first-mover status. Patients and physicians shifted to the better delivery profile once it became available. The earlier-approved drugs lost market share.

Look at biologic drugs for autoimmune disease. Adalimumab (Humira) went from monthly clinic infusions in early development to bi-weekly self-administered subcutaneous injections, and captured massive market share against earlier-approved options. Across multiple autoimmune disease categories, the same pattern: infusion-based therapies systematically displaced by subcutaneous self-injectable options as they became available.

Look at insulin therapy. Rapid-acting insulin analogs displaced regular insulin not because of first-mover advantage but because of structural improvement in patient convenience. Long-acting insulin analogs displaced earlier basal insulin options for the same reason. The structural advantage of better delivery wins, even against earlier-approved competitors.

The principle is consistent. In chronic disease therapy, the prescription decision isn’t a one-time event, it gets reconsidered constantly. As long as a structurally better option becomes available, patients and physicians switch. Brand loyalty doesn’t override structural advantages in delivery, convenience, or safety.

For Alzheimer’s specifically, this dynamic is especially powerful. Patients require chronic therapy over many years. The population is overwhelmingly aging adults managing complex medication regimens. Caregivers, often spouses or adult children, carry significant treatment burden. Geographic accessibility matters because most patients don’t live near a specialized neurology center. The difference between quarterly intrathecal procedures (requiring a clinic visit, a sterile environment, an interventional radiology team, and recovery time) and quarterly subcutaneous injections (administered at home by a patient or caregiver) is enormous.

Diranersen, if approved first, will compete with subsequent therapies on delivery, dosing convenience, safety profile, and clinical effect. ARO-MAPT’s subcutaneous quarterly dosing isn’t a marginal improvement over intrathecal, it’s a structural difference that matches how patients actually want to receive chronic therapy. The first-mover advantage that matters in chronic disease isn’t who launches first, it’s who matches what patients need over decades of treatment.

This same dynamic explains why ARO-MAPT is structurally suited to the rarer tauopathies (PSP, CBD, FTD-MAPT) that diranersen cannot economically address. These rarer diseases have patient populations too small to support intrathecal infrastructure (specialized clinics, trained interventional staff, dedicated procedure suites) but more than large enough to support subcutaneous home administration. Diranersen’s commercial reach is limited to Alzheimer’s disease. ARO-MAPT, if it works, addresses the entire tauopathy spectrum, including diseases where intrathecal therapy simply isn’t viable.

The CNS-mediated obesity opportunity

Chris made an explicit disclosure at the Bank of America conference yesterday that hasn’t been widely discussed but is worth understanding. The question was whether obesity could be partnered. His answer:

“We are positioned to take all these for ourselves, and that’s our posture right now. I think there’s a ton of value there. We really like blowing out obesity ourselves, not just INHBE and ALK7, not just the dimers that could be made with those two candidates, but other ones. I mentioned CNS. There are really interesting obesity candidates in the brain, and we’ll have data from ARO-MAPT, our first sub-q administered CNS drug. We’ll have data later this year, and if that’s positive, then that opens up a whole new area for obesity.”

This is a substantive new framing. The Q2 prepared remarks mentioned obesity alongside CNS but didn’t explicitly link the platform validation to obesity TAM expansion. Chris is now saying directly that ARO-MAPT validation opens up CNS-targeted obesity therapy.

Why does this matter? Obesity is one of the largest commercial opportunities in medicine. The current GLP-1 franchise (Lilly’s Mounjaro/Zepbound, Novo’s Ozempic/Wegovy) generates tens of billions of dollars in annual revenue. The market is still growing rapidly as treatment expands. The bottleneck for next-generation obesity therapy is finding combinations and mechanisms that produce additional weight loss, better fat distribution effects, and improved long-term outcomes beyond what GLP-1s alone can deliver.

CNS-mediated obesity therapy targets the brain pathways that regulate appetite, energy expenditure, and metabolic control. The brain is where hunger signals originate, where satiety is registered, where reward pathways drive eating behavior. Drugs that act on CNS pathways have historically been limited by delivery, the inability to selectively target brain receptors without crossing safety thresholds in peripheral tissues. Subcutaneous TfR1-mediated delivery solves this problem. The drug crosses the blood-brain barrier through the receptor mechanism, achieving CNS exposure at doses far below where peripheral side effects would emerge.

Chris elaborated specifically: “It’s inconceivable to me that an obesity therapy could be administered by intrathecal injection. It is certainly conceivable of an obesity therapy could be a simple subcutaneous injection at home, once every two or three months.”

This is the platform extension logic made commercially specific. ARO-MAPT validates that TRiM SC can deliver siRNA drugs into the brain at therapeutic concentrations using a quarterly subcutaneous injection. Once that’s validated, the same delivery system can carry siRNAs targeting CNS pathways relevant to obesity. The platform isn’t just for neurodegenerative diseases, it’s the gateway to centrally-acting therapies across multiple therapeutic areas, with obesity being among the largest commercial opportunities.

Chris’s framing here is decisive. Arrowhead has $1.8 billion in cash and is positioned to retain the obesity franchise wholly-owned. Plozasiran, zodasiran, ARO-DIMER-PA, and the obesity programs (ARO-INHBE, ARO-ALK7, dimer variants, plus the CNS-mediated obesity opportunity ARO-MAPT enables) are all explicitly off the partnership table. The strategic posture is to capture this value within Arrowhead, not distribute it to partners.

Updated probability framework

This early morning’s TIDES note outlined a three-biomarker framework for interpreting ARO-MAPT’s eventual full readout. The three numbers were spinal fluid tau reduction, plasma p-tau217 movement, and Tau PET signal direction. With the BofA clarification that the late-2026 readout is healthy volunteer data, the framework needs calibration to what’s actually measurable in healthy volunteers.

The cleanest healthy volunteer biomarker is spinal fluid tau reduction. Healthy volunteers don’t have AD pathology, so Tau PET reduction and p-tau217 movement aren’t expected at this stage, those biomarkers track disease-relevant tau in patients with established pathology. What healthy volunteers do have is normal tau production, which subcutaneous delivery should be able to suppress measurably.

The expected number from Arrowhead’s preclinical model is 50% or greater reduction in spinal fluid tau. Diranersen’s Phase 1b in patients showed approximately 60%. ARO-MAPT’s preclinical NHP data showed greater than 70% mRNA knockdown and 50-65% protein reduction. The healthy volunteer readout testing whether subcutaneous TfR1-mediated delivery achieves this benchmark in humans is the central question for the late-2026 catalyst.

Safety and tolerability data is the parallel question. Healthy volunteer studies test what doses the drug can be given at without producing meaningful side effects. The TRiM SC preclinical safety margin (more than 10x above the effective dose) supports the expectation that ARO-MAPT will be well tolerated. CELIA’s inverse dose response finding actually strengthens this expectation because it suggests the relevant safety constraint is delivery-specific to intrathecal, not a general property of tau lowering.

The AD patient cohort data, which will test cognitive endpoints and tau pathology imaging, comes later in 2027 from the multi-ascending dose portion of the trial. By that point, the platform translation question will have been answered by the healthy volunteer data. The patient cohorts will test clinical efficacy given that the underlying pharmacology has been validated.

Probability framework: the probability that ARO-MAPT shows positive healthy volunteer biomarker effects has increased meaningfully based on CELIA. The mechanism is clinically validated. The biomarker bar (50% or greater spinal fluid tau reduction) is established by diranersen’s intrathecal data. The structural delivery advantage suggests ARO-MAPT should meet or exceed those benchmarks. The safety expectation is reinforced by the preclinical margin combined with the inverse dose response evidence that intrathecal delivery, not tau lowering itself, is what constrains tolerability.

Chris Anzalone’s framing at BofA puts this in context: “If those are the case, you know, it opens up a lot of opportunities for us in CNS and beyond. And we’re preparing for that, we’ve got a number of CNS programs that should this initial readout be positive, we’re going to push as quickly as we can. I think you’ll see a number of new CNS candidates in clinical studies in 2027, and you might see the first one at the end of 2026.”

This is operational specificity beyond what Q2 disclosed. First new CNS candidate could enter clinical development at the end of 2026. Multiple candidates entering clinical studies in 2027. The pipeline expansion isn’t a single program launch, it’s a multi-program rollout queued and ready to execute on positive readout.

What this means for the broader thesis

CELIA’s clinical validation of tau-targeting therapy extends beyond the immediate ARO-MAPT readout question. Several specific implications worth thinking through.

The platform extension story gains commercial concreteness in two directions. First, validated tau lowering supports the broader tauopathy commercial opportunity. PSP (progressive supranuclear palsy), CBD (corticobasal degeneration), and FTD-MAPT (frontotemporal dementia caused by mutations in the tau gene) all become more concrete commercial opportunities for any drug that can reach the brain regions where these diseases live. ARO-MAPT can. Intrathecal therapies struggle to. Second, Chris’s explicit framing of CNS-mediated obesity as a downstream opportunity opens the platform to an entirely separate commercial vector. ARO-MAPT validation isn’t just about tau, it’s about establishing that the TRiM SC platform delivers therapeutic doses of siRNA into the brain via subcutaneous injection. That platform capability applies across CNS pathways relevant to obesity, addiction, mood disorders, and other indications.

The acquisition framework strengthens. The investment thesis I’ve been developing across The Setup and The Endgame argues that Arrowhead becomes a strategic acquisition target if ARO-MAPT validates the platform. For potential acquirers like Lilly and Roche, the validated tau hypothesis makes CNS franchise value more defensible. Synergy estimates for the CNS component become more concrete because the underlying mechanism is now clinically proven, not just preclinically validated. The CNS-mediated obesity opportunity strengthens Lilly’s and Roche’s strategic case specifically, given Lilly’s tirzepatide franchise and Roche’s CT-388 obesity drug in Phase 3, and the established combination logic with Arrowhead’s ARO-INHBE program.

The wholly-owned strategic posture is decisive. Chris made clear at BofA that Arrowhead intends to retain plozasiran, zodasiran, ARO-DIMER-PA, and the entire obesity franchise (including CNS-mediated obesity) within the company. This concentrates the commercial value within Arrowhead rather than distributing it across partners. An acquirer wanting access to these programs has to acquire Arrowhead. The $1.8B cash position supports the standalone posture and reduces pressure to partner from a position of weakness.

The pipeline expansion commitment gets more specific and credible. As I argued in last week’s Q2 reaction note, substantial CNS pipeline expansion within months of a readout requires that programs be IND-ready today, sitting in the queue waiting to be triggered. Chris’s BofA framing (first new CNS candidate at end of 2026, multiple candidates in 2027) is more specific operational detail. CELIA’s clinical validation of the tau hypothesis means those queued programs are now anchored to a validated mechanism, not just to platform hope. The operational commitment Arrowhead made in May becomes more economically defensible after today’s data.

The competitive landscape clarifies. Diranersen, mivelsiran (Alnylam’s drug targeting amyloid via intrathecal delivery), and other intrathecal CNS RNA programs are now competing in a category where tau-targeting therapy works but where intrathecal delivery has specific limitations. ARO-MAPT enters this category with structural delivery advantages and the clinical validation that the underlying mechanism works.

What I’m watching for next

The four to six months between now and ARO-MAPT’s healthy volunteer readout include several developments worth tracking.

CELIA detailed data presentations at AAIC 2026 (the major annual Alzheimer’s research conference) and other scientific congresses. The topline release covered the headline findings. Detailed data on specific cognitive subtests, biomarker correlations, and patient subgroup analyses will provide more granular insight into how tau-targeting therapy actually works. KOL (key opinion leader) commentary at these conferences will shape the longer-term interpretation.

Biogen’s Phase 3 trial design and FDA discussions. The regulatory pathway for tau-targeting therapy in early Alzheimer’s is being established by Biogen’s discussions with FDA over the coming months. Whatever framework emerges, dose selection, patient population definition, endpoint requirements, will inform how the agency eventually evaluates ARO-MAPT’s registrational program. Watch for specific FDA guidance, breakthrough designation discussions, and trial design precedents.

Arrowhead’s ongoing Phase 1/2a execution. Late September through October 2026 remains the healthy volunteer readout window. Multi-dose AD patient cohort data follows in 2027. The trial is well underway, with single-dose healthy volunteer enrollment nearly complete and multi-dose cohorts (including AD patients) beginning. The next several months will produce the data that resolves the central translation question.

The R&D Webinar Summer Series. Arrowhead committed on the Q2 call to three educational webcasts, including one specifically on ARO-MAPT and the blood-brain barrier platform. Timing wasn’t specified beyond “the coming months.” Each webcast represents an opportunity for management to share additional context ahead of the readout.

ARO-ALK7 data updates through the second half of 2026. Chris framed the ARO-ALK7 readout this year as a parallel platform validation event to ARO-MAPT, testing safety, target knockdown, and whether the activin E/ALK7 axis translates from animals to humans with effects on weight loss and fat distribution. Arrowhead’s obesity franchise has multiple data points coming.

EASL ARO-INHBE late-breaker on May 27-30. The next major data event for the cardiometabolic franchise specifically. Combination data with tirzepatide will inform the obesity strategy and reinforce the partnership value with Lilly.

European Commission Marketing Authorization decision for REDEMPLO in Europe. The CHMP (Committee for Medicinal Products for Human Use, the European equivalent of an FDA advisory committee) issued a positive opinion in April. The EC decision in June-July formalizes the approval. The continued international commercial trajectory adds standalone value independent of the CNS thesis.

Bottom line

CELIA validates the tau hypothesis clinically. This is the single most important fact for Arrowhead’s investment thesis since the company began ARO-MAPT trials.

The primary endpoint miss is real but secondary. The data Biogen reported, taken together, demonstrates that tau-targeting therapy produces both biomarker engagement and cognitive benefit in early Alzheimer’s disease. The mechanism works. The bear case that has constrained tau-targeting therapy for years is answered.

ARO-MAPT enters its healthy volunteer readout window with the underlying mechanism clinically validated, structural delivery advantages over intrathecal alternatives, evidence that the inverse dose-response problem affecting diranersen may not apply to subcutaneous delivery, and a platform extension story that gained commercial concreteness today, both in the broader tauopathy spectrum and in the new CNS-mediated obesity opportunity Chris disclosed at BofA.

The first-mover advantage concern that some investors will raise about Biogen’s lead misreads how chronic disease therapy with structurally different delivery modalities actually plays out commercially. Patients on years-long treatment for Alzheimer’s will prefer quarterly subcutaneous injection at home over quarterly intrathecal procedures at a specialized clinic. The category of tau-targeting therapy is large enough for multiple winners, and the structural advantage of subcutaneous delivery is durable.

The framework I established early this morning in “ARO-MAPT: The Last Open Question“ held up against Biogen’s data. The healthy volunteer readout in late September through October remains the binary catalyst for platform translation. The probability that ARO-MAPT meets the biomarker benchmarks has increased based on CELIA’s validation of the mechanism.

The platform extension implications, the CNS pipeline expansion commitment, the acquisition framework, the wholly-owned cardiometabolic and obesity strategic posture, the broader investment thesis, all of these become more economically defensible after today.

The data itself will tell, but CELIA changed the question ARO-MAPT has to answer.

Subscribe now

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed; and

• he was not compensated in any form for producing this note.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of May 2026.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Note Biib Arwr 05142026

243KB ∙ PDF file

Download

Download

Arrowhead presented updated ARO-MAPT data at TIDES USA 2026 yesterday. Most of what was shown has been public for months. The mechanism of how the drug crosses into the brain has been disclosed since September 2025. The competitive case against the existing intrathecal-delivered tau drugs has been on slides since September. The 65% reduction in tau biomarkers in monkeys has been public since September. Sell-side will write up the deck this week and most of what they cover will be material that has been sitting in Arrowhead’s investor relations page for the better part of a year.

Two things in the deck were genuinely new, and they matter more than the rest combined. This note explains what they are, what they mean, and what they do to the case heading into the Phase 1/2a readout.

Before going further, a quick primer for readers who don’t live in this corner of biology. Alzheimer’s disease (AD) involves two abnormal proteins building up in the brain: amyloid (which forms plaques) and tau (which forms tangles inside neurons). The current FDA-approved AD drugs, Leqembi and Kisunla, go after amyloid. They produce modest cognitive benefit at the cost of brain bleeding and swelling side effects, and they don’t reduce tau. The next frontier in AD is reducing tau, because tau tangle burden, not amyloid, is what correlates with how fast patients decline cognitively.

ARO-MAPT is Arrowhead’s drug that aims to reduce tau. MAPT is the name of the gene that produces tau protein. ARO-MAPT is a small RNA molecule that goes into the brain, finds the MAPT gene’s instructions for making tau, destroys those instructions, and stops new tau from being produced. Less tau being made means less tau available to misfold into tangles. That’s the thesis.

1. The pathology data: why “AT8” matters

Every tau-lowering drug has faced the same bear case for years. The argument runs like this: tau exists in healthy brains too. It is a normal protein that stabilizes the internal structure of neurons. The problem in Alzheimer’s is not that tau exists, the problem is that a subset of tau gets chemically modified, phosphorylated, in ways that cause it to misfold, clump up, and form the toxic tangles that kill neurons. The bear case asks: if you lower all tau indiscriminately, are you actually reducing the toxic tangles, or are you just lowering the healthy pool while the bad version keeps accumulating?

Several companies tried to solve this by developing antibodies that target only the bad version of tau. Roche, AbbVie, Biogen, UCB all ran trials with anti-tau antibodies. Most have failed. The implicit message from those failures was that maybe you cannot get to the toxic version by going at the upstream gene. Maybe the species-selectivity problem is fatal to the whole approach.

Arrowhead had not, until today, shown that ARO-MAPT actually reduces the toxic version of tau specifically. They had shown they could reduce total tau and the gene’s RNA output, but they had not shown the pathological species itself coming down. That was the last open question on the preclinical case.

The answer is in the TIDES deck. In mice engineered to develop tauopathy (a disease that mimics human Alzheimer’s tau pathology), ARO-MAPT cut the toxic phospho-tau species in the hippocampus by 53%. The hippocampus is the memory center of the brain, it is also the region where Alzheimer’s pathology starts. The toxic species is detected using a research tool called the AT8 antibody, which is the standard way scientists identify pathological tau in tissue samples. In short: in disease-model animals, ARO-MAPT cut the bad tau in the brain region where Alzheimer’s begins by roughly half.

This is the data point the field has been waiting for. It says that going after the gene works for the toxic species, not just total tau. The bear case is answered.

One important caveat. These mice are engineered to produce a mutant form of human tau at high levels. They develop tangle pathology on a fast clock that human disease does not follow. Mouse models of human disease are useful but imperfect, and a successful result in PS19 mice does not guarantee the same result in humans whose tau pathology arises from aging rather than a transgene. The AT8 data is preclinical proof of a mechanism. Whether the mechanism translates is what the Phase 1/2a will test.

The clinical trial is set up to test exactly that. One of the exploratory imaging endpoints is Tau PET, a brain scan that lights up tau tangles in living human patients. Tau PET is the human equivalent of what the AT8 antibody measures in mouse tissue. BIIB080, the Biogen/Ionis tau drug discussed later in this note, has produced Tau PET reductions in its Phase 1, but BIIB080 is an antisense oligonucleotide (ASO), a different class of RNA-targeting drug than ARO-MAPT’s small interfering RNA (siRNA). If ARO-MAPT produces a Tau PET signal in the Phase 1/2a, Arrowhead will have shown the first siRNA drug to reduce tangle burden in human brains, and will have done so using a simple under-the-skin injection rather than the spinal taps that BIIB080 requires.

Tau PET signal is not the cognition readout that takes years to mature, it is the biomarker readout that could show up within the 270-day study window. Late 2026 to 2027 is the realistic catalyst window.

2. The dosing reveal: why quarterly is now the working case

The second new piece of data extends a long-running monkey study that has been the backbone of Arrowhead’s CNS package.

Here is the setup. Arrowhead has been dosing monkeys with ARO-MAPT in a study that involves three weekly loading doses followed by monthly maintenance doses. The September 2025 presentation showed data through day 156 of this study, which is the time point when the last maintenance dose was given. At that point, tau mRNA was down 65-80% from normal and tau protein was down 70-90%.

The TIDES deck extends the same study to day 239, almost four months past the last dose. The mRNA suppression has substantially lifted; the gene is back to producing 55-80% of normal output, but the tau protein in the brain is still down 50-65% from normal.

This is the pharmacology that matters. Tau is a long-lived protein. Even after the drug’s effect on the gene fades and new tau starts being produced again, the existing pool of tau in the brain has been depleted, and it takes a long time to refill. The protein suppression persists long after the mRNA suppression has worn off.

Why does this matter commercially? It means quarterly dosing is realistic, and possibly less frequent than quarterly. Arrowhead’s PK/PD model, which the September deck disclosed, projects that monthly maintenance dosing keeps tau knockdown at roughly 80% indefinitely, and quarterly dosing keeps it at 50-70%. The TIDES data is the experimental confirmation that the model’s duration assumption is correct.

Now compare the patient experience. Leqembi starts with twice-monthly IV infusions at an infusion center for 18 months, then transitions to monthly IV or weekly at-home subcutaneous injection for maintenance. An expanded subcutaneous formulation that would eliminate the IV initiation phase entirely is currently under FDA review. Kisunla requires monthly IV infusions throughout the course of treatment. ARO-MAPT, if the human data tracks the monkey data, would be the first disease-modifying Alzheimer’s therapy whose dosing schedule consists of a quarterly subcutaneous injection from the very first dose; no IV phase, no clinic visit cadence, just an under-the-skin injection at home four times a year.

For a patient population that is overwhelmingly still working, still driving, and still managing their own life, this is not a minor convenience improvement, this is the difference between a drug that fits into a normal life and a drug that organizes a normal life around itself. It is also what makes ARO-MAPT economically viable in the rarer tauopathies, PSP, corticobasal degeneration, frontotemporal dementia, where small patient populations cannot support infusion infrastructure. A single drug, a single dosing paradigm, the entire tauopathy spectrum addressable.

3. What the Phase 1/2a actually has to show

With the pathology data and the dosing extension in hand, the preclinical case for ARO-MAPT is as complete as it gets before human translation. Every reasonable question that could be asked of an animal study has been answered.

1. Delivery works: the drug crosses from a subcutaneous injection into the bloodstream and then into the brain.

2. Distribution works: the drug reaches all regions of the brain uniformly, including the deep regions that have historically been impossible to reach with competing approaches.

3. Knockdown works: 70-80% reduction in tau mRNA across the brain. Protein follows: total tau down, pathological tau down.

4. Durability is there: protein down 50-65% sixteen weeks after the last dose.

5. Safety margin is wide: more than ten times higher than the effective dose in animal toxicology studies.

6. The clinical trial application is filed. The first human subjects were dosed in December 2025.

This brings up the competitive question. Biogen and Ionis have a drug called BIIB080 that also lowers tau. It is in Phase 2 (the CELIA trial) and reads out in 2026. BIIB080 has shown that lowering tau can reduce tau biomarkers and tangle imaging in humans, which is genuine proof-of-concept for the approach. Arrowhead’s own deck acknowledges this and gives BIIB080 credit for it.

But BIIB080 is delivered into the spinal fluid via lumbar puncture; a needle into the lower back that has to be done at a clinic. Arrowhead has data showing that drugs delivered this way cannot reach the deep regions of the brain at therapeutic concentrations. The drug pools near the injection site and distributes mostly to the spinal cord and surface of the brain. The deep regions, caudate, putamen, parts of the brainstem, get essentially no drug. This is not a problem specific to BIIB080, it is a problem of spinal fluid mechanics that affects every drug delivered by lumbar puncture.

Arrowhead’s data shows the spinal-tap route delivers drug 22 times more to surface regions than deep regions. The under-the-skin injection route delivers drug evenly across the whole brain, with less than 2-fold variation. For Alzheimer’s, where the disease starts in deeper structures and spreads outward, this difference matters. For the other tauopathies, PSP affects the substantia nigra and basal ganglia, corticobasal degeneration affects basal ganglia and cortex, it matters even more, because those diseases live entirely in the regions intrathecal delivery cannot reach.

BIIB080 is the better-validated drug today. ARO-MAPT is structurally a better-built version of the same idea. CELIA will tell us whether tau reduction translates to cognitive benefit in patients. ARO-MAPT will tell us whether the same translation happens with a delivery system that can actually reach the disease, dosed quarterly at home rather than via a procedure every few months at a clinic.

The Phase 1/2a study is now the translation event between a complete preclinical package and clinical proof. Three numbers will tell readers whether the platform translates to humans.

1. First, tau in the spinal fluid. Patients in the trial will have a small amount of spinal fluid drawn before and after dosing, and tau protein levels in that fluid will be measured. The animal data and the predictive model say a 50%+ reduction in spinal fluid tau is the expected number. BIIB080’s Phase 1b showed about 60%. If ARO-MAPT lands in that range, the drug translates as designed and the platform is calibrated. This is the cleanest readout in the study and the most directly comparable to existing data.

2. Second, p-tau217 in the blood. A newer biomarker that has become the gold-standard blood test for Alzheimer’s pathology. Unlike spinal fluid tau, plasma p-tau217 specifically tracks the disease-relevant tau pool rather than total tau. If this number moves in patients who got the drug compared to placebo, it indicates ARO-MAPT is engaging the specific tau species that drives disease, not just tau in general. A movement here is corroborating evidence on top of the spinal fluid signal.

3. Third, Tau PET brain imaging. The hardest endpoint and the one that bridges the AT8 mouse data to human disease. Tau PET imaging shows tangle burden in living patients’ brains. In normal Alzheimer’s progression, the signal grows over time as more tangles form. If ARO-MAPT-treated patients show their Tau PET signal flatten or decrease while placebo patients progress normally, that would be the first such data point for a subcutaneously-delivered siRNA in CNS medicine. It does not need to be statistically significant in a Phase 1/2a to be a re-rating event for the stock. Directional change is enough.

Three positives, or two of three with the third pointing in the right direction, and the platform translates. The cognitive testing data from a Phase 1/2a is too small in sample size to be statistically conclusive on its own, but if the biomarkers move, the cognitive direction sets the expectation heading into Phase 2.

This is the read on what TIDES set up. The biology is closed. The dosing case is sharpened. The clinical study is designed to read out on biomarkers that map directly back to the preclinical package. The Phase 1/2a interim biomarker disclosure, whenever Arrowhead chooses to share it, is the catalyst that re-rates the stock. It does not require cognition data. It does not require Phase 2. It requires the spinal fluid number to hit, the blood biomarker to move, and the brain imaging to point in the right direction.

If those three things happen, ARO-MAPT is no longer a preclinical platform story. It is a clinical platform story, and the rest of the TRiM CNS pipeline re-rates with it. That pipeline includes ARO-HTT for Huntington’s disease (preclinical, partnered with Sarepta), ARO-SNCA for Parkinson’s disease and synucleinopathies (preclinical, partnered with Novartis), ARO-ATXN3 for spinocerebellar ataxia 3 (preclinical, Sarepta), ARO-ATXN1 for spinocerebellar ataxia 1 (discovery, Sarepta), and an undisclosed cardiometabolic CNS target showing roughly 90% knockdown in NHP. Five disclosed subcutaneous CNS programs across two partners plus Arrowhead’s own wholly-owned ARO-MAPT, all riding on the same delivery system that the Phase 1/2a is about to validate or invalidate. The platform is what gets re-rated, not the individual bets.

Lastly, management has signaled there is more behind it. On the Q2 FY2026 earnings call, CEO Chris Anzalone said: “If early ARO-MAPT data are encouraging, expect a substantial expansion of our CNS pipeline beginning at the end of 2026.” Substantial pipeline expansion within months of a Phase 1/2a interim readout is not something a company assembles on the fly. It requires programs already in IND-enabling work, manufacturing capacity already reserved, regulatory strategies already drafted, and capital already allocated. Chris’s commitment implies that work has been done, and is sitting queued, waiting for the readout. The five disclosed CNS programs are not the ceiling, they are the floor.

Subscribe now

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed; and

• he was not compensated in any form for producing this note.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of May 2026.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Note Arwr 05142026

189KB ∙ PDF file

Download

Download

The Q2 FY2026 disclosures and conference call from Arrowhead yesterday included headline numbers that will get most of the attention: REDEMPLO prescriptions exceeding 400 with 40% growth in the last four weeks, $1.78B in cash resources, the ARO-INHBE/ARO-ALK7 obesity data, and the expected SHASTA-3/4 readouts in calendar Q3 2026.

But the most analytically informative disclosure wasn’t a number. It was a single sentence buried in Chris Anzalone’s prepared remarks that, when unpacked carefully, reveals more about management’s confidence in the upcoming ARO-MAPT readout than any individual data point or financial metric.

This note works through what that sentence means and how it should inform how investors think about the timeline ahead.

The sentence that reveals everything

Chris Anzalone, discussing the upcoming ARO-MAPT Phase 1/2a readout, said this:

“We believe that positive early data could be substantially disruptive. It could represent a great leap forward in treating tauopathies and more broadly, open the door to using RNAi to treat a broad range of conditions from neurodegenerative disorders to obesity. If early ARO-MAPT data are encouraging, expect a substantial expansion of our CNS pipeline beginning at the end of 2026.“

The bolded sentence is the load-bearing analytical disclosure of the entire call.

The ARO-MAPT readout timing was specified to “end of Q3 or early Q4”, meaning approximately late September through October 2026, calendar quarters. That’s roughly 5-6 months away. The “end of 2026” timing for substantial CNS pipeline expansion is therefore approximately 2-3 months after the readout.

Here’s why that matters: substantial CNS pipeline expansion in 2-3 months requires preparation that takes years.

Building substantial new CNS programs requires discovery work and target validation completed and ready for IND-enabling studies. It requires preclinical safety and efficacy packages assembled. It requires manufacturing capacity reserved for new programs. It requires senior scientific leadership and clinical operations staff in place. It requires regulatory strategy developed for each new candidate. It requires capital allocated to fund the expansion across multiple programs simultaneously.

You don’t build all of that in 60-90 days. You build it over years and hold it ready to execute.

This means Arrowhead has been quietly preparing a substantial CNS pipeline expansion that is queued and waiting. The expansion isn’t speculative future work that might happen if ARO-MAPT succeeds, it’s an operational plan that has been pre-positioned, contingent on the readout. Programs are essentially IND-ready today, sitting in the queue waiting for the trigger event.

What this reveals about management’s internal probability assessment

Companies don’t pre-announce conditional pipeline expansion unless they’re already preparing for it. The cost of that preparation, discovery work, preclinical investment, manufacturing capacity, staff allocation, is real. Management doesn’t make these investments speculatively.

The conditional language is the precise calibration of a confident management team that’s also legally constrained from making definitive predictions about a blinded trial. They’re saying: “We’ve prepared this. We expect to execute it. We just can’t legally promise you the trigger event will happen.”

Consider the alternative scenarios:

A management team that thinks ARO-MAPT has a 30% probability of success doesn’t pre-announce substantial pipeline expansion two to three months post-readout. They wait for the data first to avoid creating expectations they may not meet, and they don’t tie up resources in preparation for a low-probability trigger.

A management team with a 50-60% probability assessment might position discovery work quietly but wouldn’t commit publicly to specific timing for expansion that requires programs to be IND-ready essentially now.

A management team with a 70%+ internal probability assessment, and that has already made the operational pre-investments, would commit to specific timing because the preparation has already been made and the cost of the public commitment is low.

The quote is consistent with management’s internal probability assessment of meaningful success being substantially above the typical Phase 1/2a base rate. That doesn’t mean the trial will succeed at that probability, base rates of trial failure are real, and management’s assessment can be wrong, but it tells us about management’s read of the trial, and management has access to information (the unblinded analytical team’s safety and PK observations, early biomarker patterns from completed cohorts) that shapes their internal probability differently than the external market’s read.

The compressed timeline

The 60-90 day window between readout and substantial pipeline expansion is structurally significant. It tells us about the operational tempo Arrowhead is preparing for:

• Within days of readout, scientific leadership reviews the data and validates the trigger conditions.

• Within weeks, regulatory strategy is finalized for the queued programs.

• Within a month, IND filings could begin for the first wave of expansion programs.

• Within two months, manufacturing capacity is allocated and clinical operations infrastructure activated.

This is a compressed operational tempo that requires not just queued programs but also pre-coordinated decision-making across multiple functions. Management has clearly worked through the post-readout playbook in detail.

For investors thinking about positioning, this changes the relevant question. The conventional framing is “when will the data come?” The more sophisticated framing is “when will the operational expansion become visible?” The answer is roughly 60-90 days after readout, meaning by year-end 2026, investors should expect to see specific announcements about new CNS programs entering clinical development.

What’s in the queued pipeline

The substantial CNS pipeline expansion at end of 2026 isn’t speculative, but the specific programs Arrowhead has queued aren’t fully disclosed. We can make some informed inferences.

The TRiM SC platform that delivers ARO-MAPT was developed for transferrin-receptor-mediated subcutaneous BBB transit. Once that delivery technology is validated, it can be applied to multiple CNS targets. The discovery engine has been working on preclinical CNS programs for years.

The Sarepta partnership covers ARO-HTT (Huntington’s) and ARO-ATXN3 (spinocerebellar ataxia) on the licensed side. The Novartis partnership covers ARO-SNCA (Parkinson’s). The wholly-owned CNS portfolio that would expand likely includes additional tauopathy programs (PSP, CBD, FTD-MAPT-specific approaches), other neurodegenerative targets, and potentially novel CNS-mediated metabolic targets.

Chris’s reference to “neurodegenerative disorders to obesity” within the same context is striking because obesity isn’t typically discussed alongside CNS programs. The implication is that the BBB delivery platform is being thought about more broadly than traditional CNS targets, possibly for centrally-mediated metabolic regulation, appetite signaling, or other neurochemical pathways that affect peripheral organ systems.

The “substantial” framing combined with the specific timing suggests multiple programs are queued for advancement. Three to five new CNS programs entering clinical development by end of 2026 would be consistent with the language, though management hasn’t specified the exact number. Either way, it would be a meaningful expansion that would materially reshape how investors value the CNS franchise.

How to interpret the readout when it happens

The conventional framing of binary catalysts is “did the trial succeed?” The cumulative pattern of management’s pre-positioning suggests a more sophisticated framing: did the trial clear the bar that triggers the operational expansion?

Chris used the word “encouraging” rather than “positive” or “successful.” This is deliberate calibration. “Encouraging” sets a lower bar, meaning even directional success rather than home-run results would trigger the queued expansion. Management appears to have set the threshold at a level they’re confident the data can meet, not at a level requiring exceptional results.

For investors thinking about the readout, this changes the question structure:

• Did the data clear “encouraging”? Pipeline expansion proceeds. Re-rate the company.

• Did the data substantially exceed “encouraging”? Pipeline expansion proceeds at potentially higher pace. Re-rate the company more aggressively.

• Did the data fall below “encouraging”? The platform argument remains, but the immediate expansion plan pauses. Some pipeline preparation becomes sunk cost. The thesis takes a meaningful hit but not a fatal one, alternative tauopathy indications (PSP, CBD, FTD-MAPT) and the cardiometabolic franchise remain.

In Q&A, James Hamilton explicitly outlined this contingency: “Even if those data are not positive, we still have the option of pursuing all the other tauopathies. A knockdown approach of tau should improve any condition that’s really driven by tau gain-of-function or tau pathology.” The platform thesis has real downside protection through alternative indication pathways.

Connecting to the cardiometabolic floor case

The CNS pipeline expansion commitment doesn’t operate in isolation. It sits alongside continued execution on the cardiometabolic franchise that anchors the standalone valuation:

REDEMPLO prescriptions exceeded 400 in the U.S. with 40% growth in the most recent four weeks. Patient mix is 85% APOC3-naïve, physicians are identifying and treating patients who never had access to effective therapy, growing the addressable market rather than just taking share.

The pricing decision deserves clearer framing than the press release provided. REDEMPLO launched at $60,000 WAC in November 2025. It has been reduced to $45,000, a 25% reduction. Chris explicitly stated the reduction “had nothing to do with any pushback from payers” and was driven by strategic positioning for the SHTG launch and unified pricing across indications. At $45,000, REDEMPLO sits at a $5,000 premium over Tryngolza’s $40,000, justified by what Andy Davis characterized as “no contraindications, no warnings, no precautions” on the FDA label, plus convenience advantages (four injections per year vs. monthly).

SHASTA-3 and SHASTA-4 readouts are expected in calendar Q3 2026 with sNDA filing before year-end. The SHTG opportunity addresses over one million high-risk patients in the U.S. alone, substantially larger than the FCS population. International expansion proceeds with positive CHMP opinion already received in April, European Commission Marketing Authorization decision expected June-July, Australian approval received, Canadian approval received, Chinese approval through Sanofi.

ARO-DIMER-PA Phase 1/2a is initiated and on track for first clinical readout in calendar Q3, the first dual-functional siRNA targeting two genes simultaneously. The mixed hyperlipidemia opportunity addresses approximately 20 million U.S. patients.

The Madrigal ARO-PNPLA3 deal monetizes a non-core asset for $25M upfront, up to $975M in milestones, plus tiered royalties to mid-teens. Chris confirmed ARO-C3 (complement C3 inhibitor) as the next likely BD candidate, signaling continued discipline in monetizing peripheral assets while retaining core programs.

The cumulative cardiometabolic execution provides a meaningful floor under the standalone valuation independent of ARO-MAPT outcomes.

What the cumulative pattern suggests

The disclosures from yesterday’s call layer onto the broader pattern of management behavior over the past several months:

• Management committed to a major commercial real estate expansion (Pasadena lease doubled to 98,444 square feet).

• They’re actively recruiting senior international leadership (VP EU General Manager).

• They’re hiring across 71 open positions including Quality, Plant Operations, Commercial, Medical Affairs, and Regulatory Affairs roles.

• They monetized ARO-PNPLA3 to Madrigal.

• They confirmed ARO-C3 as next BD candidate.

• They specified end-of-2026 CNS pipeline expansion contingent on ARO-MAPT success.

• They tightened the readout window to end of calendar Q3 or early Q4, approximately 5-6 months away.

Each individual decision could be ordinary corporate behavior. The cumulative pattern is extraordinary. The pattern is most parsimoniously explained by management having genuine, well-grounded confidence about the company’s near-term trajectory, calibrated through behavioral commitments rather than rhetorical claims.

That confidence is most consistent with, though not proof of, favorable expectations for ARO-MAPT. The readout itself will resolve the uncertainty.

What I’m watching for next

The next four to six months include a dense calendar of events that could provide additional signals:

• May 13: TIDES USA presentation. Madhivanan’s platform talk on tau suppression across the CNS using TRiM SC. Watch for additional brain region characterization or mechanistic detail that primes the platform argument.

• May 13: Bank of America Healthcare Conference fireside chat. Chris will be in front of institutional investors. Watch for any specific commentary on capital allocation.

• May 20: RBC Capital Markets Healthcare Conference. Additional investor engagement.

• May 24-27: European Atherosclerosis Society 2026 Congress. Plozasiran presentations.

• May 27-30: European Association for the Study of the Liver 2026. ARO-INHBE late-breaker with combination tirzepatide data.

• June-July: European Commission Marketing Authorization decision for REDEMPLO in Europe (CHMP positive opinion already received in April).

• Calendar Q3 2026 (July-September): SHASTA-3/4 topline readouts. ARO-DIMER-PA first clinical readout. Beginning of ARO-MAPT readout window.

• Late September through October 2026: ARO-MAPT first readout window.

• End of 2026: Substantial CNS pipeline expansion to begin if ARO-MAPT data are encouraging.

The compressed timeline means the next several months will resolve significant uncertainty about the structural thesis. The framework for interpreting the readout has been established by yesterday’s call. The cumulative pattern of management behavior continues to validate the structural argument.

Bottom line

The most telling disclosure from Q2 FY26 wasn’t the prescription numbers, the obesity data, or the timing tightening, though each of these matters.

The most telling disclosure was Chris Anzalone’s commitment to “substantial expansion of our CNS pipeline beginning at the end of 2026” if ARO-MAPT data are encouraging.

Substantial pipeline expansion in 60-90 days post-readout requires preparation that takes years. Management has been quietly making those preparations. The conditional language reveals discipline, not uncertainty, the precise calibration of a confident management team navigating securities-law constraints around a blinded trial.

The framework I’ve built across The Setup and The Endgame continues to be validated by Arrowhead’s revealed-preference behavior. The end-of-Q3 / early-Q4 readout remains the binary catalyst. Until then, management is acting like they know what’s coming.

The question for investors isn’t whether management’s confidence is justified, that gets resolved by the data. The question is whether the cumulative pattern of management behavior, calibrated through real operational commitments, raises the probability of meaningful success above the typical Phase 1/2a base rate enough to justify positioning ahead of the readout.

The pattern, examined honestly, suggests the answer is yes. The data itself will tell.

A Note on Supporting Independent Research

If this reaction note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this reaction note accurately reflect his personal opinions about the topic discussed; and

• he was not compensated in any form for producing this note.

This reaction note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of May 2026.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Bbs Reaction Note Arwr 05082026

240KB ∙ PDF file

Download

Download